Breaking symmetry by Visco, Ilaria
Breaking symmetry:
reconstitution of unmixing and
polarization events in model
membranes
Ilaria Visco
Mu¨nchen 2015

Breaking symmetry:
reconstitution of unmixing and
polarization events in model
membranes
Ilaria Visco
Dissertation
an der Fakulta¨t fu¨r Biologie
der Ludwig–Maximilians–Universita¨t
Mu¨nchen
vorgelegt von
Ilaria Visco
aus Latina (Italien)
Mu¨nchen, den 05. Ma¨rz 2015
Erstgutachter: Prof. Dr. Kirsten Jung
Zweitgutachter: Prof. Dr. Marc Bramkamp
Tag der mu¨ndlichen Pru¨fung: 30. Juli 2015
Eidesstattliche Erkla¨rung
Hiermit versichere ich an Eides statt, dass die vorliegende Dissertation von mir selbststa¨ndig
und ohne unerlaubte Hilfe angefertigt wurde. Des Weiteren erkla¨re ich, dass ich nicht ander-
weitig ohne Erfolg versucht habe, eine Dissertation einzureichen oder mich der Doktorpru¨fung
zu unterziehen. Die vorliegende Dissertation liegt weder ganz, noch in wesentlichen Teilen
einer anderen Pru¨fungskommission vor.
Mu¨nchen, 05. Ma¨rz 2015
(Ilaria Visco)

Contents
Eidesstattliche Erkla¨rung v
List of Figures xiii
List of Tables xv
List of Publications xvii
Abstract xix
Zusammenfassung xxi
I INTRODUCTION 1
1 Introduction 3
1.1 Relevance of polarity for living systems . . . . . . . . . . . . . . . . . . . . . 3
1.2 Bottom-up synthetic biology: a viable approach to understand polarity . . . . 6
1.3 GUVs and SLBs as model membranes to reconstitute polarization events . . 9
1.4 Biophysical characterization of model membranes dynamics and lipid-protein
interactions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13
1.5 Experimental approaches to reconstitute unmixing and polarization events in
model membranes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16
II MATERIALS AND METHODS 19
2 Materials and sample preparation 21
2.1 Materials . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21
2.1.1 Lipids . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21
2.1.2 Protonation of phosphoinositides using acid . . . . . . . . . . . . . . . 21
2.1.3 Fluorescent lipids . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22
2.1.4 Fluorescent dyes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22
2.1.5 eGFP-His6 expression and purification . . . . . . . . . . . . . . . . . . 22
2.1.6 PLAP purification and labeling . . . . . . . . . . . . . . . . . . . . . . 22
2.1.7 HA TM peptides synthesis and labeling . . . . . . . . . . . . . . . . . 22
2.1.8 LGL-1 expression and purification . . . . . . . . . . . . . . . . . . . . 23
2.1.9 LGL-1 MTS peptides synthesis and labeling . . . . . . . . . . . . . . . 23
viii CONTENTS
2.1.10 Additional materials . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23
2.2 In vitro LGL-1 phosphorylation by human PKC-z . . . . . . . . . . . . . . . 24
2.3 Model membranes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24
2.3.1 Preparation of SUVs for circular dichroism measurements . . . . . . . 24
2.3.2 Preparation of LUVs . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24
2.3.3 Preparation of GUVs . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
2.3.4 Preparation of SLBs . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26
2.4 Budding of intramembrane domains in GUVs . . . . . . . . . . . . . . . . . . 27
2.5 Protein reconstitution in model membranes . . . . . . . . . . . . . . . . . . . 27
2.5.1 PLAP reconstitution in SLBs . . . . . . . . . . . . . . . . . . . . . . . 27
2.5.2 HA TM peptide reconstitution in SLBs . . . . . . . . . . . . . . . . . 29
2.5.3 HA TM peptide reconstitution in GUVs . . . . . . . . . . . . . . . . . 29
2.6 Cyclodextrin-mediated lipid exchange . . . . . . . . . . . . . . . . . . . . . . 29
2.6.1 Cyclodextrin-lipid complexes preparation . . . . . . . . . . . . . . . . 29
2.6.2 Formation of asymmetric SLBs . . . . . . . . . . . . . . . . . . . . . . 30
2.6.3 Formation of asymmetric GUVs . . . . . . . . . . . . . . . . . . . . . 30
2.6.4 Cyclodextrin-mediated GUV shape transformation . . . . . . . . . . . 30
2.7 Leaflet specific labeling . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30
2.7.1 Leaflet specific labeling in SLBs . . . . . . . . . . . . . . . . . . . . . . 30
2.7.2 Leaflet specific labeling in GUVs . . . . . . . . . . . . . . . . . . . . . 31
3 Methods 33
3.1 Confocal fluorescence microscopy and correlation spectroscopy . . . . . . . . 33
3.1.1 Optical Setup . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33
3.1.2 FRAP on GUVs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33
3.1.3 Point-FCS on SLBs . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34
3.1.4 Point-FCS on GUVs and in presence of LUVs . . . . . . . . . . . . . . 35
3.1.5 Line-scan FCS on SLBs and GUVs . . . . . . . . . . . . . . . . . . . . 36
3.2 GUV image analysis for determining partitioning coe cients . . . . . . . . . 37
3.3 Image processing and analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . 38
3.3.1 Measurements in thresholded images . . . . . . . . . . . . . . . . . . . 38
3.3.2 Determination of Lo partitioning coe cients in GUVs . . . . . . . . . 39
3.3.3 Determination of protein binding to GUVs . . . . . . . . . . . . . . . 39
3.3.4 Determination of protein binding to SLBs . . . . . . . . . . . . . . . . 39
3.4 Circular dichroism spectroscopy . . . . . . . . . . . . . . . . . . . . . . . . . . 40
3.5 Dynamic light scattering and z-potential . . . . . . . . . . . . . . . . . . . . . 40
3.6 Statistical analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40
III RESULTS AND DISCUSSION 41
4 Asymmetric supported lipid bilayer formation via methyl-b-cyclodextrin
mediated lipid exchange 43
4.1 The upper leaflet of DOPC SLBs can be enriched with SM to form asymmetric
bilayers. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45
4.2 Leaflet asymmetry is stable for several hours . . . . . . . . . . . . . . . . . . 47
CONTENTS ix
4.3 The asymmetry in a SLB can also be generated in the presence of a reconsti-
tuted membrane protein . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49
4.4 SM in the lower leaflet of an aSLB is required for phase separation in both
leaflets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52
5 Shape transformations of asymmetric giant unilamellar vesicles 61
5.1 Bulging of intramembrane asymmetric domains in GUVs . . . . . . . . . . . . 62
5.2 Shape transformations in GUVs asymmetrically enriched with PG . . . . . . 64
5.3 FRAP assay for vesicle fission . . . . . . . . . . . . . . . . . . . . . . . . . . . 67
6 Lateral organization of the influenza virus hemagglutinin transmembrane
helix into asymmetric model membranes 73
6.1 Line-scan FCS can probe lipid dynamics independently in each SLB leaflet . 75
6.2 Partitioning of influenza HA into symmetric and asymmetric domains in SLBs 75
6.3 Partitioning of influenza HA into symmetric and asymmetric domains in GUVs 77
6.3.1 Both WT and GS520AA mutant HA TM peptides partition into the
Ld domains of symmetric GUVs . . . . . . . . . . . . . . . . . . . . . 77
6.3.2 Both WT and GS520AA mutant HA TM peptides partition into the
Ld domains of asymmetric GUVs . . . . . . . . . . . . . . . . . . . . . 78
6.3.3 The WT HA TM peptide induce phase separation in symmetric and
asymmetric GUVs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 79
6.4 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 79
7 Quantification of protein partitiong into giant unilamellar vesicles by fluo-
rescence correlation spectroscopy and confocal imaging 83
7.1 Theory . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 84
7.1.1 Measurement of KP by fluorescence correlation spectroscopy in GUVs 86
7.1.2 Measurement of KP by fluorescence confocal imaging in GUVs . . . . 88
7.1.3 Measurement of KP by fluorescence correlation spectroscopy in LUVs 88
7.2 GUV-FCS assay . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 89
7.3 GUV-imaging assay . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 92
7.4 LUV-FCS assay . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 93
7.5 Comparison of methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 95
8 Reconstitution of a functional LGL/aPKC membrane binding switch 99
8.1 LGL-1 directly binds membranes containing negatively charged lipids via a
stretch of basic amino acids . . . . . . . . . . . . . . . . . . . . . . . . . . . . 101
8.1.1 The position of the basic amino acids modulate LGL-1 membrane bind-
ing specificity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 102
8.1.2 LGL-1 binds preferentially PIP2-containing membranes . . . . . . . . 102
8.1.3 LGL-1 MTS fold into an a-helix upon binding to negatively charged
membranes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 106
8.2 Phosphorylation by aPCK abolishes the binding of LGL-1 to negatively charged
membranes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 106
8.2.1 Phosphomimetic LGL-1 does not bind GUVs containing negative-charged
lipids . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 107
8.2.2 LGL-1 can be phosphorylated in vitro by the human PKC-z . . . . . . 107
x CONTENTS
8.2.3 Phosphorylation of LGL-1 inside GUVs induce its detachment from the
vesicle membrane . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 108
8.3 Determination of the LGL-1 partitioning coe cient to negatively charged mem-
branes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 110
8.3.1 KP can be determined from images of GUVs encapsulating LGL-1 . . 110
8.3.2 LGL-1 KP determined with a LUV-FCS based method . . . . . . . . 115
IV CONCLUSION AND OUTLOOK 117
9 Conclusion and Outlook 119
9.1 Pure lipid systems . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 119
9.1.1 Reconstitution of lipid transbilayer asymmetry in model membranes . 119
9.1.2 Reconstitution of lipid lateral segregation in model membranes . . . . 120
9.1.3 Using lipid transbilayer asymmetry to induce shape transformations of
GUVs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 120
9.2 Lipid-protein systems . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 121
9.2.1 Lipid transbilayer asymmetry is not su cient to restore the correct lat-
eral organization of the influenza virus HA TM helix in model membranes121
9.2.2 Direct quantification of protein-lipid interactions in GUVs . . . . . . . 121
9.2.3 Reconstitution of a functional LGL/aPKC membrane binding switch . 122
Acronyms 125
References 143
Acknowledgement 145
Curriculum Vitae 147
List of Figures
1.1 Membrane transbilayer and lateral asymmetry . . . . . . . . . . . . . . . . . 4
1.2 Examples of cell polarity in model cells and organisms . . . . . . . . . . . . . 5
1.3 Sorting of polarity determinants within a cell . . . . . . . . . . . . . . . . . . 7
1.4 Categorization of the synthetic biology approaches . . . . . . . . . . . . . . . 8
1.5 Reconstitution of minimal actin comet tails . . . . . . . . . . . . . . . . . . . 9
1.6 Liposomes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10
1.7 Supported lipid bilayers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11
1.8 Lipid lateral organization in model membranes . . . . . . . . . . . . . . . . . 12
1.9 Principle of fluorescence correlation spectroscopy . . . . . . . . . . . . . . . . 13
1.10 Characterization of lipid bilayers and lipid-protein interactions with FCS . . . 15
1.11 Experimental approaches to reconstitute unmixing and polarization events in
model membranes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16
1.12 PAR-6/PKC-3/LGL-1 mutual elimination model . . . . . . . . . . . . . . . . 17
2.1 PLAP reconstitution via direct incorporation. . . . . . . . . . . . . . . . . . . 28
3.1 FRAP ROI . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34
3.2 Point-FCS on lower and upper leaflets. . . . . . . . . . . . . . . . . . . . . . . 35
3.3 GUV image analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38
3.4 Determination of Lo partitioning coe cients in GUVs . . . . . . . . . . . . . 39
4.1 aSLB leaflet-specific labeling . . . . . . . . . . . . . . . . . . . . . . . . . . . 44
4.2 SLB integrity upon MbCD-SM treatment. . . . . . . . . . . . . . . . . . . . . 46
4.3 aSLB formation via MbCD-mediated lipid exchange method . . . . . . . . . . 47
4.4 SLB fluidity in presence of bSM . . . . . . . . . . . . . . . . . . . . . . . . . . 48
4.5 SLBs treated with MbCD-DOPC . . . . . . . . . . . . . . . . . . . . . . . . . 49
4.6 aSLB stability over time . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 50
4.7 aSLB formation in the presence of reconstituted PLAP . . . . . . . . . . . . . 51
4.8 Phase separation in symmetric SLB after cholesterol addition. . . . . . . . . . 53
4.9 Cholesterol incorporation in aSLBs . . . . . . . . . . . . . . . . . . . . . . . . 54
4.10 Phase separation in scrambled, fully and partially asymmetric SLBs after
cholesterol addition . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55
4.11 Phase separation dynamics in aSLBs . . . . . . . . . . . . . . . . . . . . . . . 56
4.12 Phase separation and coupling in symmetric, scrambled, fully and partially
asymmetric GUVs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 58
5.1 HPaCD-mediated asymmetric domain induction in GUVs . . . . . . . . . . . 63
xii LIST OF FIGURES
5.2 Bulging of intramembrane asymmetric Lo domains in GUVs . . . . . . . . . . 64
5.3 GUV transformation: prolate ellipsoid to spherical vesicle . . . . . . . . . . . 65
5.4 GUV transformation: discocyte to stomatocyte . . . . . . . . . . . . . . . . . 65
5.5 GUV transformation: vesicle budding . . . . . . . . . . . . . . . . . . . . . . 66
5.6 GUV transformation: endocytosis . . . . . . . . . . . . . . . . . . . . . . . . . 66
5.7 Imaging of adjacent GUVs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 68
5.8 FRAP assay for vesicle fission . . . . . . . . . . . . . . . . . . . . . . . . . . . 69
5.9 Budding of intramembrane domains after hyperosmotic shock . . . . . . . . . 69
5.10 FRAP measurements of budded intramembrane domains after hyperosmotic
shock . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 70
6.1 Partitioning of the HA TM peptide in SLBs containing symmetric and asym-
metric domains . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 74
6.2 Line-scan FCS on SLBs containing asymmetric domains . . . . . . . . . . . . 76
6.3 Line-scan FCS on SLBs and GUVs containing the HA WT peptide . . . . . . 77
6.4 Partitioning of the HA TM WT and GS520AA peptides into the symmetric
domains of GUVs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 78
6.5 Partitioning of the HA TM WT and GS520AA peptides into the asymmetric
domains of GUVs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 79
6.6 The WT HA TM peptide induces phase separation in symmetric GUVs . . . 80
6.7 The WT HA TM peptide induces phase separation in asymmetric GUVs . . . 81
7.1 GUV- and LUV-based methods to measure protein-lipid a nity . . . . . . . . 85
7.2 Membrane volume and surface concentrations of proteins with di↵erent mem-
brane a nities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 86
7.3 Protein concentrations determined by GUV-FCS assay . . . . . . . . . . . . . 90
7.4 KP and Kd determined by GUV assay . . . . . . . . . . . . . . . . . . . . . . 92
7.5 Di↵usion coe cients determined by GUV-FCS assay . . . . . . . . . . . . . . 93
7.6 Calibration curve for GUV-image analysis . . . . . . . . . . . . . . . . . . . . 94
7.7 LUV-FCS assay . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 95
8.1 BH-search identified a putative membrane binding region in LGL-1 . . . . . . 101
8.2 LGL-1 binds GUVs containing negative-charged lipids . . . . . . . . . . . . . 103
8.3 LGL-1-AAAA binds bPI(4,5)P2-containing membranes less than LGL-1-WT 104
8.4 LGL-1 MTS binds preferentially PIP2-containing membranes . . . . . . . . . 105
8.5 LGL-1 MTS fold into an a-helix upon binding to negatively charged membranes107
8.6 LGL-1 MTS a-helix content . . . . . . . . . . . . . . . . . . . . . . . . . . . . 108
8.7 The phosphomimetic LGL-1 EEE mutant does not bind GUVs containing
negative-charged lipids . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 109
8.8 LGL-1 can be phosphorylated in vitro by the human PKC-z . . . . . . . . . . 110
8.9 Phosphorylated LGL-1 MTS does not bind GUVs containing negative-charged
lipids . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 111
8.10 In situ LGL-1 phosphorylation inside a GUV . . . . . . . . . . . . . . . . . . 112
8.11 LGL-1 bound to the membrane is protected from the action of PKC-z . . . . 112
8.12 LGL-1 MTS encapsulated in GUVs via droplet transfer method . . . . . . . . 113
8.13 LGL-1 MTS encapsulation variability . . . . . . . . . . . . . . . . . . . . . . 113
8.14 Determination of the LGL-1 MTS partitioning coe cient in GUVs . . . . . . 114
LIST OF FIGURES xiii
8.15 Determination of the LGL-1 MTS partitioning coe cient with the LUV-FCS
method . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 116
9.1 Secondary structure of the LGL-1 MTSWT and AAAA peptide at the membrane123

List of Tables
3.1 Line-scan FCS parameters . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37
6.1 Di↵usion and Lo partitioning coe cients of fluorescent lipids in each leaflet of
asymmetric SLBs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 75
6.2 Lo partitioning coe cients of HA TM peptides in symmetric and asymmetric
SLBs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 76
6.3 Comparison of Lo partitioning coe cients . . . . . . . . . . . . . . . . . . . . 78
7.1 Comparison of KP s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 91
7.2 Kd determined by GUV-FCS assay . . . . . . . . . . . . . . . . . . . . . . . . 91
7.3 Comparison of methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 96
8.1 Particle Size and polydispersity index values . . . . . . . . . . . . . . . . . . . 104
8.2 LGL-1 MTS KP and KB values . . . . . . . . . . . . . . . . . . . . . . . . . . 114

List of Publications
The results presented in this work have, in part, been communicated before in the following
articles:
Visco, I.; Chiantia, S.; Schwille, P. Asymmetric Supported Lipid Bilayer Formation via
Methyl-B-Cyclodextrin Mediated Lipid Exchange: Influence of Asymmetry on Lipid Dynam-
ics and Phase Behavior. Langmuir 2014, 30, 7475-7484.
Thomas, F.;Visco, I.; Petrasek Z.; Heinemann, F.; Schwille, P. Introducing a Fluorescence-
based Standard to Quantify Protein Partitioning into Membranes. Biochim. Biophys. Acta,
Biomembr., submitted.

Abstract
Polarity is a fundamental feature of almost all cells. It generally refers to the asymmetric or-
ganization of several cellular components. The plasma membrane, for example, exhibits both
a transbilayer and a lateral asymmetry in most eukaryotic cells. Lipids are asymmetrically
distributed between the cytoplasmic and the extracellular leaflet of the membrane and seg-
regate laterally together with specific proteins to form dynamic nanoscale assemblies, known
as rafts. Polarity can also specifically describe the asymmetric distribution of key molecules
within a cell. These molecules, known as polarity determinants, can orient a multitude of
specialized cellular functions, such as cell shape, cell division and fate determination.
In the framework of this thesis, we aimed to reconstitute essential features of membrane
unmixing and cell polarity with a “bottom-up” synthetic biology approach. We worked with
both: pure lipid systems, whose unmixing is driven by the asymmetric distribution of lipids
in the two leaflets, and a lipid-protein system, whose polarization is instead due to reaction-
di↵usion mechanisms. In both cases, we used Giant Unilamellar Vesicles (GUVs) and Sup-
ported Lipid Bilayers (SLBs) to model biological membranes and employed modern biophys-
ical techniques, such as fluorescence correlation spectroscopy, to quantitatively characterize
lipid bilayers and protein-lipid interactions.
In the pure lipid systems, we first reconstituted membrane transbilayer asymmetry, ap-
plying a cyclodextrin-mediated lipid exchange method, which enables us to enrich membranes
with lipids of choice. The enrichment of the membrane with sphingomyelin and/or choles-
terol triggers the segregation of lipids into two coexisting asymmetric phases both in SLBs and
GUVs, whereas exchanging di↵erent amounts of phosphatidylglycerol with the outer leaflet
of the GUV membranes controls vesicle shape. Tuning the lipid content of model membranes
revealed that small changes in the composition of one leaflet a↵ect the overall lipid miscibility
of the bilayer and that membrane shape transformations are possible also in absence of a
protein machinery and as a consequence of the lipid redistribution in the membrane.
In the protein-lipid system, we aimed to reconstitute a minimal polarization system in-
spired by the C. elegans embryo at one-cell stage, which polarize along the anterior-posterior
axis by sorting the PARtitioning defective (PAR) proteins into two distinct cortical domains.
In this system polarity is maintained by the mutual inhibition between anterior (aPARs:
PAR-3, PAR-6 and PKC-3) and posterior (pPARs: PAR-1, PAR-2 and LGL-1) PARs, which
reciprocally antagonize their binding to the cortex, mutually excluding each other. We focused
on LGL-1, which acts directly on PAR-6. Submitting LGL-1 to model membranes allowed us
to identify a conserved region of the protein that binds negatively-charged membranes and
to determine its lipid binding a nity and specificity. Selected LGL-1 mutants were then gen-
erated to better understand the electrostatic mechanism involved in the membrane binding.
LGL-1 was finally combined with PKC-3 to generate a functional membrane binding switch.

Zusammenfassung
Polarita¨t ist eine Grundeigenschaft fast aller Zellen und bezeichnet die asymmetrische Organ-
isation verschiedener zellula¨rer Bestandteile. Zum Beispiel besitzt die Zellmembran bei den
meisten eukaryotischen Zellen sowohl eine Asymmetrie zwischen als auch innerhalb der Lipid-
schichten. Das heißt, Lipide sind asymmetrisch in der zytoplasmatischen und der extrazel-
lula¨ren Lipidschicht der Membran verteilt und bilden zusammen mit spezifischen Proteinen
auf lateraler Ebene dynamisch-geordnete Nanostrukturen, sogenannte Lipid Rafts.
Polarita¨t kann zudem die asymmetrische Verteilung bestimmter Schlu¨sselmoleku¨le inner-
halb einer Zelle beschreiben. Diese als Polarita¨tsdeterminanten bekannten Moleku¨le bedin-
gen eine Vielfalt spezieller Zellfunktionen so wie z.B. Zellform, Zellteilung und Zellschicksal.
Diese Arbeit versucht wesentliche Eigenschaften von Zell- und Membranpolarita¨t mit Hilfe
des sogenannten “Bottom-up”-Ansatzes (“von unten nach oben”) der synthetischen Biolo-
gie nachzubilden. Es wurden zwei Systeme etabliert, um Polarisation mit Minimalsyste-
men zu reproduzieren. Zum einen reine Lipidsysteme, deren Polarisation durch die asym-
metrische Verteilung von Lipiden in den zwei Lipidschichten entsteht, zum anderen Lipid-
Proteinsysteme, deren Polarisation sich stattdessen aus Reaktions-Di↵usions Mechanismen
herleitet. In beiden Fa¨llen wurden Riesenvesikel (GUVs) sowie gestu¨tzte Lipiddoppelschichten
(SLBs) fu¨r die Modellierung biologischer Membranen verwendet und moderne biophysikalische
Techniken, wie die Fluoreszenz-Korrelations-Spektroskopie, fu¨r eine quantitative Charakter-
isierung von Lipiddoppelschichten und Protein-Lipid Interaktionen angewendet.
Um die Asymmetrie der Membrandoppelschicht in reinen Lipidsystemen zu rekonstru-
ieren, wurde eine Anreicherung einer der Lipidschichten der Membran mit den gewu¨nschten
Lipiden durch Anwendung eines mit Cyclodextrin kontrollierten Lipidaustauschprotokolls
vorgenommen. Die Anreicherung der Membran mit Sphingomyelin und/oder Cholesterol
induzierte die Aufteilung der Lipide in zwei koexistierende, asymmetrische Phasen sowohl in
SLBs als auch GUVs. Die Vesikelform hingegen wurde durch den Austausch verschiedener
Mengen Phosphatdylglycerol in der a¨usseren Lipidschicht der GUV-Membranen vera¨ndert.
Eine Anpassung des Lipidgehaltes von Membranen im Modellsystem zeigte, dass kleine
A¨nderungen in der Zusammensetzung einer Lipidschicht die Mischbarkeit der Lipide der Dop-
pelschicht beeinflusst und dass Formvera¨nderungen der Membran, selbst in Abwesenheit eines
Proteingeru¨stes, als Konsequenz einer Lipidumverteilung in der Membran mo¨glich sind.
Im Protein-Lipid System wurde die Nachbildung eines Minimalpolarisationssystems
angestrebt, wie man es beim C. elegans Embryo im Einzellstadium beobachten kann. Dieser
wird durch Anordnung der PARtitioning defective (PAR) Proteine in zwei unterschiedliche
kortikale Bereiche entlang der Vorder-Hinterachse polarisiert. In dem PAR-System wird die
Polarita¨t durch gegenseitige Inhibition der vorderen (aPARs: PAR-3, PAR-6 und PKC-3) und
hinteren (pPARs: PAR-1, PAR-2 und LGL-1) PAR-Proteine aufrechterhalten. Diese hem-
men die gegenseitige Bindung an den Kortex. Da LGL-1 direkt auf PAR-6 einwirkt, wurde es
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als potentielles Schu¨sselmoleku¨l der Zellpolarization in ku¨nstlichen Membranen rekonstruiert.
Durch Rekonstruktion von LGL-1 in Membranmodellen konnte die konservierte Region des
Proteins, die mit negativ geladenen Membranen interagiert, sowie dessen Bindungsa nita¨t
und -Spezifita¨t gegenu¨ber Lipiden quantitativ gemessen werden. Darauf folgend wurden LGL-
1 Mutationen hergestellt, um die bei der Membranbindung auftretenden elektrostatischen
Mechanismen besser zu verstehen. Zuletzt wurden LGL-1 und PKC-3 kombiniert, um die
Membranbindung von LGL-1 reproduzierbar zu inhibieren.
Part I
INTRODUCTION

Chapter 1
Introduction
1.1 Relevance of polarity for living systems
Polarity is a fundamental feature of almost all cells [1], it generally refers to the asymmetric
spatial organization of several cellular components, including cytoskeleton, cellular organelles,
and plasma membrane [2]. The plasma membrane, for example, exhibits both a transbilayer
and a lateral asymmetry in most eukaryotic cells. Lipids are asymmetrically distributed be-
tween the cytoplasmic and the extracellular leaflet of the membrane (Figure 1.1, A), with Sph-
ingoMyelin (SM) being enriched in the extracellular leaflet and PhosphatidylEthanolamine
(PE) and PhosphatidylSerine (PS) in the cytoplasmic one. In cells transbilayer asymmetry
results from the movement of selected lipids across the bilayer. At least three mechanisms
to exchange lipids between leaflets are known: (1) spontaneous lipid transbilayer movement,
whose rate is determined by the biophysical properties of both the lipid and the membrane; (2)
ATP-independent protein-mediated transbilayer movement, which can be lipid selective, but
cannot move lipids against gradient. (3) ATP-dependent protein-mediated lipid translocation,
which is lipid-selective and can move lipids against gradient upon ATP hydrolysis [3]. At the
same time, lipids segregate laterally in the membrane and form dynamic nanoscale assemblies
together with specific proteins (Figure 1.1, B). Those assemblies, also known as rafts, are rich
in sterols and sphingolipids and are responsible for membrane subcompartmentalization and
functions such as tra cking, endocytosis and signaling [4].
Polarity can also specifically describes the asymmetric distribution of key molecules within
the cell [5]. These molecules, known as polarity determinants or regulators, are essential
for polarity and can orient a multitude of specialized cellular functions, such as cell shape,
cell adhesion and migration, the uptake and release of molecules, and cell division and fate
determination [1]. Examples of model cells and organisms to study polarity are:
Epithelial cells show an apical-basal polarization pattern with four distinct cortical do-
mains: the apical domain, the Tight Junction (TJ), the Adherens Junction (AJ), and
the basolateral domain (Figure 1.2, A). This polarized organization allows epithelial
cells to arrange in sheets, which function as barriers between compartments and to
regulate the transport of molecules between them [6].
Motile cells assume an elongated morphology (Figure 1.2, B) and relocate selected proteins
or restrict their activities either to the leading or lagging edge [7]. This polarized
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Figure 1.1 – Membrane transbilayer and lateral asymmetry. [A] SM is enriched in the extracellular
leaflet, whereas PE and PS in the cytoplasmic leaflet. [B] Lipids segregate laterally in the membrane
and form dynamic nanoscale assemblies rich in sterols and sphingolipids known as rafts.
distribution allows motile cells to generate a distinct front and back and thus to move
in one direction [5].
Neurons polarize by forming a single axon and multiple dendrites [8], which are radically
di↵erent in morphology, signaling properties, cytoskeletal organization, and physiolog-
ical function [9] (Figure 1.2, C). This polarization provides neurons with specialized
domains for either receiving (dendrites) or transmitting (axons) cellular signals, thus
allowing neural activities [9].
The budding yeast Saccharomyces cerevisiae breaks symmetry to switch from isotropic
growth to growth along a polarized axis in order to enter the mitotic cell cycle and
grow a bud or to form a mating projection (shmoo) toward a cell of the opposite mating
type [10] (Figure 1.2, D).
The soil nematode Caenorhabditis elegans at one-cell stage polarizes along the anterior-
posterior axis by sorting polarity determinants, the PARtitioning defective (PAR) pro-
teins, into distinct cortical domains [11] (Figure 1.2, E). The posterior PARs (pPARs)
(pPARs: PAR-1, PAR-2 and LGL-1) localize to the posterior pole where the fertilizing
spermatozoan entered the oocyte [12, 13, 14, 15], whereas the anterior PARs (aPARs)
(aPARs: PAR-3, PAR-6 and PKC-3) localize to the opposite anterior pole [16, 17, 18].
This polarized distribution allows the C. elegans embryo to undergo asymmetric cell
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division, thus generating two daughter cells that inherit distinct molecular components
and, ultimately, distinct fates [5].
Bud
or
shmoo (mating)
Nucleus
Cell body motility
Trailing edge Leading edge
A
B
C
D
E
Figure 1.2 – Examples of cell polarity in model cells and organisms: [A] epithelial cells (adapted
from Coradini and colleagues [19]), [B] a motile cell (adapted from Cramer [20]), [C] a neuron
(adapted from http://www.med.nagoya-u.ac.jp/Yakuri/projects_e/projects_e03.htm), [D] the
budding yeast S. cerevisiae (adapted from Mogilner and colleagues [21]), and [E] the C. elegans
embryo at one-cell stage (adapted from Seydoux [22]).
The importance of polarity for living systems is emphasized by the close connection be-
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tween its loss and tumor formation and development [23, 24, 25]. The first tumor suppressor
gene discovered and described in the modern scientific literature was in fact a polarity reg-
ulator, the Drosophila Lethal (2) Giant Larvae (LGL). Loss of LGL causes massive tissue
disorganization, tumor-like growth and lethal phenotypes in several organisms. At the cel-
lular level it leads to disruption of cell polarity, failure of asymmetric cell division, and thus
loss of proper cell fate determination [26].
Tracing back the discoveries that led to the current understanding of polarity, one realizes
that multiple research approaches were necessary and contributed synergically to unravel
the cell biological roles and working mechanisms of polarity determinants. The polarity
determinants of the C. elegnas embryo, for example, were discovered by genetic analysis, which
also provided first indications about their corresponding protein functions. Following gene
cloning and sequence analyses provided details about protein domains whereas cell biology
approaches and biochemical investigations shedded light on both protein cell localization and
interactions [27]. At the same time, models characterized by di↵erent levels of biological detail
and mathematical complexity were developed and started to play an increasingly important
role in the discovery of polarity mechanisms [21]. In particular the combination of computer
modeling and experimental testing, the so called experiment-theory feedback loop appears to
be an extremely powerful tool.
Besides individual di↵erences of each system, the distribution of polarity determinants
could be mathematically described with reaction-di↵usion models. In a reaction-di↵usion
system, pattern formation arises by the interaction of two components with di↵erent di↵usion
rates [28]: a slowly di↵using“activator” and a rapidly di↵using“inhibitor”. Gierer and Mein-
hardt specified that pattern formation is possible only if a locally restricted self-enhancing
reaction is coupled with a long-ranging antagonistic reaction [29]. In these conditions a ho-
mogeneous distribution of the two components is unstable and any random fluctuation can
initiate pattern formation. There are di↵erent conceivable ways to satisfy these general re-
quirements for pattern formation within a cell [30]: the self-enhancing reaction can take place
at the membrane in the form of a cooperative binding of one component to the membrane or
of a mutual exclusion of the two components from the membrane; the antagonistic reaction
on the other hand must spread more rapidly within the cytoplasm in the form of a depletion
of or an equilibrium with the unbound molecules (Figure 1.3, A-B).
Recently, a synthetic biology approach was presented as an alternative and complementary
strategy to investigate polarity. Chau and colleagues engineered an artificial polarization
circuit that produces phosphatidylinositol (3,4,5)-trisphosphate poles when expressed in yeast,
demonstrating that it is possible to design a polarizing system from scratch and that synthetic
biology could potentially reveal the design principles of polarity [5].
1.2 Bottom-up synthetic biology: a viable approach to under-
stand polarity
Reconstituting essential features of polarity with a minimal set of physically controllable
molecules represents a parallel and viable approach to understand polarity. This strategy,
also known as “bottom-up”, belongs to the large and heterogeneous field of synthetic biology,
whose di↵erent streams were attemptively categorized in five interconnected branches [31,
32]: bio-engineering, synthetic genomics, unnatural molecular biology, protocell, and in silico
(Figure 1.5).
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A
B
Figure 1.3 – Sorting of polarity determinants within a cell. [A] Simulations showed that two
polarity determinants (red and green) can sort into distinct cortical domains within a cell. [B] In this
model, both molecules are assumed to aggregate at the membrane, but their aggregation is mutually
exclusive (locally restricted self-enhancing reaction). At the same time, any aggregation at the
membrane reduces the number of monomers dispersed in the cytoplasm (long-ranging antagonistic
reaction) (adapted from Meinhardt [30]).
Bio-engineering, synthetic genomics and unnatural molecular biology work all at the ge-
netic level, either to integrate designed genetic circuits in a cell [33], to replace the natural
genome with a minimal chemically-synthesized one [34], or to develop new types of nucleic
acid and genetic codes [35]. On the other hand, the protocell branch of synthetic biology aims
to construct a synthetic cell that shows the minimal and su cient structural conditions for
life [36], either incorporating a minimal and su cient amount of existing macromolecules into
liposomes (protocell “top down” approach), or building more and more complex biological
structures from very simple molecules with prebiotic reactions. The interest of in silico syn-
thetic biology, instead, crosses all other branches, providing them with computational models,
e.g. for the design of standard biological components or synthetic circuits [31].
Although the “bottom-up” approach could be assimilated to the protocell “top down”
approach and shares with it the common ultimate goal of designing a minimal cell [37, 38],
the originating scientific disciplines as well as the techniques and strategies used to achieve
this goal di↵er significantly. “Bottom-up” synthetic biology originates from biophysics and
quantitative biology, from which it inherited the reductionist and quantitative nature, and
aims to understand a biological system identifying the smallest functional unit that repro-
duce the essential features of the system, and at the same time can also be quantitatively
understood and technically mastered [37]. Several biological functions, such as cytokeletal
rearrangements, protein-driven membrane transformations, and circadian oscillations were
already successfully reconstituted in in vitro systems of reduced complexity [37]. Among
those systems, the reconstitution of actin comet tails (Figure 1.5) perfectly exemplifies the
“bottom-up” synthetic biology approach and demonstrates that it is indeed possible to re-
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Figure 1.4 – Categorization of the synthetic biology approaches. Synthetic biology comprises five
interconnected branches: bio-engineering, synthetic genomics, unnatural molecular biology, bottom-
up/protocell, and in silico (adapted from Deplazes [31]).
constitute polarization events with a small and well-characterized sets of molecules, and by
doing this to learn more about the fundamental requirements of the system.
Actin comet tails are cylindrical structures made of a large number of short actin fila-
ments cross-linked together in a dendritic meshwork [43]; they are formed by several intra-
cytoplasmic pathogens (e.g. Listeria monocytogenes, Shigella flexneri, and Rickettsia spp.)
to move rapidly through the host cell. This network of cross-linked actin filaments can be
stripped down to five key components: (1) actin, (2) Actin-Related-Protein 2 and 3 com-
plex (Arp2/3), which nucleates branched actin networks, (2) a Nucleation Promoting Fac-
tor (NPF), such as the Wiskott-Aldrich Syndrome protein (WASp) or the Actin assembly-
inducing protein (ActA), which recruits and activates Arp2/3, (4) an Actin Depolymerizing
Factor (ADF)/Cofilin, which disassembles actin filaments, and (5) a capping protein, which
prevents the further growth of actin filaments by capping their barbed ends [44, 42]. When
NPFs are bound to the surface of bacteria (Figure 1.5, A) [39], immobilized on plastic beads
(Figure 1.5, B) [40] or anchored on phospholipids vesicles (Figure 1.5, C) [41, 45], in presence
of the other four components, the actin filaments polymerize allover their surface forming
a homogeneous cloud. The actin-coated particles do not move at first, the actin cloud gets
eventually polarized resulting in a directed movement of the particle (Figure 1.6, D). This
symmetry breaking in the polymerization of the actin filaments is thought to be a consequence
of the stochastic variation in actin filament polymerization and crosslinking dynamics in the
cloud surrounding the particle. Random local fluctuations in filament density and crosslink-
ing are in fact self-reinforced and can lead to the symmetrically coated particle being forced
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out of the cloud and initiating a comet tail formation [43]. The reconstitution of minimal
actin comet tails allowed to individually probe each system component, such as actin regula-
tors [46], protein surface density [40], particle size [43] and shape [47], revealing their specific
role and interplay with other components. Additionally, this approach helped to clarify the
general mechanism of actin-based motility [44] and to quantitatively describe its fundamental
parameters, i.e., the forces arising from actin polymerization [41, 45].
Nucleation Promoting Factor (NPF) 
actin network
D
A B C
Figure 1.5 – Reconstitution of minimal actin comet tails. Actin comet tails can be reconstituted
anchoring NPFs: [A] on the surface of bacteria (adapted from Loisel and colleagues [39]), [B] on
plastic beads (adapted from Bernheim-Groswasser and colleagues [40]) or [C] on phospholipids vesi-
cles (adapted from Upadhyaya and colleagues [41]). [D] Actin-coated particles do not move at first,
the actin network gets eventually polarized resulting in a directed movement of the particle (adapted
from Loose and Schwille [42]).
1.3 GUVs and SLBs as model membranes to reconstitute po-
larization events
In order to reconstitute minimal actin comet tails, NPFs needed to be localized on a spherical
object that mimic the bacterial surface. ActA, which acts as a NPF in L. monocytogenes, is in
fact localized on the bacterial surface. Moreover, ActA is not homogeneously distributed, but
it is rather polarized and its density is higher at the site of the comet tail [43]. Similar to ActA,
most other polarity determinants localize to specific domains of the plasma membrane where
they polarize the action of other cellular systems [1]. Therefore any attempt to reconstitute
polarization events with a “bottom-up” synthetic biology approach cannot prescind from
using model systems for phospholipid membranes that resemble their biological counterparts.
Phospholipid model membranes can be either free-standing or supported on a solid surface.
Liposomes are an example of free-standing membranes. They are vesicles whose lumina are
enclosed by a lipid bilayer made of phospholipids, and they are usually categorized according
to their size, lamellarity and production strategy in four main groups (Figure 1.7):
MLVs are large (hundreds of nanometers to several microns), their walls are made of mul-
tiple concentric layers of lipid bilayer which confer them the characteristic “onion-like”
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Figure 1.6 – Liposomes. Liposomes with di↵erent sizes and lamellarity can be generated with
distinct methods: Small Unilamellar Vesicless (SUVs), Large Unilamellar Vesicles (LUVs), Multi-
Lamellar Vesicless (MLVs) and Giant Unilamellar Vesicles (GUVs). Liposomes are not drawn to
scale.
structure, and they form when phospholipids dried in sheets are hydrated. MLVs are
the starting point for the production of small and large unilamellar vesicles.
SUVs are small (few nanometers), their walls are made of a single lipid bilayer and are
usually prepared from MLVs by sonication using a cuphorn, bath, or probe tip sonicator.
SUVs are unstable and fuse spontaneously at temperatures below the phase transition
of the lipid forming the vesicle [48], which makes them ideal to prepare supported
membranes. Their small size helps minimizing unwanted light scattering in circular
dichroism measurements.
LUVs are large (hundreds of nanometers), their walls are made of a single lipid bilayer
and can be prepared by a variety of methods including extrusion of MLVs, detergent
dialysis, fusion of SUVs, reverse evaporation, and ethanol injection. Alike SUVs, LUVs
are stable few days on storage [48] and can be produced within a very narrow diameter
range.
GUVs are giant (few to hundreds of microns), their walls are made of a single lipid bilayer
and can be formed in several ways [49] including electroformation [50] and inverted
emulsion [51, 52, 53]. Their giant size made those vesicles extremely appealing for
scientists: they are, in fact, in the range of most biological cells, they can easily be
investigated by optical microscopy, and their membranes are almost flat with vanishing
curvature.
Supported Lipid Bilayers (SLBs) are, on the other hand, a supported membrane model
system. They consist of a lipid bilayer made of phospholipids adsorbed on the surface of a
solid substrate, such as glass or mica, and they can also be produced using di↵erent strategies
(Figure 1.8), which confer them specific characteristics and experimental advantages [54]:
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Figure 1.7 – Supported lipid bilayers. SLB can be prepared by a variety of methods which con-
fer them specific characteristics and experimental advantages: Langmuir-Blodgett (LB), Langmuir-
Schae↵er (LS), Vesicle Fusion (VF) and hybrid LB/VF or LS/VF bilayers. Adapted from Sanderson
[54].
LB and LS bilayers are assembled, transferring each preformed monolayer from an air/water
interface to the support in two subsequent steps [55]. These methods allow to control
the lateral pressure and the lipid composition of each leaflet [56].
VF bilayers are formed, exposing an hydrophilic support to SUVs, which adsorb to it,
eventually rupturing and spreading into a planar membrane [57]. This method is usually
preferred to any other because of its simplicity and protein compatibility. However, it
did not traditionally allow to control the lipid composition of each leaflet [58] - a feature
that we implemented as described in details in Chapter 4.
Hybrid LB/VF and LS/VF bilayers are produced fusing vesicles onto an existing mono-
layer. This method combined some of the advantages of the original methods.
Independently from the used method, the bilayer is not in direct contact with the support:
a thin layer of water (10-20 A˚) separates the absorbed bilayer from the solid support [59].
This water layer makes possible that the lipids in the leaflet close to the support (lower leaflet)
are kept mobile; their lateral mobility, in fact, does not di↵er significantly from the upper
leaflets’ one [60]. Nevertheless, the support influences the bilayer, e.g. slowing its overall lipid
mobility in comparison to free-standing membranes [61]. In order to minimize the e↵ect of
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the support on the bilayer, a polymer cushion can be introduced between the solid support
and the bilayer, providing a deeper water layer, which not only reduces the frictional drag
between bilayer and solid surface [62], but is also convenient when transmembrane proteins
with bulky cytosolic or extracellular domains need to be reconstituted in SLBs [63].
GUVs and SLBs have been a particularly successful tool to model biological membranes.
They can in fact be produced with almost any biologically relevant lipid composition and
therefore exhibit features similar to their biological counterparts. Lipid lateral organization,
for example, could be investigated in both membrane model systems using raft-mimicking
mixtures of saturated and unsaturated lipids mixed with Cholesterol (Chol). The lipids of
a raft-mimicking mixture segregate into two di↵erent liquid phases coexistent in the same
membrane: a Liquid disordered (Ld) phase rich in unsaturated lipids and a Liquid Ordered
(Lo) phase rich in saturated lipids and Chol (Figure 1.9, A-B). GUVs and SLBs allow to
thoroughly and quantitatively characterize the lipid dynamics and structure of each phase,
being fully compatible with modern biophysical techniques including Fluorescence Correlation
Spectroscopy (FCS) [64, 65].
A
B
Ld
Ld
Lo
Lo
Figure 1.8 – Lipid lateral organization in model membranes. Lipids of a raft-mimicking mixture
segregate in GUVs [A] and SLBs [B] into two di↵erent liquid phases: a Ld phase rich in unsaturated
lipids and a Lo phase rich in saturated lipids and Chol. Scale bars are 5 and 10 µm, respectevely
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1.4 Biophysical characterization of model membranes dynam-
ics and lipid-protein interactions
Introduced in 1972 by Magde and colleagues [66], FCS became a popular technique for the
investigation of dynamic processes, which take place in solution or at the membrane, and
is now commonly used to measure local fluorophore concentrations and translational and
rotational di↵usion coe cients [67, 68].
FCS is a single molecule technique based on the temporal autocorrelation analysis of the
signal fluctuations detected from fluorophores within a very small volume (⇠ fL). Such a small
detection volume can be provided by any Confocal Laser Scanning Microscope (CLSM) setup,
where the laser is focused to a di↵raction limited spot by the objective and where a pinhole in
the emission channel provides tight axial confinement (Figure 1.9, A). The fluorescence signal
in the detection volume can vary both because the fluorophores move into and out of the
detection volume, as a consequence of di↵usion or transport, and because of photophysical or
photochemical reactions, which cause fluctuations in the detected emission. This fluctuating
fluorescence signal is recorded as a fluorescence intensity trace (Figure 1.9, B) and analyzed
by calculating the autocorrelation curve (Figure 1.9, C), which measures the self-similarity of
the signal in time, relating the fluorescence signal with itself at di↵erent lag times.
w0
Sw0
D
Figure 1.9 – Principle of fluorescence correlation spectroscopy. [A] Typical FCS setup: fluorophores
in the detection volume are excited with an appropriate laser beam, emitted photons are collected by
the objective, spectrally filtered and detected with an Avalanche PhotoDiode (APD). Fluorescence
fluctuations are recorded as a fluorescence intensity trace [B] and correlated to yield an autocorre-
lation curve.[C]. The autocorrelation curve (black circles) is fitted to an appropriate model function
(solid line), thus determining the Di↵usion time (⌧D) and the number of particles N of the fluo-
rophore. [D] Three-dimensional Gaussian detection volume with radius w0 and aspect ratio S. In
order to transform N into concentration C and ⌧D into Di↵usion coe cient (D), w0 and S have to
be known. Adapted from Chiantia and colleagues [68].
The autocorrelation curve is calculated from the fluorescence intensity trace as follows:
G(⌧) =
h F (t)· F (t+⌧)i
hF (t)i2 (1.1)
Here G(⌧) is the autocorrelation function as a function of the lag time ⌧ , F is the fluorescence
intensity as a function of the time t or t + ⌧ , and the angular brackets 〈 〉 refer to the time
average, so that  F (t) = F (t)  hF (t)i.
The autocorrelation curve is then fitted to a mathematical function (Figure 1.9, C), which
best models the fluorescence fluctuations inside the detection volume, according to the char-
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acteristics of the system under investigation, e.g. single or multiple di↵using fluorophores
species. The model function should also account for fluorescence fluctuations which do not
originate from the di↵usion of the fluorophores in the detection volumes, e.g. from photo-
physical phenomena such as triplet transitions and fluorophore blinking. Most importantly,
the model function takes into account the size and shape of the detection volume, which is
approximated by a three-or a two-dimensional Gaussian profile for measurements in solution
and at the membrane, respectively (Figure 1.9, D). As an example the autocorrelation model
functions describing three- and two- dimensional Brownian di↵usion through these profile are:
G(⌧) =
1
N
(1 +
⌧
⌧D
) 1(1 +
⌧
S2⌧D
)1/2 (1.2)
G(⌧) =
1
N
(1 +
⌧
⌧D
) 1 (1.3)
Fitting the autocorrelation curve to the appropriate mathematical model function allows
to extract parameters of interest, such as the average number of particles N and the di↵usion
time of the fluorophore ⌧D. N is the average number of fluorophores in the detection volume
VFCS = ⇡2/3Sw30 (measurements in solution) or area AFCS = ⇡w
2
0 (measurements at the
membrane) and can be used to calculate the fluorophore concentrations C = N/VFCS or
C = N/AFCS . ⌧D is the decay time of the correlation curve and can be used to calculate the
fluorophore di↵usion coe cient D =
w20
4⌧D
. In order to transform N and ⌧D into C and D,
the radial dimension w0 and eventually the aspect ratio S of the Gaussian detection volume
have to be known (Figure 1.10, D). Those parameters are usually determined calibrating the
system with a dye of known D.
Standard FCS as well as several improved FCS variations have been used to investigate
the properties of lipid bilayers [69, 67, 68, 70] and di↵erent aspects of protein-lipid interactions
[71] both in GUVs and SLBs. In particular:
The lateral organization of lipids can be investigated measuring the D of lipids in model
membranes [64]. Lipids in di↵erent domains show distinct dynamics, i.e. lipids in Lo
domains di↵use slower than lipids in Ld domains due to the higher lipid order and
packing (Figure 1.10, A).
Protein partitioning into lipid domains can be assessed measuring local concentrations
of fluorescently labeled proteins in di↵erent domains of the membrane (Figure 1.10,
B). These studies provided new insights into how lipid environment regulates protein
localization [72, 73, 65].
Membrane binding a nity and specificity of peripheral proteins can be probed
measuring changes in the ⌧D of fast-di↵using proteins upon their binding to slowly dif-
fusing liposomes [74, 75, 76, 77, 78] (Figure 1.10, C). Measurement of membrane binding
a nities with FCS was only reported for LUVs. In order to determine membrane-protein
a nities in GUVs, we developed two complementary strategies to measure Partitioning
Coe cients (KP s), in which the ligand is either added to the external solution (Chapter
7) or encapsulated in GUVs (Chapter 8). These strategies combine the advantages of
both established separation and titration methods, that is they allow to directly mea-
sure the free and membrane bound ligand concentrations without the need of physically
separating them.
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Figure 1.10 – Characterization of lipid bilayers and lipid-protein interactions with FCS. Standard
FCS and its variations have been used to investigate the lateral organization of lipids in a membrane
[A], and di↵erent aspect of protein-lipid interactions, including: [B] protein partitioning into lipid
domains, [C] membrane binding a nity and specificity of peripheral proteins, [D] protein dimeriza-
tion in membranes, [E] e↵ect of protein binding on membrane structure and dynamics, and [F] e↵ect
of lipids on protein structure and function.
Protein-protein interactions and protein oligomerization in membranes can be de-
termined performing Fluorescence Cross-Correlation Spectroscopy (FCCS), a FCS vari-
ation that allows to quantify protein interactions and their regulation by lipids [79, 80,
81, 82] (Figure 1.10, D).
E↵ect of protein binding on membrane structure and dynamics can be addressed
measuring changes in the D of lipids upon protein binding to the membrane (Figure
1.10, E). These studies demonstrated that proteins can slow down the lateral di↵usion
of fluorescently labeled lipids not involved in the binding, i.e. inducing or expanding Lo
domains [83].
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E↵ect of lipids on protein structure and function can be studied combining FCS with
other techniques, e.g. electrophysiology, to quantitatively assess the e↵ect of lipid phase
separation on ion channel structure and function [84] (Figure 1.11, F).
1.5 Experimental approaches to reconstitute unmixing and
polarization events in model membranes
In order to reconstitute unmixing and polarization events in a minimal system, we worked
with pure lipid systems, whose unmixing is driven by the asymmetric distribution of lipids
in the two leaflets, and with a lipid-protein system, whose polarization is instead driven by a
reaction-di↵usion mechanism (Figure 1.11).
Lipid-Protein System
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Lipid System
Phase
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Shape
Transformation
Determinants
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Membrane
binding switches
Lipid
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Lipid Asymmetry
Figure 1.11 – Experimental approaches to reconstitute unmixing and polarization events in model
membranes. In pure lipid systems, lipid unmixing or vesicle shape transformations can be driven
by the asymmetric distribution of lipids in the two leaflets. In lipid-protein systems, polarization
is driven by a reaction-di↵usion mechanism. In particular two determinants can polarize if they
reciprocally antagonize their binding to the cortex. The opacified parts of the cartoon were not
achieved experimentally.
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In the lipid approach, we first reconstitute the transbilayer asymmetry of an eukaryotic
plasma membrane producing SLBs and GUVs with lipids asymmetrically distributed among
the two leaflets. To do so, we applied a so called cyclodextrin-mediated lipid exchange method
[85, 86], which allows to enrich membranes with lipids of choice in a controlled fashion. The
enrichment of the membrane with SM and/or Chol triggers the segregation of lipids into two
coexisting asymmetric phases both in SLBs and GUVs (Chapter 4 and 6), whereas exchanging
di↵erent amounts of PhosphatidylGlycerol (PG) with the outer leaflet of the GUV membranes
allows us to control vesicle shape (Chapter 5). We then explored how a transmembrane
protein, the influenza virus HemAgglutinin (HA), behaves in the presence of asymmetric
domains and, more specifically, whether its phase partitioning is a↵ected. Tuning the lipid
content of model membranes allowed biologically relevant observations. Small changes in
the composition of the inner leaflet (e.g. of the plasma membrane) were found to a↵ect
the overall lipid miscibility of the bilayer (Chapter 4), and the HA TransMembrane (TM)
domain was found to induce phase separation both in symmetric and asymmetric model
membranes (Chapter 6). Similarly, tuning the shape of giant vesicle proved that membrane
shape rearrangements, which resemble those taking place in biological systems, are possible
in absence of a protein machinery and as a consequence of the lipid redistribution in the
membrane (Chapter 5).
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Figure 1.12 – PAR-6/PKC-3/LGL-1 mutual elimination model. The PAR-6/PKC-3/LGL-1 com-
plex forms at the boundary between the anterior and posterior PAR domains. Here PKC-3 can
phosphorylate LGL-1 causing the whole complex to leave the cortex (Adapted from Hoege and
colleagues [14]).
In the protein-lipid approach, we aimed to reconstitute a minimal polarization system
inspired by the C. elegans embryo at one-cell stage. In this system polarity is maintained by
the mutual inhibition between aPARs and pPARs, which reciprocally antagonize their bind-
ing to the cortex, mutually excluding each other. We focused on LGL-1, which in nematodes
acts redundantly with PAR-2 to maintain polarity and can compensate for PAR-2 depletion
[14, 15]. Additionally to the several common features shared with PAR-2, LGL-1 o↵ered one
interesting advantage, which makes the reconstitution of a minimal polarity system easier: it
directly antagonizes the aPARs acting on PAR-6. Based on this, a so-called “mutual elim-
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ination model” was proposed (Figure 1.12), in which the PAR-6/PKC-3/LGL-1 complex is
formed at the boundary between the anterior and posterior PAR domains. Here PKC-3 can
phosphorylate LGL-1 causing the whole complex to leave the cortex [14]. This is the minimal
system we intended and partially succeed to reconstitute in GUVs. We first submitted LGL-1
to model membranes, allowing us to identify a very well conserved region of the protein that
binds negatively-charged membranes and to determine its lipid binding specificity. Selected
LGL-1 mutants were then generated to better understand the electrostatic mechanism in-
volved in the membrane binding. LGL-1 was finally combined together with its antagonist
complex to generate a functional LGL/atypical Protein Kinase C (aPKC) membrane binding
switch (Chapter 8).
Part II
MATERIALS AND METHODS

Chapter 2
Materials and sample preparation
2.1 Materials
2.1.1 Lipids
Cholesterol from ovine wool (Chol), 1,2-DiOleoyl-sn-glycero-3-PhosphoCholine (DOPC),
1-Palmitoyl-2-Oleoyl-sn-glycero-3-PhosphoCholine (POPC), 1,2-Di-(9Z-Octadecenoyl)-sn-
glycero-3-Phospho-L-Serine (DOPS), 1-Palmitoyl-2-Oleoyl-sn-glycero-3-Phospho-L-Serine
(POPS), 1,2-DioleOyl-sn-glycero-3-PhosphAte (DOPA), 1,2-DiOleoyl-sn-glycero-3-Phospho-
(1’-rac-Glycerol) (DOPG), L-a-PhosphatidylInositol (Soy) (sPI), Cardiolipin (Heart,
Bovine), 1,2-dioleoyl-sn-glycero-3-(phosphoinositol-3-phosphate) (PI(3)P), 1,2-dioleoyl-
sn-glycero-3-phospho-(1’-myo-inositol-4’-phosphate) (PI(4)P), 1,2-dioleoyl-sn-glycero-3-
phospho-(1’-myo-inositol-5’-phosphate) (PI(5)P), 1,2-dioleoyl-sn-glycero-3-phospho-(1’-
myo-inositol-3’,4’-bisphosphate) (PI(3,4)P2), 1,2-dioleoyl-sn-glycero-3-phospho-(1’-myo-
inositol-3’,5’-bisphosphate) (PI(3,5)P2), 1,2-dioleoyl-sn-glycero-3-phospho-(1’-myo-inositol-
4’,5’-bisphosphate) (PI(4,5)P2), 1,2-dioleoyl-sn-glycero-3-phospho-(1’-myo-inositol-3’,4’,5’-
trisphosphate) (PI(3,4,5)P3), L-a-phosphatidylinositol-4,5-bisphosphate (bPI(4,5)P2),
SphingoMyelin from porcine brain extract (bSM) and 1,2-di-(9Z-octadecenoyl)-sn-glycero-
3-(N-(5-amino-1-carboxypentyl)iminodiacetic acid)succinyl nickel salt (DGS-NTA(Ni)) were
purchased from Avanti Polar Lipids, Inc. (Alabaster, AL). Ganglioside GM1 was purchased
from Merck Millipore (Billerica, MA)
2.1.2 Protonation of phosphoinositides using acid
All phoshoinositides were protonated to enhance their incorporation into liposomes. The pro-
tonation protocol was originally developed by Olga Perisic (MRC Laboratory of Molecular
Biology, Cambridge, UK) and used with minor modification. Briefly, lyophilized phoshoinosi-
tides were resuspended at 2.5 mM final concentration in subsequent steps with di↵erent
solvent mixtures: (1) chloroform; (2) 2:1:0.01 (v:v:v) mixture of chloroform, methanol and
hydrochloric acid 1N; (3) 3:1 (v:v) mixture of chloroform and methanol; and (4) chloroform.
After each step the lipid solution was dried 15 min under N2; after step (1) and (2), the
solution was additionally dried for 1 h under vacuum. In step (2), the lipid solution was
incubated 15 min before drying. The lipid film was finally resuspended in chloroform at 1
mM final concentration and stored at -20￿ up to few months.
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2.1.3 Fluorescent lipids
Atto655 and Atto647N-DOPE were purchased from ATTO-Tec (Siegen, Germany).
Atto647N-SM was was a gift of Erdinc Sezgin (University of Oxford, UK). 1,2-dioleoyl-
sn-glycero-3-phosphoethanolamine-N-(7-nitro-2-1,3-benzoxadiazol-4-yl) (NBD-DOPE) and
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-(7-nitro-2-1,3-benzoxadiazol-4-yl) (NBD-
DSPE) were purchased from Avanti Polar Lipids. Texas Red® 1,2-Dihexadecanoyl-sn-
Glycero-3-Phosphoethanolamine (Texas Red DHPE) triethylammonium salt was purchased
from Life Technologies Corporation (Carlsbad, CA).
2.1.4 Fluorescent dyes
Atto488 NHS-Ester was purchased from ATTO-Tec. Alexa Fluor® 488 carboxylic acid,
succinimidyl ester (Alexa488), Alexa Fluor® 488 hydrazide (Alexa488), Alexa Fluor® 647
carboxylic acid, succinimidyl ester (Alexa647) and DiIC18(3) (DiI) were purchased from Life
Technologies.
2.1.5 eGFP-His6 expression and purification
His6 tagged enhanced Green Fluorescent Protein (eGFP-His6) was cloned into the pGEX-
6P-1 vector using the restriction enzymes SalI and NotI and expressed in the E. coli strain
BL21(DE3). The protein was purified using Glutathione Sepharose 4 Fast Flow according to
the manufacturer’s instructions, followed by direct cleavage of the glutathione S-transferase
tag with PreScission Protease on the column.
2.1.6 PLAP purification and labeling
Commercially available Alkaline Phosphatase from human PLacenta (PLAP) was further pu-
rified and labeled with Alexa647 as previously described [87, 73, 88] with minor modifications.
In particular, Triton X-114 was precondensed before usage [89] and Superdex 200 10/300 GL
(GE Healthcare, Little Chalfont, United Kingdom) columns were used to both remove the
detergent and separate the labeled protein from the free dye. Labeled-PLAP purity and con-
centration were assessed by SDS-PAGE and absorbance at 280 nm, respectively. The degree
of labeling was approximately one dye molecule per PLAP monomer.
2.1.7 HA TM peptides synthesis and labeling
HA TM WildType (WT) and GS520AA peptides were a gift of Dr. Jo¨rg
Nikolaus (Yale School of Medicine, CT). HA TM peptides contain 28 amino
acid residues of the transmembrane segment of the HA (strain Japan/305/57,
H2; WT: Rh-bA-ILAIYATVAGSLSLAIMMAGISFWMCSN-KKK, Mutant: Rh-bA-
ILAIYATVAAALSLAIMMAGISFWMCSN-KKK). Both peptides were synthesized using
Fmoc-chemistry and 5-(and-6)-carboxyTetrAMethylRhodAmine (TAMRA), succinimidyl es-
ter at the N-terminus via a b-alanine. Three lysine residues were added at the C-terminal
to enhance peptide solubility and membrane insertion [90]. Both peptides were dissolved in
2,2,2-Trifluoroethanol (TFE) at 1 mg/mL and store at -20￿.
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2.1.8 LGL-1 expression and purification
LGL-1 (469-702) WT was cloned into the pGEX-6P-1 vector in which eGFP-His6 was
previously cloned using the restriction enzymes BamHI and NotI. The LGL-1 mutants
S661A/S665A/T669A (AAA), S661E/S665E/T669E (EEE) and R658A/K660A/RR671AA
(AAAA) were generated with the QuikChange® Lightning Site-Directed Mutagenesis Kit
(Agilent Technologies, Santa Clara, CA) according to the manufacturer’s instructions. All
clones were expressed in the E. coli strain BL21(DE3). The proteins were purified in presence
of 1% Triton X-100 using GSTrap HP columns, followed by direct cleavage of the glutathione
S-transferase tag with PreScission Protease on column and a second purification step with
a HisTrap HP column according to the manufacturer’s instructions. Protein concentrations
were determined using the BicinChoninic Acid (BCA) protein assay. Purified LGL-1 (469-
702) was pre-cleared at 120,000 g, 4￿ for 30 min in a MLA-130 rotor (Beckman Coulter,
Pasadena, CA) and stored at -80￿ in presence of 10% glycerol.
2.1.9 LGL-1 MTS peptides synthesis and labeling
The LGL-1 Membrane Targeting Sequence (MTS) WT and EEE peptides were synthesized
by Stefan Pettera and labeled by Dr. Stephan Uebel (Max Planck Institute of Biochem-
istry, Martinsried, Germany). The LGL-1 MTS peptide has 26 amino acid residues, which
corresponds to the part of the C-terminal LGL-specific domain of the C. elegans LGL-1
containing the three phosphorylation sites for PKC-3 (G5EEI1 CAEEL 656-681, acetyl-
FQRFKSLKKSLRKTFRRKKKGTETLM-amide). For imaging and FCS experiments the
peptides were labeled by coupling Atto488 NHS-Ester at the N-terminus. Both unlabeled and
labeled peptides were synthesized using Fmoc-chemistry and purified to > 90% by preparative
Reversed-Phase High-Performance Liquid Chromatography (RP-HPLC). Purity and identity
of the peptide were checked by analytical RP-HPLC and electrospray mass spectrometry.
Both peptides were store -80￿ lyophilized or in water at 1 mg/mL final concentration.
2.1.10 Additional materials
a-hemolysin (powder) from Staphylococcus aureus, Bovine Serum Albumin (BSA), PLAP, 3-
(3-CHolAmidopropyl)dimethylammonio-1- PropaneSulfonate (CHAPS), Ficoll® PM 70, (2-
HydroxyPropyl)-a-CycloDextrin (HPaCD), Methyl-b-CycloDextrin (MbCD), mineral oil, 4-
nitrophenyl phosphate disodium salt hexahydrate (pNPP), TFE, Triton X-100 and X-114
were purchased from Sigma-Aldrich (St. Louis, MO). The Alexa647 conjugate of Cholera
toxin subunit B (CtxB) was purchased from Life Technologies. [g-32P]ATP was purchased
from PerkinElmer (Waltham, MA). Reducing Agent Compatible BCA Protein Assay was
purchased by Thermo Fisher Scientific (Waltham, MA). The pGEX-6P-1 vector, Glutathione
Sepharose 4 Fast Flow, GSTrap HP 1 mL column, HisTrap HP 1 mL column, PreScission
Protease and 100 nm polycarbonate membranes were purchased from GE Healthcare. n-Octyl-
b-D-Glucopyranoside (OG) was purchased from Glycon Biochemicals GmbH (Luckenwalde,
Germany). Active recombinant human PKC-z (PKC-z) was purchased from Merck Millipore.
All solvents were of Uvasol® spectroscopic purity grade, other chemicals were of reagent
grade.
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2.2 In vitro LGL-1 phosphorylation by human PKC-z
In vitro phosphorylation was performed similarly as described before [91] with the following
modifications. 5.0 µM LGL-1 MTS WT and EEE peptides were incubated with 1 nM PKC-
z in kinase bu↵er (20 mM HEPES pH 7.4, 5 mM MgCl2, 1 mM DiThioThreitol (DTT))
containing 60 µM cold ATP and 1.315 µCi [g-32P]ATP at Room Temperature (RT). Kinase
reactions were carried out by incubating samples on ice (for time 0 samples) or at 30￿ and
terminated by adding 5X Laemmli loading bu↵er at di↵erent time points (10, 20, 30, 40, and
50 min). Proteins were separated by a handcast 18% Tris-glycine gel, stained with Coomassie,
fixed and dried on 1.5 mm filter paper. The dried gels were exposed to radiographic films
at RT Over Night (ON) and digitalized with a LAS-3000 (Fujifilm, Tokyo, Japan) exposing
them for 1-8 s on a DIA tray. The autoradiographs were analyzed with the gel analysis tool
of Fiji (http://rsb.info.nih.gov/ij/docs/menus/analyze.html#gels) [92]. LGL-1 MTS
WT phosphorylated for 50 min was included in every gel and used as a reference to normalize
the amount of phosphorylation.
2.3 Model membranes
2.3.1 Preparation of SUVs for circular dichroism measurements
DOPC alone or mixed with negatively charged lipids at the desired molar ratio in chloroform
was dried 15 min under N2 and 1 h under vacuum. The dried lipids were rehydrated in
circular dichroism bu↵er (1 mM NaH2PO4, 50 mM NaF, pH 7.4) to a final concentration of
10 mg/mL, vortexes for 5 min and bath sonicated until the solution became clear. SUVs
formation was performed at at least 10￿ above the highest transition temperature of the
lipid used. When the temperature used was higher than RT, the samples were slowly cooled
down before further usage. SUVs were used for circular dichroism experiments on the same
day they were prepared.
2.3.2 Preparation of LUVs
Lipids were mixed in chloroform at the desired molar ratio. After solvent evaporation, the
lipid film was rehydrated at 10 mg/mL lipid concentration and resuspended by vortexing.
The vesicle suspension was then subjected to eight freeze-thaw cycles and extruded 21 times
(Avanti Mini-Extruder, Avanti Polar Lipids) through a polycarbonate membrane.
LUVs formation for Fluorescence Correlation Spectroscopy measurements
Experiments were carried out in homemade observation chambers obtained by gluing cut
PCR tubes on a #1.5 coverslip (Gerhard Menzel GmbH, Thermo Fisher Scientific) with a UV
optical adhesive (NOA63, Norland Products Inc., Cranbury, NJ). The wells were passivated
with a 2 mg/mL BSA solution for at least 30 min and rinsed with water and working bu↵er.
For experiments in Chapter 7, DOPC was mixed with 2, 3, 4 or 5 mol% DGS-NTA(Ni)
and rehydrated in Phosphate Bu↵ered Saline (PBS) (137 mM NaCl, 2.7 mM KCl, 4.3 mM
Na2HPO4, 1.4 mM KH2PO4, pH 7.4). LUV size and monodispersity were checked via dy-
namic light scattering (DynaPro NanoStar™, Wyatt Technology Corporation, Santa Barbara,
CA) and lipid concentration in LUV preparations was determined by phosphorous assay [93]
after extensive dialysis in presence of non-solubilizing concentrations of Triton X-100. The
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measured LUV size and lipid concentration were used to calculate the accessible LUV con-
centration [LUV ] [77] and the number of lipids NLUV contained in a LUV. LUVs were 10-fold
serially diluted in PBS, incubated at the desired final concentrations with 50 nM eGFP-His6
and transferred in the homemade observation chambers.
For experiments in Chapter 8, POPC and POPS were mixed at 4:1 molar ratio and
rehydrated in LUVs bu↵er (100 mMKCl, 10 mM HEPES pH 7.4). Kinase reactions containing
25.60 nM of the labeled LGL-1 MTS peptide were used either in absence (LGL-1 MTS not
phosphorylated) or in presence (LGL-1 MTS phosphorylated) of ATP. LUVs were sequentially
added to each sample at di↵erent final concentrations (0, 1, 10, 100, and 1000 µM) and
incubated for 5 minutes before measuring.
LUVs formation for dinamic light scattering and z-potential measurements
DOPC was mixed with DOPS or phosphoinositides at di↵erent molar ratios and rehydrated
in SLB bu↵er (10 mM HEPES pH 7.4, 150 mM NaCl) at 1 mg/mL lipid concentration. After
extrusion, LUVs were diluted to a final concentration of 100 µM, filtered with a 0.45 µm
mixed cellulose esters filter and aliquoted. Each aliquot was incubated with none or di↵erent
amounts of the LGL-1 MTS peptide (0, 0.5, 1, 2, 4, 6, and 8 µM) for 15 min at RT.
2.3.3 Preparation of GUVs
GUVs were prepared on PlaTinum (Pt) wires or on Indium Tin Oxide (ITO) coated round
coverslips using the electroformation method or using the droplet transfer method.
GUVs electroformation on platinum wires
GUVs were prepared in home-made teflon and Pt wires chambers as previously described with
minor modifications [94]. Lipid stock solutions were prepared by dissolving lyophilized lipids
into chloroform at a final concentration of 1 mg/mL. Lipid stock solutions were either used
immediately or stored at -20￿ up to few months. When frozen, the lipid stock solutions were
allowed to warm to RT before usage. 6 µL of the lipid solution were spread uniformly on the
Pt wires and dried under vacuum at RT for 1 h to allow complete evaporation of the solvents.
Vesicles were formed using the electroformation method [50] with 2 V, 10 Hz for minimum
90 min in a water solution of sucrose matching the osmolarity of the working bu↵er used for
the following experiments. The frequency was then decreased to 2 Hz for ca. 15-30 min, so
that the formed GUVs gently detach from the Pt wires. Electroformation was performed at
least 10￿ above the highest transition temperature of the lipid used. When the temperature
used was higher than RT, the samples were slowly cooled down. After electroformation, the
GUVs were diluted in working bu↵er and transferred to an observation chamber (Nunc®
Lab-Tek® II chambered coverglass, Thermo Fisher Scientific) previously passivated with a 2
mg/ml BSA solution for at least 30 min and rinsed with water and working bu↵er.
For experiments in Chapter 7, DOPC were mixed with 2, 3, 4 or 5 mol% DGS-NTA(Ni)
and labeled with 0.05 mol% Atto647N-DOPE. 5 µL of corresponding 2 mg/mL lipids mixtures
were spread and dried onto Pt wires. Experiments were carried out in 120 µL MatriCal 384-
multiwell plates (Brooks Life Science Systems, Spokane, WA). The wells were passivated with
2 mg/mL BSA for at least 30 min and washed two times with PBS. The obtained GUVs were
diluted 1:50 in sucrose solution and then 1:3 in PBS bu↵er. 20 µL of the dilution in PBS were
transferred into a well, containing 80 µL of PBS bu↵er.
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GUVs electroformation on ITO-coated round coverslips
GUVs were formed on ITO-coated round coverslips (thickness #1.5, GeSiM, Grosserkmanns-
dorf, Germany) assembled in a home-built flow chamber [94]. 1.5 µL of the desired lipid
mixture at 7.5 mg/mL in chloroform were spread on the ITO glasses at 65￿ and allowed
to dry. Vesicles were formed using the electroformation method [50] with 1.2 V, 10 Hz for
minimum 90 min in a water solution of trehalose or sucrose matching the osmolarity of the
cyclodextrin-lipid complexes used for the following treatment. If the lipid mixture used con-
tained SM and/or Chol the electroformation was performed at 65￿; in this case the GUVs
were slowly cooled down before further usage.
For experiments in Chapter 5, a lipid mixture containing DOPC, SM and Chol at 75, 5
and 20 %mol ratio, respectively, was used. The fluorescent lipid analogue NBD-DOPE was
added at a final concentration of 0.5 %mol to the lipid mixture and used to monitor phase
separation. This original lipid composition corresponds to the final composition of the inner
leaflet of the asymmetric Giant Unilamellar Vesicles (aGUVs).
For experiments in Chapter 5, A lipid mixture containing 100 %mol of DOPC was used.
The fluorescent lipid analogue NBD-DOPE was added at a final concentration of 0.5 %mol to
the lipid mixture and used to monitor GUVs shape changes. This original lipid composition
corresponds to the final composition of the inner leaflet of the aGUVs.
GUVs formation using the droplet transfer method
GUVs were prepared as previously described [51, 52, 53] with minor modifications. Lipids
were first mixed in a glass vial rinsed with acetone and chloroform and dried 15 min under
N2 and 1 h under vacuum. The lipid film was then dissolved in 5 or 10 mL of mineral oil at
a final concentration of 0.5 mg/mL and sonicated in a bath at RT for 20 min (Bransonic®
Ultrasonic Cleaners Model 2510, Branson Ultrasonics, Danbury, CT). The oil-lipid mixture
was either used immediately or stored at 4￿ up to one week. Before each usage, the oil-lipid
mixture was allowed to warm to RT and sonicated at RT for 5 min. 500 µL of the outer
bu↵er (20 mM HEPES pH 7.4, 5 mM MgCl2, 100 mM glucose, 1 mM DTT) were placed in
a 2 mL tube, overlaid with 500 µL of the oil-lipid mixture, and incubated for at lest 2 h at
RT to allow a lipid monolayer to assemble at the interface. 15 µL of the internal solution
(kinase reactions at 1:5 dilution in internal bu↵er: 20 mM HEPES pH 7.4, 5 mM MgCl2, 100
mM sucrose, 1 mM DTT, 50 g/L Ficoll 70) were added to 500 µL of the oil-lipid mixture
and suspended by gentle pipetting back and forth until a cloudy emulsion was obtained. The
whole volume of the emulsion was then slowly poured on top of the oil-lipid mixture, thus
resulting in a three-level sample with the outer bu↵er at the bottom, the oil-lipid mixture in
the middle, and the emulsion on top. The tube was then centrifuged in two subsequent steps
(10 min at 100 g, 10 min at 350 g) in which emulsion drops of di↵erent size passed through
the lipid monolayer to form GUVs filled with the internal solution and surrounded by the
outer bu↵er. The outer bu↵er containing the GUVs was gently collected and transferred to
an observation chamber previously passivated with a 2 mg/ml BSA solution for at least 30
min and rinsed with water and outer bu↵er.
2.3.4 Preparation of SLBs
SLBs were prepared either on freshly cleaved mica or on glass using the VF method [57].
SUVs and SLBs formation was performed at least 10￿ above the highest transition temper-
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ature of the lipid used. When the temperature used was higher than RT, the samples were
slowly cooled down before further usage. SLBs were imaged and Fluorescence Recovery After
Photobleaching (FRAP) was recorded to assess the correct formation of the bilayer.
SLBs formation on freshly cleaved mica
For experiments in Chapter 4, SLBs were prepared on freshly cleaved mica. SUVs were
obtained by sonication in an ultrasonic bath. DOPC, SM and NBD-DOPE were mixed in
chloroform at di↵erent molar ratios; NBD-DOPE concentration was kept at 0.5 %mol for
imaging and 0.05 %mol for FCS measurement. After solvent evaporation, the lipid film was
rehydrated in SLB bu↵er at 4 mg/mL lipid concentration and resuspended by vortexing.
After sonication, 10 µl of the suspension were diluted in SLB bu↵er to ca. 0.5 mg/mL final
lipid concentration and deposited on freshly cleaved mica, glued on a glass coverslip and
sealed attaching a plastic cylinder of 7 mm diameter around it. Adding CaCl2 to a final
concentration of 3 mM induced SUVs fusion and the formation of a lipid bilayer on mica.
After 30 min incubation, the sample was vigorously rinsed with SLB bu↵er to remove any
unfused SUVs.
SLBs formation on glass
For experiments in Chapter 8, SLBs were prepared directly on glass as described for freshly
cleaved mica. Pure DOPC or DOPC doped with either 20 %mol DOPS or 7.5 %mol bPI(4,5)P2
were used as lipid mixtures.
2.4 Budding of intramembrane domains in GUVs
Budding of intramembrane domains in GUVs was induced as previously described [95] with
minor modifications. GUVs were grown from a DOPC:SM:Chol lipid mixture at 36:36:28
%mol ratio in a 12 mM sucrose solution. GM1 and DiI were added to the lipid mixture at
a final concentration of 0.1 and 0.5 %mol, respectively, to monitor domain budding. Once
cooled down, GUVs were incubated with 10 µg/mL CtxB-647 in sucrose for several minutes
until the binding to GM1 reached equilibrium. We then incubated the GUVs with 350 µL of
an ipertonic sucrose solution (26 mM) at RT. After each treatment the sample was delicately
washed with 1 mL of a 12 mM sucrose solution.
2.5 Protein reconstitution in model membranes
2.5.1 PLAP reconstitution in SLBs
PLAP was reconstituted in SLBs either via a direct protein reconstitution method [96] or
from proteoliposomes.
In the direct reconstitution method, DOPC SLBs labeled with 0.05 %mol NBD-DOPE
formed as described above were incubated with PLAP at 2 µg/mL final concentration in
presence of 0.22 mM CHAPS for 2 h at RT or overnight at 4￿ (Figure 2.1). After PLAP
incorporation, SLBs were washed extensively with SLB bu↵er. No pre-incubation of the
membrane with detergent was needed for the incorporation of PLAP into the SLB.
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Figure 2.1 – PLAP reconstitution via direct incorporation. SLBs labeled with 0.05 %mol NBD-
DOPE were incubated with Alexa647-PLAP at 2 µg/mL final concentration in presence of 0.22 mM
CHAPS for 2 h at RT. [A] Fluorescence confocal images were acquired at the membrane every five
min, a selection of these images for a SLB is presented. Scale bars are 10 µm. [B] For each acquired
image the mean fluorescence intensity was calculated, normalized to the fluorescence intensity of the
NBD-DOPE channel and plotted as a function of time. The intensity of the fluorescently labeled-
PLAP increased over time, indicating that the protein is incorporating into the membrane. The
incorporation was stopped after 2 h with extensive washing.
In the proteoliposomes method, PLAP was reconstituted into DOPC LUVs as described
earlier [88]. PLAP-containing LUVs were incubated 30 min with 0.3 µM NBD-DOPE and
used similarly to SUVs to form SLBs as described above. The incorporation and mobility of
the reconstituted PLAP in both methods was confirmed by confocal microscopy imaging and
FRAP; the activity assessed by pNPP assay in the solution above the SLBs. Briefly, the SLB
bu↵er was changed to glycine bu↵er (Glycine 0.1 M pH 10.4, 1 mM MgCl2, 1 mM ZnCl2)
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and pNPP at 1 mg/mL final concentration was added. SLBs were then incubated 1 h at RT.
The reaction was stopped with 3 N NaOH and the absorbance read at 405 nm.
2.5.2 HA TM peptide reconstitution in SLBs
In order to reconstitute the HA TM peptide in supported bilayers, SLBs were prepared in
home made chambers as described in 2.3.4. Symmetric SLBs had a lipid composition of
DOPC:brain SphingoMyelin (bSM):Chol 2:2:1 (molar ratio). asymmetric Supported Lipid
Bilayers (aSLBs) had a lipid composition of DOPC:bSM:Chol 9:1:0 or 7:1:2 before MbCD- or
HPaCD-mediated lipid exchange, respectively. When the peptide needed to be incorporated
directly in the SLB, either 0.1 %mol of the HA TM WT or 0.025 %mol of the GS520AA
peptide was mixed with the lipids in TFE before SUVs formation. Alternatively the peptide
was incorporated once the SLB was already formed adding 10-25 µM peptide to the bu↵er
above the SLB. In this case, non solubilizing amounts of OG (0.5 mM) were eventually
added to facilitate the incorporation of the peptide into the bilayer as reported for the direct
reconstitution of membrane proteins in SLBs [96].
2.5.3 HA TM peptide reconstitution in GUVs
In order to reconstitute the HA TM peptide in giant liposomes, GUVs were prepared as
described in 2.3.3. Symmetric GUVs had a lipid composition of DOPC:bSM:Chol 2:2:1,
whereas symmetric GUVs had a lipid composition of DOPC:bSM:Chol 3:3:1, 7:1:4 or 15:1:4
before HPaCD-mediated lipid exchange. 1 %mol of either the HA TM WT or the GS520AA
peptide was mixed with the desired lipid mixture as well as 0.5 %mol NBD-DOPE to label
the Ld phase of the vesicles. 1.5 µL of the lipid-peptide mixture at 7.5 mg/mL in TFE or
100 µL at 0.88 mg/mL in TFE were spread on the ITO glasses at 65￿ and allowed to dry.
Vesicles were formed in a water solution of sucrose matching the osmolarity of the HPaCD-SM
complexes used for the following treatment (ca. 100 mOsm/kg). The electroformation was
performed at 65￿ and the GUVs were slowly cooled down before further usage.
2.6 Cyclodextrin-mediated lipid exchange
2.6.1 Cyclodextrin-lipid complexes preparation
MbCD-SM and MbCD-Chol complexes were prepared as described by London and co-workers
[86] with minor modifications. For preparing MbCD-SM complexes, SM MLVs and MbCD
were mixed together at 71 and 16 mM final concentration, respectively. The mixture was
next incubated with moderate shaking for 2 h at 65￿ and centrifuged at 54000 g for 15 min
at 4￿. The supernatant contains the MbCD-SM complexes and is deprived of any residual
MLVs. To prepare MbCD-Chol complexes, 80 µL of cholesterol 15 mM in isopropanol were
slowly added to 2.2 mL of MbCD 60 mM in H2O pre-heated in a water bath at 80￿. The
mixture was then incubated with moderate shaking for 1 h at 60￿ and centrifuged at 40000
g for 15 min at 4￿. Incubation and centrifugation temperatures were chosen to optimize the
MbCD complexes preparation: a high incubation temperature allows the binding reaction to
faster reach equilibrium, whereas a low centrifugation temperature enhances the pelleting of
any residual SM MLVs. The supernatant was filtered with 0.22 µm filters. The osmolarity of
both MbCD-SM and MbCD-Chol complexes was measured (Micro-Sample Osmometer Model
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210, Advanced Instruments, Norwood, MA). The nominal MbCD concentration was assumed
to still be 71 mM and 60 mM in the MbCD-SM and MbCD-Chol complexes, respectively.
This is based on the assumption that no MbCD is lost during the incubation with the SM
MLVs or cholesterol and in the following centrifugation runs. MbCD-SM and MbCD-Chol
complexes were stored at -20￿ until needed or at 4￿ and used within few days.
MbCD-DOPC, MbCD-DOPG and HPaCD-SM were prepared as described for MbCD-
SM, using DOPC or DOPG instead of SM or HPaCD instead of MbCD. To prepare MbCD-
SM/Atto655-DOPE and HPaCD-SM/Atto655-DOPE complexes, 0.05 %mol Atto655-DOPE
was added to SM before forming MLVs. When these cyclodextrin-lipid complexes were pre-
pared, the MLVs-CD mixtures were incubated longer (overnight at 55￿) to reach equilibrium
and centrifuged longer and at higher speed (60000 g for 30 min at 4￿) to pellet the residual
SM MLVs.
2.6.2 Formation of asymmetric SLBs
For experiments in Chapter 4, SLBs were incubated with di↵erent concentrations of MbCD-
SM (5-20 mM) or MbCD-Chol (1-10 mM) complexes at RT for 20 and 15 min, respectively.
Prolonging the SLB incubation with MbCD-SM or MbCD-Chol complexes up to 1 h did not
influence dramatically the final results.
For experiments in Chapter 6, SLBs were incubated with 12 mM MbCD-SM and 5 mM
MbCD-Chol at RT for 20 and 15 min, respectively. Alternatively, SLBs which already con-
tained cholesterol were treated with 40 mM HPaCD-SM.
After each incubation, samples were delicately washed with SLB bu↵er. Note that the
osmolarity of the CD-SM and MbCD-Chol solutions used to treat the bilayers was always
matched to the osmolarity of the SLB bu↵er in which the SLBs were formed.
2.6.3 Formation of asymmetric GUVs
aGUVs were prepared as previously described [86] with the following modifications. GUVs
were incubated with 350 µL of undiluted HPaCD-SM or HPaCD-SM/Atto655-DOPE com-
plexes (nominal concentration of 71 mM) for 30 min at RT. HPaCD does not bind cholesterol
and can be used to exchange lipids with a cholesterol-containing bilayer without extracting
the cholesterol from the membrane, as recently reported for SUVs [97]. Prolonging the treat-
ment up to 1 h did not dramatically influence the final results. After each treatment the
sample was delicately washed with 1 mL trehalose or sucrose isosmotic solution.
2.6.4 Cyclodextrin-mediated GUV shape transformation
GUVs were incubated with di↵erent concentrations of MbCD-DOPG (nominal concentration
of 1.42-35.5 mM) up to 1 h at RT. After each treatment the sample was delicately washed
with 1 mL trehalose isosmotic solution.
2.7 Leaflet specific labeling
2.7.1 Leaflet specific labeling in SLBs
In order to probe both leaflets of the same bilayer, each of them was individually labeled with
spectrally separated dyes: NBD-DOPE and Atto647N-SM in the lower and upper leaflet,
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respectively (Figure 4.1 and 4.12).
NBD-DOPE was directly incorporated in the lipid mixture of SUVs or PLAP-containing
LUVs used to produce the SLB. This resulted in the formation of bilayers labeled in both
leaflets with NBD-DOPE. The dye in the upper leaflet was then quenched by treatment
with sodium dithionite. Quenching of the NBD moiety is a well established strategy to
probe asymmetry in vesicles of di↵erent sizes [98]. Attempts to treat supported bilayers with
sodium dithionite were reported to be not successful [56]. As stated by Crane and colleagues,
the exposure of the SLB to high concentrations of sodium dithionite leads to the complete
bleaching of the fluorescence in both leaflets of the bilayer, probably due to permeation of the
reducing agent through small defects of the membrane. We have systematically tried di↵erent
conditions and found that when SLBs are exposed to concentrations of dithionite relatively
lower in comparison to the concentrations used with vesicles (10-100 ng/mL), the fluorescence
of the upper leaflet is preferentially quenched.
To achieve a complete quenching of the NBD-DOPE present in the upper leaflet of the
bilayer, each SLB was treated with slightly variable concentrations of sodium dithionite ac-
cording to the initial amount of NBD-DOPE in the bilayer. In the direct reconstitution
method, the SLB was exposed to an amount of detergent that could not solubilize com-
pletely the bilayer, but introduced discontinuities in it (data not shown). Those defects in
the membrane rendered the SLB even more sensitive to the sodium dithionite treatment.
Consequently, the concentration of sodium dithionite had to be decreased in those bilayers
to avoid a complete quenching of the NBD-DOPE on both leaflet. To be sure that all the
upper NBD was promptly quenched, the total number of NBD-DOPE particles in the laser
focus was monitored by point FCS before and after the sodium dithionite treatment and the
number of remaining particle after the treatment was kept always inferior to half of the initial
NBD-DOPE particle number, assuming the distribution of NBD-DOPE was homogeneous in
the two bilayers. In these conditions, we can safely assume that almost the totality of the
NBD-DOPE in the upper leaflet (and probably some in the lower leaflet as well) was quenched.
Quenching part of the NBD-DOPE particles of the lower leaflet does not negatively influence
the FCS measurements.
To label the upper leaflet of the SLB, Atto647N-SM at 5 pg/µL (for FCS measurement) or
250 pg/µL (for imaging) was next added to the bu↵er above the SLB. The samples were then
mixed properly and incubated for 2 min before extensive washing. When a concentration of
5 pg/µL was used, the number of incorporated Atto647N-SM particles was suitable for FCS
measurement (1-20 particles in average in the focal volume). When fluorescentely labeled
PLAP was reconstituted in SLB, no additional probe for the upper leaflet was added.
For experiments in Chapter 6, either NBD-DOPE or NBD-DSPE was used to label the
lower leaflet. Labeling of the upper leaflet, on the other hand, was induced by CD-mediated
lipid exchange, doping the SM MLV with fluorescently labeled lipids.
2.7.2 Leaflet specific labeling in GUVs
GUVs were incubated with 1 mg/mL dithionite in trehalose for 1.5 min. In these conditions,
we can safely assume that almost the totality of the NBD-DOPE in the outer leaflet (and
probably some in the lower leaflet as well) was quenched. The remaining NBD-DOPE was
used as fluorescence probe for the inner leaflet.

Chapter 3
Methods
3.1 Confocal fluorescence microscopy and correlation spec-
troscopy
3.1.1 Optical Setup
All measurements were performed on a commercial laser scanning LSM 780 ConfoCor3 system
using a water immersion C-Apochromat 40x/1.2 W Corr M27 objective (Carl Zeiss, Jena,
Germany). Samples were excited by a 488 nm (green channel, i.e. Alexa488, enhanced Green
Fluorescent Protein (eGFP) or Nitro-2-1,3-BenzoxaDiazol-4-yl (NBD)), a 561 nm (orange
channel; i.e. DiI, TAMRA or Texas Red DHPE and/or a 633 nm (red channel, i.e. Atto655,
Atto647N or Alexa647) lasers. The fluorescence was then collected through appropriate band-
pass or long pass filters: green channel, 491-569 nm (imaging in Chapter 7), 493-543 (all
measurements in Chapters 5 and 6), 505-575 nm (FCS-GUV measurements in Chapter 7 and
all measurements in Chapter 4) or 505-610 nm (FCS-LUVmeasurements in Chapter 7); orange
channel, 569-630 nm (all measurements); and red channel, 638-759 (imaging in Chapter 7)
or 655 nm (all other measurements). Pinhole was kept at one airy unit in all measurements,
except for FRAP experiments on GUVs. In this case the pinhole was fit to the vesicle size in
the Z-plane. A l/4 plate (Melles Griot, Rochester, NY) was implemented into the light pass
to generate excitation light with circular polarization and thus to ensure that the laser focus
is rotationally symmetric as needed for line-scan FCS [99] as well as to provide an uniform
excitation of the GUVs as required for a correct determination of fluorescent intensities [100].
3.1.2 FRAP on GUVs
For FRAP experiments (Chapter 5), GUVs were grown in presence of 0.5 µM Alexa488 and
budding was induced via either an hypertonic sucrose solution (control phase separated GUVs)
or MbCD-DOPG complexes. A square area surrounding one of the two daughter vesicles
originated by a budding event was bleached at full power of the laser. The bleaching time
was fixed at 50X the acquisition time of the bleached spot. After bleaching, the fluorescence
recovery of the square together with the surrounding area were imaged at low laser power with
a scan time of 5 s. For each bleaching experiment, three di↵erent Region Of Interest (ROI)
were selected and measured: (1) the FRAP ROI, corresponding to the bleached daughter
vesicle; (2) reference (ref) ROI, corresponding to the unbleached daughter vesicle; and (3)
Background (Bkg) ROI, corresponding to an area where no GUVs or vesicles fragments are
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present throughout the whole acquisition time (Figure 3.1). To identify a good Bkg ROI all
slices of a stack were summed, z-projected and the contrast was strongly enhanced. The ref
ROI is used to measure the decay in fluorescence due to acquisition bleaching and/or di↵usion
of the fluorophore from the unbleached to the bleached vesicle. On the other hand, the Bkg
ROI, where there should be no fluorescence, is used to measure the o↵set intensity. The
FRAP ROI average intensity (Ifrap) was normalized with both a single (Equation 3.1) and
double (Equation 3.2) normalization [101]:
Ifrap norm(t) =
Ifrap(t) Ibkg(t)
Ifrap pre
(3.1)
Ifrap norm(t) =
Iref pre
Iref (t) Ibkg(t)
Ifrap(t) Ibkg(t)
Ifrap pre
(3.2)
where
Ifrap pre =
Ptbleach 1
t=0 (Ifrap(t) Ibkg(t))
fprebleach
(3.3)
Iref pre =
Ptbleach 1
t=0 (Iref (t) Ibkg(t))
fprebleach
(3.4)
fprebleach is the number of frames acquired before the bleaching event.
A B C FRAP  ROI
ref  ROI
bkg  ROI
Figure 3.1 – FRAP ROI. Example of the ROIs used for FRAP analysis: [A] original image; [B]
selected FRAP and ref ROIs; [C] Z-project with sum slices of the whole stack and selected Bkg ROIs.
3.1.3 Point-FCS on SLBs
For point-FCS measurements on SLBs (Chapter 4), usually 5 to 9 independent SLBs prepara-
tions were analyzed. In each preparation, the SLB was typically measured in 6 to 8 randomly
chosen membrane spots and for each of them, 10 independent fluorescence intensity time
tracks of 10 s were acquired. The FCS correlation curves were calculated using the Zeiss ZEN
2011 Black edition software and fitted using a nonlinear least squares algorithm to a single-
component 2D di↵usion model. Typical normalized average correlation curves and fitting
curves are shown for both upper and lower leaflet probes in a symmetric and aSLB (Figure
3.2). Di↵usion times ⌧D of both probes at each SLB spot were calculated and averaged for all
spots in the same preparation. In order to translate ⌧Ds into Ds, the system was calibrated
daily using a symmetric DOPC SLB with the same configuration of fluorescent probes as used
in the aSLBs. This approach accounts for changes in the confocal volume and allows us to
calculate a Relative Di↵usion coe cient (D⇤), i.e. the di↵usion coe cient of a probe in an
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aSLB relative to the di↵usion coe cient of the same probe in a symmetric DOPC SLB. D⇤
can be easily calculated from the ratio between the tD of the probe in the symmetric DOPC
SLB used for calibration and the tD of the probe in the aSLB sample.
Figure 3.2 – Point-FCS on lower and upper leaflets. SLBs were labeled with NBD-DOPE and
Atto647N-SM in the lower and upper leaflet, respectively and point-FCS was measured before and
after MbCD-mediated lipid exchange. Typical normalized correlation curves are shown for both
lower and upper leaflets. In this example the SLB was treated with 12 mM bSM-MbCD complexes.
Each curve is the average of 10 correlation curves obtained in a single SLB spot. The solid lines are
the best fit of the data to a single-component 2D di↵usion model. The lower panel shows the fit
residuals.
3.1.4 Point-FCS on GUVs and in presence of LUVs
For point-FCS measurements on GUVs and in presence of LUVs (Chapter 7), laser powers
were kept very low in order to avoid laser power related problems such as in focus bleaching or
saturation [70]. The experiments were carried out at 26.0 ±0.5￿, measured in solution with a
digital electrode thermometer Voltcraft K202 (Conrad Electronic, Hirschau, Germany). The
setup was calibrated using an aqueous solutions (ca. 50 nM) of freely di↵using Alexa488
(D=435 µm2/s 22.5±0.5￿[102]) and in case of the GUV assay free Atto655 (D=426 µm2/s
25￿[103]) in a 1:1 ratio. The objective correction collar and the pinhole position were adjusted
to maximize the fluorescence intensity. Correction of di↵usion coe cients to the measurement
temperature [70] and subsequent weighted fit of the auto-correlation curves (Equation 7.7;
Alexa488: 3D+T di↵usion model, Atto655: 3D di↵usion model without triplet correction),
allowed us to determine the parameters of the detection volume: the focal radius w0 (Equation
7.10), the focal volume VFCS (Equation 7.9) and the focal area AFCS = ⇡w20.
For point-FCS measurements on GUVs, a minimum of eight GUVs per sample were se-
lected and measured at least at five increasing concentrations of eGFP-His6. Before protein
addition the background signals in solution and on the membrane were recorded. Images were
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taken at approximately their equator using avalanche photodiodes and analyzed by the image
analysis method described below. Furthermore, point FCS was performed at the top pole of
the GUVs by maximizing the fluorescence intensity and measuring five times 30 s. To get Nf
a measurement of ten times 30 s was conducted in solution. The obtained auto-correlations
curves were analyzed using PyCorrFit 0.7.4 [104]. The after pulsing was removed (2 µs), ⌧T
fixed to 0.02 ms and S to the one obtained by the calibration measurement. A non-weighted
3D+T-fit was used to get N 0f , which was subsequently corrected for the background signal.
A weighted fit was used to get ⌧D of the protein and that average value was used in the
following fit of the bound fraction. To obtain N 02D3D, a non-weighted 2D3D+T-fit (Equation
7.11) was applied and then background corrected. The free and bound protein concentrations
were plotted using Origin 9.0.0G (OriginLab Corporation, Northampton, MA) and analyzed
by defining a x/y-weighted linear fit in the nonlinear implicit curve fit dialog. From ⌧2D
obtained by a weighted 2D3D+T-fit the D were calculated by rearrangement of Equation
7.10.
For point-FCS measurements in presence of LUVs, each DOPC:DGS-NTA(Ni) molar ratio,
at least three independent samples were investigated at eight di↵erent LUV concentrations
(1 nM - 10 mM). For each LUV concentration, point-FCS was measured four sequential
times and for each of them ten independent fluorescence intensity tracks of 10 s each were
acquired. The FCS auto-correlation curves were calculated using the Zeiss ZEN 2011 Black
edition software and analyzed using PyCorrFit 0.8.1 [104]. The after pulsing was removed
(1 µs) and S was fixed to the one obtained by the calibration measurement. [P ] and ⌧f
were measured by point-FCS in absence of LUVs and to calculate the protein concentration
in each sample. A non-weighted 3D+T-fit (Equation 7.7) was used to get the number of
particles, whereas a weighted fit was used to get the ⌧f ; the average ⌧f value was used in
the following fits in presence of LUVs. To obtain the total number of particles Nf+m (free
+ vesicle bound protein) a non-weighted two components 3D+T-fit was applied (Equation
7.23). From Nf+m obtained from the fit, an average normalized G(0) value was calculated for
each LUV concentration of a sample, then plotted against the accessible [LUV ] and fitted to
the Equation 7.26 to obtain Kd using SigmaPlot 12.3 (Systat Software, Inc., San Jose, CA).
Kds were finally converted to KP s (Equation 7.27).
3.1.5 Line-scan FCS on SLBs and GUVs
Line-scan FCS measurements and analysis (Chapter 6) were performed similarly as previously
described [99]. Detectors were set in photon counting mode and the correction collar of the
objective was adjusted by maximizing the fluorescence intensity while focusing on the plane
of the membrane. Usually 3 to 5 independent SLBs preparations were analyzed. In each
preparation, the SLB was typically measured in 4 to 5 randomly chosen membrane spots and
for each of them, 10000 line scans of 10.65 µm were acquired. The movement of the detection
volume was controlled directly with the Zeiss ZEN 2011 Black edition software (Table 3.1),
selecting a linear scan path in a SLB image.
On phase-separated SLBs, correlation curves were calculated independently for each lipid
phase. The phases could be identified due to the di↵erent a nity of the upper and lower
fluorescent dyes to the Lo (low a nity, dim) and the Ld phase (high a nity, bright). The
line-scans can be visualized as a pseudo-image where the vertical axis is the time. The pho-
ton counts per pixel were saved as raw data and analyzed with a self-written MATLAB
(MathWorks, Natick, MA) script (Dr. Salvatore Chiantia, Humboldt Universita¨t zu Berlin,
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Parameter Unit
Line Size 512 x 1 pixel x pixel
Zoom 20 X
Pixel Size 20.80 nm
Speed 13 X
Pixel Dwell Time 0.64 µs
Line Time 0.768 ms
Cycles 104 X
Scan Time 7.64 s
Table 3.1 – Line-scan FCS parameters. Optimized parameters for performing line-scan FCS on
phase-separated SLBs with a Zeiss LSM 780 system.
Germany). The spatiotemporal correlation curves G(x, ti) were calculated binning the pixels
2x2 and restricting the temporal range to ti = t1-t30 to limit the computation time. When
it was necessary to correct for depletion due to photobleaching, a correction scheme which
allows to extract correct concentrations from the measurement was applied [99]. The spa-
tiotemporal correlation curves were then fitted using a non-weighted nonlinear least squares
fitting algorithm to to a single-component 2D flow-di↵usion model with a Gaussian detection
area:
G(⇠, ⌧i) =
1
C⇡w20
exp(  ⇠
2
w20+4D(⌧i+⇠/v)
)x(1 +
4D
w20
(⌧i +
⇠
v
)) 1 (3.5)
Typical spatiotemporal correlation and fitting curves for ti = t1-t5 are shown for both
upper and lower leaflet probes in aSLBs (Figure 6.2). The focal volume waist (w0) as well as
D and concentrations (C) of both probes were obtained directly from the fit to Equation 3.5.
3.2 GUV image analysis for determining partitioning coe -
cients
In order to extract the surface and bulk fluorescence intensities I2D and If from the confocal
GUV images, a semi-automated MATLAB script (Dr. Zdeneˇk Petra´sˇek, Graz University of
Technology, Graz, Austria) was used. For each GUV to analyze, the user enters approximate
coordinates of the GUV center and an approximate radius (Figure 3.3). The software then
determines the precise GUV center position and approximates the circumference of the GUV
cross-section by a smooth closed curve. This allows the extraction of the radial intensity
profile of the GUV. From the intensity profile the surface fluorescence intensity I2D and the
solution fluorescence intensity If are determined. Additionally, it is possible to exclude a
range of angles (a wedge) from the analysis, which is useful, for example, when two GUVs
are in contact. The ring region outside the GUV (an interval of radial distance in the radial
intensity profile) from which I2D is determined is typically constant for all GUVs and need not
be adjusted individually. If necessary the background of the GUVs before protein addition was
subtracted from mean intensity. Each point was correlated to the corresponding concentration
[P2D] determined by FCS in Origin 9.0.0G and analyzed by a linear fit passing through the
origin of the graph. Analogously the averaged mean intensities in solution were related to
[Pf ].
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Figure 3.3 – GUV image analysis. [A] GUV with rescaled intensity and a marked area from which
the background intensity is calculated, [B] the ring area between the two dashed lines is used to
determine the surface concentration (bound fraction, I2D), the mean intensity inside the GUV is
calculated from the innermost ring area, and the intensity outside the GUV from the outermost ring
[C] fit of the GUV shape and intensity within the selected area, [D] fit residuals, [E] the experimental
(blue) and fitted (red) radial profile of GUV. Image scale: [A]-[D] x- and y-axis in pixel, [E] x-axis
in pixel and y-axis in average photons per pixel.
The KP of the LGL-1 MTS peptide encapsulated in GUVs was determined similarly as
described for solutes incubated outside the GUVs. Briefly, several GUVs for each sample
were imaged at the equator, their fluorescence intensities at the GUV membrane and inside
the GUV were extracted with the customized MATLAB script and transformed in peptide
concentrations at the GUV membrane [P2D] and inside the GUV [Pf ], respectively. In order
to perform this conversion, the system was calibrated with di↵erent peptide solutions whose
concentration were determine by FCS. P2D and Pf normalized by the GUV radius rGUV were
plotted against each other and fitted to Equation 8.3 to determine KP (Figure 8.14).
3.3 Image processing and analysis
Fluorescence confocal images were processed and analyzed with Fiji (http://fiji.sc/Fiji).
When needed, image contrast was enhanced through normalization.
3.3.1 Measurements in thresholded images
Number and average size of Lo domains (Chapter 4) were measured in locally thresholded
images, whereas average fluorescence intensities of the FRAP and ref areas (Chapter 5) were
measured using globally thresholded images.
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3.3.2 Determination of Lo partitioning coe cients in GUVs
The fraction of labeled HA TM peptides partitioning into the Lo phase (Chapter 6) was
determined from intensity radial profiles of confocal images using the radial profile angle plug-
in (http://rsbweb.nih.gov/ij/plugins/radial-profile.html), similarly as described by Sezgin and
colleagues [100] for line profiles. The fluorescence intensities of the Lo and Ld phases, FLo
and FLd, were determined from the peaks of the radial profile plots, where the di↵erent
phases were identified by the Ld phase marker NBD-DOPE (Figure 3.4). The background
value obtained from an area outside the vesicles was subtracted from peak values. The Lo
partitioning coe cient (%Lo) was calculated as follow:
%Lo =
FLo
FLo+FLd
(3.6)
A B C
B1 C1
1.34
47.86
1.57
N
o
rm
a
li
z
e
d
In
te
g
ra
te
d
  I
n
te
n
s
it
y
127.00Radius  [pixels] 1.34
27.62
1.34
N
o
rm
a
li
z
e
d
In
te
g
ra
te
d
  I
n
te
n
s
it
y
127.00Radius  [pixels]
Figure 3.4 – Determination of Lo partitioning coe cients in GUVs. Example of a phase separated
GUVs imaged at its equator and labeled with the Ld phase marker NBD-DOPE. The fluorescence
intensities of the Ld [B] and Lo [C] phases, FLd and FLo, were determined from the peaks of the
respective radial profile plots [Ld, B1; Lo, C1].
3.3.3 Determination of protein binding to GUVs
The binding of the labeled LGL-1 (469-702) WT and EEE mutant was determined from the
picks of the intensity radial profile plots of confocal images taken at GUVs equator using the
radial profile angle plug-in (http://rsbweb.nih.gov/ij/plugins/radial-profile.html).
3.3.4 Determination of protein binding to SLBs
The binding of the labeled LGL-1 (469-702) WT and AAAA mutant was determined from
intensity profiles of confocal z-stack images taken parallel at the SLBs plane using the z-
project function. LGL-1 fluorescence intensity values were background corrected, averaged
and normalized by the value obtained in SLBs containing DOPC only.
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3.4 Circular dichroism spectroscopy
Far-UV circular dichroism spectra were acquired at 25￿ on a Jasco J-715 spectropolarimeter
(Jasco, Easton, MD) as previously described [105, 106]. The unlabeled LGL-1 MTS peptide
concentration was kept at 50 µM and mixed with di↵erent amount of SUVs (1:10, 1:50, and
1:100 molar ratio) in circular dichroism bu↵er. Eight scans were accumulated and background
signal (bu↵er only and lipid only) was subtracted from the spectra. The a-helix content of the
peptide in presence of di↵erent lipid mixtures was estimated from the circular dichroism spec-
tra with the CDPro software package (http://lamar.colostate.edu/~sreeram/CDPro/)
using the CONTIN method and the SMP56 protein set. Circular dichroism spectra of the
peptide in absence of lipids in TFE were acquire and used to normalize the a-helix content of
the peptide.
3.5 Dynamic light scattering and z-potential
Dinamic Light Scattering (DLS) and z-potential measurements were performed with a Malvern
Zetasizer Nano ZSP system (Malvern, Malvern, UK) as previously described with minor mod-
ifications [107]. Ultra-micro UV-transparent spectrophotometry cuvettes (Brand, Essex, CT)
and disposable folded capillary cells DTS 1070 (Malvern) were used in DLS and z-potential
measurements, respectively. For DLS experiments 2 scans (13 runs each) were performed
at 25￿ with an initial equilibration time of 5 min. For z-potential measurements 15 scans
(20-100 runs each) were performed at 25￿ with constant voltage of 40 mV and an initial
equilibration time of 5 min. After each scan the instrument paused for 90 s and every 5
scans for 5 min. Values of the viscosity and refractive index were set at 0.8882 cP and 1.330,
respectively. Experiments were performed in duplicate.
The z-potential values ⇣ obtained from the instrument software were plotted against the
peptide concentration [P ] and fit to Equation 3.7 to obtain the Apparent Binding Constant
(KB):
⇣ =
⇣0+⇣limKB [P ]
1+KB [P ]
(3.7)
where ⇣0 is the z-potential value in absence of peptide and ⇣lim the z-potential value at
saturating peptide concentration. The fitting was performed using SigmaPlot 12.3.
3.6 Statistical analysis
Statistical analysis was performed using SigmaPlot 12.3. When the means of two sets of data
were compared (Figure 4.3 B, 4.5, 4.7, 4.9 A, 8.3 B and 8.7 E), a t-test or a paired t-test was
used for independent or before-and-after samples, respectively. For both t-tests two-tailed
P-values are reported. Comparison of more than two sets of data (Figure 4.3 A, 4.6 and 8.4),
were carried out with one-way ANalysis Of VAriance (ANOVA) or one-way repeated measures
ANOVA for independent samples or samples measured over time, respectively. To isolate the
group or groups that di↵er from the others, ANOVA was followed up with an all-pairwise
multiple comparison procedure (Tukey Test or Holm-Sˇ´ıda´k Method). The level of alpha was
kept at 0.05 for all statistical analyses.
Part III
RESULTS AND DISCUSSION
The experimental work presented in Chapter 4 was designed together with Dr. Salvatore
Chiantia (Humboldt Universita¨t zu Berlin, Germany) and Prof. Petra Schwille (Max Planck
Institute of Biochemistry, Martinsried, Germany) .
Size-exclusion chromatography steps of the PLAP purification and labeling were per-
formed by Dr. Sabine Suppman (Biochemistry Core Facility of the Max Planck Institute of
Biochemistry, Martinsried, Germany).
Chapter 4
Asymmetric supported lipid bilayer
formation via methyl-b-cyclodextrin
mediated lipid exchange
The transversal asymmetry in lipid composition is one of the most challenging features of a
biological membrane to reproduce in SLBs. In many eukaryotic cells SM is enriched in the
extracellular leaflet of the plasma membrane, whereas phosphatidylethanolamine and negative
charged lipids e.g. PS are predominantly located in the cytoplasmic leaflet [3]. To date, the
production of aSLB with a specific lipid composition in each leaflet has only been established
for the LB/LS deposition and for the hybrid LB/VF method [56, 108]. In few cases, VF has
been reported to spontaneously generate asymmetric SLBs depending on lipid mixture, VF
conditions and type of support used [109]. For example, electrostatic repulsion/attraction
between lipids and support was successfully used to form SLBs containing asymmetrically
distributed charged lipids. In particular, PS was preferentially found in the lower leaflet
of SLBs on titanium dioxide [110] or in the upper leaflet of SLBs on a silicon block [111].
However, the asymmetry in SLBs produced by VF can be only partially controlled, and a
more general approach is still missing.
A MbCD-mediated lipid exchange technique was recently devised to prepare SUVs with
stable asymmetric lipid compositions [85] and later tailored to produce asymmetric GUVs at
high yield [86]. This method is based on the ability of MbCD to bind phospholipids [112]
and to exchange them with a preformed lipid bilayer. Briefly, in this method a lipid bilayer
is exposed to a concentrated solution of MbCD loaded with the desired lipid species. Only
the accessible leaflet of the bilayer can directly exchange lipids with the MbCD complexes,
i.e. can be enriched with the lipid previously in complex with the MbCD. This confined
enrichment generates asymmetry in the lipid composition of the bilayer. The ability of MbCD
to bind phospholipids or, more generally, lipophilic compounds (e.g. cholesterol) derives from
its chemical structure: cyclodextrins are in fact cyclic oligomers of glucose, in which the
interior of the circle of glucose units forms a non-polar cavity [113]. The approach of the
MbCD-mediated lipid exchange method is in principle applicable to every model lipid bilayer,
including SLBs.
Individual lipids are not only asymmetrically distributed, but also supposed to be laterally
segregated in biological membranes.Lipid lateral organization could be addressed in a variety
of membrane model systems using so-called raft-mimicking lipid mixtures. Although their
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phase behavior was extensively investigated, the e↵ect of compositional asymmetry on phase
separation remains unclear. In a series of seminal articles, Tamm and coworkers [56, 114, 115]
investigated the coupling of cholesterol-rich Lo domains in asymmetric bilayers of di↵erent
lipid composition, and showed for the first time that Lo domains in one leaflet can induce
phase separation in an opposing leaflet with lipid compositions that would not spontaneously
phase separate. In the cases in which phase separation is not induced, domains are observed
in at least one leaflet. At the same time, Collins and Keller [116] showed that a leaflet with
a lipid composition that does not phase separate can also suppress domain formation in the
leaflet with a lipid composition that would phase-separate in a symmetric bilayer. In these
experiments, phase separation was observed either in both leaflets or not at all. The results
described in the above-mentioned works were obtained in two quite diverse model membranes
(tethered polymer-SLBs and free-standing black lipid membranes). A third independent
approach is needed to better understand the observed di↵erences in the two systems. The
biological relevance of studying lipid lateral organization in asymmetric membrane systems
was recently underlined by the work of Hussain and colleagues; they could demonstrate that
bilayer asymmetry influences the sequestering of integrins in raft-mimicking lipid mixtures
[117].
??????? ????????? ?????????? ????????
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Figure 4.1 – aSLB leaflet-specific labeling. A schematic diagram of aSLB formation via MbCD-
mediated lipid exchange and of the leaflet-specific labeling strategy used to quantitatively assess
it.
In this chapter we describe how the MbCD-mediated lipid exchange method can be applied
to SLBs formed by VF to easily produce flat bilayers with asymmetric lipid composition.
Specifically we selectively enriched the upper leaflet of a dioleoylphosphatidylcholine SLB
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with SM, incubating the bilayer with MbCD-SM complexes (Figure 4.1). SM incorporation is
known to a↵ect membrane fluidity [86]. Therefore, to assess the asymmetric SM enrichment in
the bilayer, we labeled each SLB leaflet with a di↵erent fluorescent lipid probe and measured
their di↵usion by FCS. To selectively label each leaflet, the nitrobenzoxadiazole NBD moiety
of the lipids in the upper leaflet was quenched with sodium dithionite and lipids conjugated
with a spectrally separated dye were subsequently incorporated in it from the above bu↵er.
Selective labeling of each leaflet allows us to probe both leaflets independently and measure
local lipid dynamics. We additionally show that the produced asymmetric SLBs are stable for
at least four hours, fully compatible with the most common protein reconstitution methods
and suitable for studying phase separation and transbilayer lipid movement of raft-mimicking
lipid mixtures.
4.1 The upper leaflet of DOPC SLBs can be enriched with
SM to form asymmetric bilayers.
Symmetric DOPC SLBs were prepared on freshly cleaved mica using the VF method [57].
Mica supports typically had an area of 38 mm2 and were kept hydrated with 200 µL of
SLB bu↵er at all times after SLB formation. Assuming the lipid packing constant, the total
amount of lipids in SLB samples (ca. 10-10 mol) is two orders of magnitude lower than that
typically found in vesicles preparations (e.g. ca. 10-8 mol for GUV samples prepared on ITO
glass), for which high concentrations of MbCD and SM in solution can be used to produce
asymmetric bilayers [85, 86]. High MbCD-SM:lipid ratios could lead to extensive extraction
and solubilization of lipids from the SLB. To determine whether and at which concentration
MbCD a↵ects the integrity of the bilayer, several SLBs labeled with 0.05 %mol NBD-DOPE
were treated with di↵erent concentrations of MbCD-SM complexes (Figure 4.2). Treatment
of SLBs with high concentrations of MbCD-SM (20 mM), comparable to those normally used
for the preparation of asymmetric free standing bilayers, results in extensive damage and
eventually complete solubilization of the membrane. Time-lapse confocal imaging shows that
dark areas form and enlarge in the SLBs. The dark areas are indeed discontinuities of the
SLB, as suggested by the absence of NBD-DOPE and confirmed by the addition of a highly
hydrophilic fluorescent protein with no membrane a nity (i.e. eGFP) to the bu↵er above
the SLB. The protein colocalizes completely with the dark areas, confirming that in those
regions the mica is not covered by a bilayer, but exposed to the bu↵er (data not shown). In
contrast, at lower MbCD-SM concentrations (5-16 mM) SLBs showed less or no damage at
all, allowing the treatment of SLBs with MbCD-SM.
Thus, MbCD-SM concentration needs to be low enough to preserve SLBs integrity, but
su cient to enrich the upper leaflet of SLBs with SM. The SM enrichment of a membrane
leaflet is generally expected to reduce membrane fluidity, due to the increased lipid order [85,
86]. FCS has been proven to be a very useful tool to characterize the fluidity of lipid bilayers;
in particular, the D of fluorescently labeled lipids measured by FCS have been extensively
used to evaluate membrane organization [67]. In case of successful enrichment of a membrane
leaflet with SM, the D⇤ of a fluorescent probe included therein should decrease. We therefore
performed FCS on several DOPC SLBs labeled with Atto647N-SM in the upper leaflet before
and after treatment with di↵erent MbCD-SM concentrations (10-16 mM) to identify the
MbCD-SM concentration needed to minimize the Atto647N-SM D⇤, i.e. to maximize the
SM enrichment (Figure 4.3, A). Atto647N-SM D di↵ers significantly across the four MbCD-
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Figure 4.2 – SLB integrity upon MbCD-SM treatment. SLBs labeled with 0.05 %mol NBD-DOPE
were treated for 20 min with di↵erent concentrations of MbCD-SM (5-20 mM). After extensive
washing, fluorescence confocal images were acquired. High concentrations of MbCD-SM (20 mM)
result in a complete destruction of the bilayer. Scale bars are 10µm.
SM concentrations tested (one-way ANOVA, F(3, 20)=29.20, p<0.001). Tukey post-hoc
comparisons confirmed that concentrations equal or above 12 mM minimize the Atto647N-
SM D (12 mM: M=66%, SD=1; 14mM: M=68%, SD=2; 16mM: M=66%, SD=2) and make
it significantly lower than that resulting after treatment with 10 mM MbCD-SM (M=76%,
SD=2, ***p<0.001). Atto647N-SM D after incubation with 12, 14 and 16 mM MbCD-SM
are statistically not distinguishable (p>0.05). An MbCD-SM concentration of 12 mM is
su cient to decrease the D⇤ of the upper probe to the lowest value obtained in the MbCD-
SM concentration range tested, while keeping the damage of the SLBs to a minimum. When a
nominal MbCD-SM concentration of 12mM is used, the MbCD-SM:lipid ratio can be estimated
to be approximately 25000:1.
Having optimized the MbCD-SM concentration, we then asked whether the enrichment
in SM after MbCD-SM treatment is confined to the upper leaflet of the SLB, in other words
whether an asymmetric SLB is formed. For this purpose, several symmetric DOPC SLBs were
labeled with NBD-DOPE and Atto647N-SM in the lower and upper leaflet, respectively. We
then measured the mobility of the di↵erent probes by point-FCS before and after treatment
with 12 mM MbCD-SM (Figure 4.3, B). The D⇤ of Atto647N-SM decreases to about 67%
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Figure 4.3 – aSLB formation via MbCD-mediated lipid exchange method. [A] Upper leaflet D⇤s
are plotted before and after incubation with di↵erent concentrations of MbCD-SM (10-16 mM).
Concentrations equal or above 12 mM minimize the upper leaflet D⇤ and make it significantly lower
than that resulting after treatment with 10 mM MbCD-SM (***p<0.001).[B] Lower and upper leaflet
D⇤s are plotted before and after incubation with 12 mM MbCD-SM. Upper leaflet D⇤ significantly
decreases to about 67% of the original value (****p<0.0001), whereas the upper leaflet D⇤ exhibits
a meaningful but minor reduction of ca. 10% (**p<0.01), suggesting that the incorporation of the
SM was mostly limited to the upper leaflet and the formation of asymmetric SLBs was achieved.
NBD-DOPE and Atto647N-SM mean relative D values are plotted with error bars of one standard
deviation (A, n=5; B, n=9). Reported D values are relative to those measured in symmetric DOPC
SLBs with the same configuration of fluorescent probes.
of the original value (M=67%, SD=5; ****Paired t-test, t(8)=25.72, p<0.0001), as expected
in case of SM incorporation. From the calibration curve (Figure 4.4), the SM incorporation
can be estimated to be 50-70 %mol of the total lipids in the upper leaflet of the membrane.
In contrast, the D⇤ value of the NBD-DOPE exhibits a very small decrease of ca. 10%
(M=89%, SD=9; **Paired t-test, t(8)=4.94, p<0.01), probably due to limited interleaflet
coupling [118]. The observed decrease in NBD-DOPE di↵usion might alternatively be due to
the incorporation of small amounts of SM in the lower leaflet during MbCD-SM lipid exchange,
although this possibility seems less likely (Figure S4 [86]). Altogether, these data suggest that
the incorporation of the SM was mostly limited to the upper leaflet and that the formation
of an asymmetric bilayer was achieved. Moreover, it is worth noting that the influence of
the support on the lower leaflet is not substantially stronger than that exerted on the upper
leaflet, as confirmed by unsuccessful attempts to measure di↵erences in the di↵usion rate of
lipid dyes in each leaflet [60] (Table 6.1). Finally the slower NBD-DOPE dynamics after lipid
exchange in the bottom leaflet is not a result of nanoscopic defects introduced in the bilayer
through the MbCD treatment, as suggested by control experiments in which the SLBs were
treated with 12mM MbCD-DOPC (Figure 4.5).
4.2 Leaflet asymmetry is stable for several hours
Experimentally useful aSLBs need to be stable for a reasonable amount of time required to
run the desired experiments. The scrambling of the SLB is supposed to alter the local lipid
packing, and consequently, the di↵usion coe cient of the lipids in each leaflet. As SM flips
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Figure 4.4 – SLB fluidity in presence of bSM. Symmetric DOPC SLBs containing di↵erent amount
of bSM were labeled with Atto647N-SM in the upper leaflet and its D was measured by point-FCS. A
relativeD was calculated relatively to symmetric DOPC SLBs without bSM and plotted as a function
of the amount of bSM in the bilayer. Each point represents the average of measurements collected
from two or more independent SLBs preparations, each of them probed in five to eight randomly
chosen spots. Error bars are the corresponding standard deviations. The data points were fit with
a linear equation; 95% confidence bands are traced in grey. The obtained curve is used to estimate
the amount of bSM incorporated into the upper leaflet of the SLBs after the MbCD-mediated lipid
exchange, assuming that the behavior of the Atto647N-SM (which is always confined to the upper
layer) is similar in both symmetric and asymmetric DOPC SLBs with the same amount of bSM.
from the upper to the lower leaflet during equilibration, the Atto647N-SM D⇤ should increase
up to the value estimated for symmetric SLB containing 30 %mol SM (ca. 80%, Figure 4.4).
Also, the NBD-DOPE D⇤ should decrease until the ratio between lower and upper D is ca.
1 (i.e. fully scrambled lipids and fluorescent lipid probes). To determine how stable aSLBs
produced via MbCD-mediated lipid exchange are, the D⇤ of NBD-DOPE and Atto647N-SM
were measured by point-FCS at di↵erent times after MbCD-SM treatment in randomly chosen
positions (Figure 4.6).
The lower/upper D⇤ ratio does not decrease significantly until at least 4 hours after the
MbCD-mediated lipid exchange, suggesting that the asymmetry in the SLB is retained for
several hours. However, after one day, the asymmetry seems to be lost. A similar stability
in time was reported for asymmetric POPC bilayers prepared by the LB/VF method [56].
Moreover, the time scale of SM flip-flop appears comparable to the previously reported DSPC
rates [119, 120]. The major constituent of the used SM is in fact 18:0 SM (Product specifica-
tion, http://www.avantilipids.com), and its flip-flop time scale at RT can be estimated to be
of the order of hundreds of minutes. Thus, due to their stability in time, aSLB can be used
experimentally as asymmetric membrane models.
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Figure 4.5 – SLBs treated with MbCD-DOPC. SLBs were labeled with NBD-DOPE and Atto647N-
SM in the lower and upper leaflet, respectively. NBD-DOPE and Atto647N-SM D were then mea-
sured by point-FCS before and after treatment with 12 mM MbCD-DOPC. Both NBD-DOPE and
Atto647N-SM Ds do not change significantly (NBD-DOPE: M=105 %, SD=6, Atto647N-SM: M=99
%, SD=5; Paired t-test, p >0.05), suggesting that the D decrease observed in bilayers treated with
MbCD-SM is specifically due to the presence of SM (rather than e.g. bilayer defects introduced by
MbCD treatment). NBD-DOPE and Atto647N-SM mean relative D values are plotted with error
bars of one standard deviation (NBD-DOPE, n=5; Atto647N-SM, n=7). Reported D values are
relative to those measured in symmetric DOPC SLBs with the same configuration of fluorescent
probes.
4.3 The asymmetry in a SLB can also be generated in the
presence of a reconstituted membrane protein
To assess whether the MbCD-mediated lipid exchange method can be used to produce asym-
metric bilayers containing membrane proteins, the PLAP was reconstituted in SLBs, both
via direct protein reconstitution [96], and from proteoliposomes [73, 88].
In the direct reconstitution method, a symmetric DOPC SLB was exposed to CHAPS
detergent to promote protein incorporation. In the proteoliposomes method, the PLAP-
containing SLBs were prepared using the same VF method applied for DOPC SLBs. In both
methods, no dye for the upper leaflet was added, since the reconstituted PLAP was previously
fluorescently labeled allowing its N-terminal amino group to react with the succinimidyl ester
moiety of the Alexa647 dye; thus labeled-PLAP might be used as a probe for the upper
leaflet of the SLB. It is worth noting that only in the case of directly reconstituted PLAP, the
protein is expected to be confined to the upper leaflet [121]. In contrast, the reconstituted
PLAP from proteoliposomes is expected to be present also in the lower leaflet, since the
orientation of the protein might be randomized e.g. during proteoliposome fusion and SLB
formation. Accordingly, we found that the ⌧D of the PLAP measured in symmetric SLB is
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Figure 4.6 – aSLB stability over time. Lower/upper leaflet D⇤ ratios are plotted before and at
di↵erent times after incubation with 12 mM MbCD-SM. Lower/upper D⇤ ratio values are expected
to be higher than 1 in case of asymmetric enrichment of the SM in the upper leaflet. Lower/upper D⇤
ratios di↵ered significantly across the five time points tested (one-way repeated measures ANOVA,
F (4, 25)=55.65, p<0.001). Tukey post-hoc comparisons of the five time points indicate that before
(M=1.01, SD=0.11) and 22 h after treatment (M=0.91, SD=0.03) D ratios are significantly lower
than those at 0, 2 and 4 h after treatment (0h: M=1.30, SD=0.06, ***p<0.001; 2h: M=1.27,
SD=0.05, ***p<0.001; 4h: M=1.25, SD=0.08, ***p<0.001). Comparisons between the 0, 2 and 4
h after MbCD-SM treatment as well as between before and 22 h after MbCD-SM treatment were
not statistically significant (p>0.05), suggesting that the SLB asymmetry is conserved until at least
4 h after MbCD-SM treatment. NBD-DOPE and Atto647N-SM mean D⇤ ratios are plotted with
error bars of one standard deviation (n=6). Reported D values are relative to those measured in
symmetric DOPC SLBs with the same configuration of fluorescent probes.
significantly lower in samples in which the PLAP was directly reconstituted than in those
prepared from proteoliposomes (Figure 4.7, A). The lower apparent di↵usion rate (i.e. higher
⌧D) of proteoliposome-reconstituted proteins in SLB can be explained as a consequence of the
interaction between the large ectodomain of the protein in the lower leaflet and the support
[63], in contrast to the limited influence of the support on the mobility of lipids in the same
leaflet.
The protein-containing SLBs were finally treated with 12 mM MbCD-SM to produce
asymmetric bilayers. Similarly to protein-free SLBs, the SM enrichment of the upper leaflet
results in an increased lipid order, and consequently, a lower lipid mobility that can be
probed at the membrane by point-FCS. If SM incorporation is restricted to the upper leaflet
of the SLB, only the D⇤ of the upper probe will experience a severe decrease. The ratio
between the D⇤ values of the lower and upper probes will therefore reach values higher
than 1. Figure 4.7 B confirms the formation of PLAP-containing aSLBs showing how the
lower/upper D⇤ ratio increases after MbCD-mediated lipid exchange. Interestingly, the D⇤ of
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Figure 4.7 – aSLB formation in the presence of reconstituted PLAP. [A] Labeled-PLAP ⌧D, and
[B] lower/upper leaflet D⇤ ratios before and after incubation with 12mM MbCD-SM are plotted for
both reconstitution methods. The ⌧D (⌧D =4.5±0.6ms) of directly reconstituted PLAP is signifi-
cantly lower (t-test *p<0.05) than the ⌧D of PLAP prepared from proteoliposomes (⌧D =5.2±0.4ms,
D⇤=87±7% relative to directly reconstituted PLAP). The presence of the PLAP in the lower leaflet
and thus its interaction with the mica could explain the lower apparent ⌧D of the PLAP reconsti-
tuted from proteoliposomes. The expected localization of the PLAP in both reconstitution methods
tested is depicted underneath the bar plot. Atto647-PLAP mean ⌧D are plotted with error bars of
one standard deviation (n=6). Relative lower/upper D ratio values are expected to be higher than 1
in case of asymmetric enrichment of SM in the upper leaflet. The lower/upper D⇤ ratio increases in
both reconstitution methods after MbCD-mediated lipid exchange (***Paired t-test: direct reconsti-
tution, t(5)=9.54, p<0.001; proteoliposomes, t(5)=8.18, p<0.001) and it is significantly lower in the
proteoliposomes samples (t-test: t(5)=3.63, p<0.01), most probably due to the fraction of PLAP
present in the lower leaflet (i.e. not a↵ected by the lipid exchange). NBD-DOPE and Atto647-PLAP
mean D⇤ ratios are plotted with error bars of one standard deviation (n=6). Reported D values
are relative to those measured in symmetric DOPC SLBs with the same configuration of fluorescent
probes.
the reconstituted PLAP decreases in both cases after MbCD-mediated lipid exchange (direct
reconstitution: D⇤=58±6%; proteoliposomes: D⇤=78±10%, relative to symmetric SLBs with
the same configuration of fluorescent probes). The decrease is lower in the PLAP reconstituted
from liposomes, probably as a consequence of the presence of a significant protein fraction in
the lower leaflet. The PLAP in the lower leaflet is not a↵ected by SM incorporation and its D⇤
should only marginally decrease, similarly to the D⇤ of the lower leaflet probe (D⇤=86±7%).
The overall PLAP D⇤ (average between upper and lower leaflet) is therefore higher than that
measured for the direct reconstitution method, in which the PLAP is confined to the upper
leaflet. The D⇤ of the lower leaflet probe exhibits a smaller decrease in both cases (direct
reconstitution: D⇤=87±16%; proteoliposomes: D⇤=86±7%) confirming the asymmetry in
the protein-containing SLBs.
Altogether, these results show that the MbCD-mediated lipid exchange method is fully
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compatible with both the proteoliposomes and the direct reconstitution methods. Used in
conjunction with one of the protein reconstitution methods, aSLBs can provide a more phys-
iological protein environment. By making accessible in the same sample the state before and
after lipid enrichment (i.e. symmetric and asymmetric state), aSLBs are also a handy tool to
study how compositional lipid asymmetry can influence protein structure and function. It is
noteworthy that although the proteoliposome reconstitution is the method of choice for many
large transmembrane proteins [122], its application in combination with aSLBs has a limited
value. The protein is in fact inserted in in both directions and therefore interacts with each
leaflet di↵erently.
4.4 SM in the lower leaflet of an aSLB is required for phase
separation in both leaflets
aSLBs produced as described before and containing up to 60 %mol SM in the upper leaflet
do not show macroscopic liquid/gel coexisting domains, as reported for the corresponding
symmetric SLBs [123, 124]. As already proposed for asymmetric GUVs [118], the upper
leaflet of aSLBs might either be in a homogeneous liquid phase or contain submicroscopic
gel domains. To address the question of whether and how compositional asymmetry a↵ects
phase separation, we prepared SLBs and aSLBs with the same overall lipid composition and
compared their behavior after addition of cholesterol. In fact, although binary mixtures of
lipids were crucial to determine the connection between phase behavior and multiple variables
such as lipid composition and temperature, ternary lipid mixtures containing cholesterol show
a richer phase behavior and can better model the animal cell plasma membranes [125].
In particular, symmetric DOPC SLBs containing up to 60 %mol of SM and aSLBs con-
taining approximately 60 %mol of SM in the upper leaflet were produced as described before
and exposed to 5 mM MbCD-Chol complexes. Similarly to MbCD-SM complexes, high con-
centrations of MbCD-Chol (10 mM) result in a complete destruction of the bilayer (Figure
4.8, A). A concentration of 5 mM was chosen because it was the lowest concentration at
which phase separation could still be induced in symmetric bilayers containing less than 50
%mol SM. When aSLBs were treated with 5 mM MbCD-Chol complexes, the incorporation
of cholesterol in the lower leaflet could be estimated to be up to 20 %mol of the total lipid
content (Figure 4.9). This value correlates well with the observed phase behavior in symmet-
ric and partially asymmetric SLBs, according to a recently improved experimentally-derived
phase diagram of the same mixture [123]. Moreover, in absence of opposing evidences, we
assume that the cholesterol equilibrates fast and distributes uniformly throughout the leaflets
of the aSLB [126].
Only in symmetric SLBs containing more than 30 %mol of SM and in scrambled aSLBs
(aSLBs after 22 h incubation time), the incorporation of cholesterol results in the formation
of Lo domains registered in both lower and upper leaflets (Figure 4.10, A and C; Figure 4.8,
A). Interestingly, in the symmetric SLBs, preexisting gel domains [123] disappeared soon after
cholesterol addition and Lo domains appeared both in the same and in new positions (Figure
4.10, A1). Same concentrations of cholesterol-loaded MbCD failed to induce phase separation
in freshly prepared aSLBs, in which SM is still confined to the upper leaflet (Figure 4.10, B).
The transition from aSLBs to scrambled aSLB and the appearance of phase separation
can be followed in time (Figure 4.11, A). Time-lapse fluorescence imaging allows to record the
time of appearance of Lo domains in partially scrambled aSLBs. Within a single bilayer, Lo
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Figure 4.8 – Phase separation in symmetric SLB after cholesterol addition. SLBs were labeled
with 0.5 %mol Atto647N-SM in the upper leaflet and treated for 15 min with 1, 2.5, 5 or 10 mM
MbCD-Chol complexes. [A] Confocal fluorescence images of symmetric SLBs containing 20, 30, 40
or 50 %mol bSM were acquired after treatment. Upon cholesterol incorporation, Lo domains formed
in both lower and upper leaflets in symmetric bilayer containing 40 and 50 %mol bSM and at all
MbCD-Chol concentration tested. High concentrations of MbCD-Chol (10 mM) result in a complete
destruction of the bilayer. Scale bars are 10 µm. [B] Domains number, average size and circularity
were measured and plotted against time; at 0 min MbCD-Chol was added to the bilayer.
domains appear simultaneously all over the sample, whereas di↵erent samples show diverse
timing (t1/2=372±129min); this is probably due to experimental variation in the SM and
cholesterol content of each bilayer. However, once the first domains appear, the time to reach
the final number of domains is comparable in all measured samples (tf-0=262±35min). Do-
mains keep growing after the final number of domains is reached, suggesting that at this point
they are not in equilibrium yet (Figure 4.11, B). As shown before, aSLBs slowly loose their
asymmetry through spontaneous flip-flop of lipids causing a gradual and inversely correlated
change of the SM amount in each leaflet. Lo domains appearance is most probably due to
this SM redistribution across the bilayer and thus to lipid flip-flop in general. The onset of
the domain appearance can be then used as an indirect measure of lipid flip-flop rate.
As a consequence of lipid flip-flop in aSLBs, the local concentration of SM in the lower
leaflet increases while decreasing in the upper one. This change in transversal lipid compo-
sition in turn induces phase separation. In order to understand whether the increase of SM
concentration in the lower leaflet (rather than its decrease in the upper leaflet) is determinant
in promoting phase separation, we produced aSLBs containing 5-10 %mol SM and ca. 60
%mol SM in the lower and upper leaflet, respectively. To do so, we first formed symmetric
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Figure 4.9 – Cholesterol incorporation in aSLBs. [A] SLBs were labeled with NBD-DOPE in the
lower leaflet and its D was then measured by point-FCS in symmetric SLBs and aSLBs both before
and after treatment with 5 mM MbCD-Chol. NBD-DOPE D significantly decreases to about 71% of
the original value in symmetric SLBs (M=71%, SD=6; ***Paired t-test, t(5)=8.08, p<0.001) and to
about 80% of the value in aSLBs before MbCD-Chol treatment (M=80%, SD=2; ***Paired t-test,
t(5)=20.46, p<0.001). NBD-DOPE mean relative D are plotted with error bars of one standard
deviation (n=6). Reported D values are relative to those measured in symmetric DOPC SLBs
with the same configuration of fluorescent probes.[B] Symmetric DOPC SLBs containing di↵erent
amount of cholesterol were labeled with NBD-DOPE in the lower leaflet and its D was measured
by point-FCS. A relative D was calculated relatively to symmetric DOPC SLBs without cholesterol
and plotted as a function of the amount of cholesterol in the bilayer. Each point represents the
average of measurements collected from two independent SLBs preparations, each of them probed
in al least three randomly chosen spots. Error bars are the corresponding standard deviations. The
data points were fit with a linear equation; 95% confidence bands are traced in grey. The obtained
curve is used to estimate the amount of cholesterol incorporated into the lower leaflet of aSLBs
after MbCD-mediated cholesterol exchange, assuming that the behavior of the NBD-DOPE (which
is always confined to the lower layer) is similar in both symmetric and asymmetric DOPC SLBs with
the same amount of cholesterol.
DOPC SLBs containing 5-10 %mol SM; this amount of SM is not su cient to induce phase
separation upon cholesterol incorporation (Figure 4.8, A). We then treated the same symmet-
ric SLBs with MbCD-SM complexes to obtain a partially aSLB. We assume that these aSLBs
have a lipid composition of the upper leaflet similar to those discussed in the previous para-
graphs, i.e. ca. 60 %mol SM. Upon cholesterol addition, phase separation could be induced
in partially aSLB containing as low as 5 %mol of SM in the lower leaflet. This observation
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Figure 4.10 – Phase separation in scrambled, fully and partially asymmetric SLBs after cholesterol
addition. Phase separation and coupling in symmetric [A], scrambled [C], and fully [B] or partially [D]
asymmetric SLB after cholesterol addition. In symmetric SLBs, scrambled and partially aSLBs Lo
domains coupled in both lower and upper leaflets form upon cholesterol incorporation. In fully aSLBs
no change in the phase behavior of the bilayer can be observed. [A1] The kymograph shows domain
dynamics in symmetric SLBs before and after cholesterol addition at the overlaying line depicted in
A. Preexisting gel domains in symmetric SLBs disappeared soon after addition of cholesterol and Lo
domains appear both in the same and new positions. Time (30 spf) is along horizontal axis. Scale
bars are 10 µm.
reinforces the hypothesis that SM is required in the lower leaflet for phase separation in both
leaflets (Figure 4.10, D). This is in line with the phase diagram for symmetric bilayers with
analogous composition [123]. Depending on the amount of cholesterol, phase separation re-
quires in fact a minimum amount of SM (ca. 10-30 %mol) and persists up to 80-90 %mol SM.
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Figure 4.11 – Phase separation dynamics in aSLBs. [A] Domain appearance in aSLBs treated with
5 mM MbCD-Chol. [B] Domains number and average size were measured and plotted against time;
at 0 min the aSLB was formed. After the final number of domains is reached, domains grow further,
suggesting that at this time point they are not at equilibrium yet.
Furthermore, it is interesting to notice that SM, although more abundant in the extracellular
leaflet, is also present in the cytoplasmic leaflet of natural membranes in many cellular types
at about 1:10 ratio [127].
The observed di↵erences in terms of phase separation in symmetric or aSLBs provide
further experimental evidence that the transversal lipid distribution a↵ect the overall lipid
miscibility. In accordance with Collins and Keller [116], the lipid composition of one leaflet
strongly influences the phase behavior of the other leaflet, suppressing or priming phase
separation; in particular, our results suggest that a minimal amount of SM is required in the
nonspontaneously phase separating leaflet for cholesterol to induce phase separation in both
leaflets. As also pointed out in the above-mentioned study, the presence of one leaflet with a
composition supporting phase separation (in a corresponding symmetric bilayer) is necessary
but not su cient to induce domain formation in the whole bilayer. Of interest, it is well
known that lipid mixtures mimicking the outer leaflet of the plasma membrane can give rise
to raft-like ordered domains. On the other hand, lipid mixtures corresponding to typical inner
leaflet compositions form membranes that are homogeneous [128]. Our results address this
incongruence, suggesting that small changes in the composition of the inner leaflet (e.g. even
low concentrations of saturated lipids such as SM, not enough to produce phase separation
in a corresponding symmetric bilayer) can have a prominent role in the formation of lipid
domains spanning the whole bilayers.
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Unlike Wan and colleagues [115], we were not able to induce formation of macroscopic Lo
domains in a single SM-containing leaflet of an aSLB. This di↵erence can be explained taking
into account the individual properties of the two used systems. In the LB/VT approach,
domains in the LB leaflet are already present in the original monolayer, which is transferred
to a support and stabilized by a tethered polymer cushion. In our system domains form
de novo after addition of cholesterol to the bilayer. These systems produce only apparently
conflicting results. It might be possible in fact that the LB leaflet resides in a local energy
minimum, and the addition of the upper layer might not be enough to perturb its state (i.e.
the bilayer system might be kinetically trapped in a nonequilibrium state). The composition
of our aSLBs is very similar, although not identical to one of the few compositions tested by
Wan and colleagues for which no phase separation could be induced in the upper leaflet (in the
presence of domains in the lower leaflet). We therefore speculate that the lipid mixtures that
in the LB/VT asymmetric system do not show domain induction from the lower to the upper
leaflet are the same that in our system would suppress phase separation in both leaflets. The
presence of phase separation in the LB leaflet might be due to the specific leaflet-by-leaflet
assembly methodology.
Similar considerations might be extended to the LB/LS system of Garg and colleagues
[129], in which both lower and upper leaflets are preformed as monolayers (LB and LS, respec-
tively) with their respectively energetically most favorable phase states and only subsequently
assembled on top of each other.
Having observed a di↵erent phase behavior in our system, we decided to investigate asym-
metric free-standing bilayers with analogous lipid compositions as alternative asymmetric bi-
layer models (Figure 4.12). Symmetric GUVs labeled with 0.5 %mol of NBD-DOPE and 0.2
%mol of Atto655-DOPE in both leaflets show Lo domains as expected. GUVs originally con-
taining 20 %mol cholesterol and di↵erent amounts of SM (0 or 5 %mol) in a DOPC bilayers
were labeled with 0.5 %mol NBD-DOPE and Atto655-DOPE in the inner (green channel)
and outer (red channel) leaflet, respectively and treated for 30 min with 71 mM HDaCD-SM.
Although we did not measure the amount of bSM in the outer leaflet of such GUVs, previous
results [97] suggest that the outer leaflet is significantly enriched in SM, compared to the
inner leaflet. GUVs originally not containing SM show no changes in the phase behavior
of the bilayer upon SM incorporation in the outer leaflet; in those GUVs, Lo domains can
be only rarely observed. When SM is present in the original mixture and thus in the inner
leaflet, phase separation can readily be induced upon treatment wHith HDaCD-SM. Similar
results were obtained with partially aGUVs containing 10 or 20 %mol SM in the inner leaflet.
When observed, Lo domains were always coupled in both inner and outer leaflets. By using
aGUVs, we were not only able to completely reproduce the domain registration observed on
SLBs, but also to rule out that the domain registration properties observed in our system are
influenced by the presence of the support.
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Figure 4.12 – Phase separation and coupling in symmetric, scrambled, and fully or partially asym-
metric GUVs. [A] Schematic diagram of the asymmetric GUVs formation via HDaCD-mediated lipid
exchange and of the leaflet-specific labeling. Confocal fluorescence images of [B] symmetric GUVs
containing DOPC:bSM:Chol 30:50:20, [C] aGUVs originally containing DOPC:Chol 80:20 soon af-
ter HDaCD-SM treatment or [D] after 24 h incubation time (scrambled aGUVs) and [E] aGUVs
originally containing DOPC:bSM:Chol 75:5:20 (partially aGUVs). Scale bars are 10 µm.

The experimental work presented in Chapter 5 was designed together with Prof. Petra
Schwille (Max Planck Institute of Biochemistry, Martinsried, Germany).
Chapter 5
Shape transformations of
asymmetric giant unilamellar
vesicles
Although GUVs have been successfully used to reconstitute single- [130, 131, 132] or multi-
proteins systems [72, 133, 134, 135], their size and shape are still di cult to control [136].
Alternative approaches to confine the protein and/or lipid machinery in compartments with
a defined size and shape were recently developed. Micro-fabricated square chambers with the
approximate dimensions of an eukaryotic cell (10-15 µm wide; 2.6 µm deep,) were successfully
used to reconstitute the interaction between dynein and dynamic microtubule ends and to
reliably center microtubule asters [137]. Similarly Min protein oscillations could be generated
in rodlike compartments resembling E. coli shapes and covered with SLBs [138]. Although
these 2D in vitro systems have been proven to be a valuable tool in selected bottom-up
approaches, the influence of the support on protein behavior remains a major obstacle for the
functional reconstitution of several minimal systems. For example when the co-reconstitution
of FtsZ with the MinCDE system, already achieved on SLBs [139], was attempted in the
above-mentioned rodlike compartments, FtsZ filaments bundles could be spatially positioned,
but failed to compact in a Z-ring like structure (Katja Zieske and Dr. Ariadna Martos, Max
Planck Institute of Biochemistry, Martinsried, Germany, personal communication). This
behavior is most probably due to the hindrance exerted by the support to freely protein
di↵usion at the membrane [63]. Thus, free-standing membranes with shapes more similar to
the biological counterpart than nearly spherical ones would be desirable.
Besides nearly spherical shapes, GUVs exhibit many di↵erent shapes that are reminiscent
of cell morphologies, such as, e.g., stomatocytes or a necklace of small vesicles [140, 141].
The great variety of non-spherical shapes of vesicles is determined by bending elasticity as
introduced independently in three seminal papers (Canham 1970, Helfrich 1973, Evans 1974).
Vesicles will acquire the shape at which their curvature energy subject to the appropriate
constraints is minimal [142]. These shapes can be transformed into one another by mechan-
ical stress, by changing the pH, the osmotic conditions, the composition of the lipid, or the
temperature [140, 141]. Additionally, shape changes can occur through local or global modi-
fications of the relative area of the two bilayer leaflets, for example due to asymmetric lipid
transbilayer di↵usion [143]. This behavior was observed by Farge and Devaux [141], which in-
duced shape changes of GUVs manipulating the fraction of phospholipids in each monolayer.
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In particular, they changed the distribution of egg PG through the bilayer by means of a pH
gradient and added or removed LysoPhospatidylCholine (L-PC) from the outer monolayer.
Similarly Khalifat and colleagues showed that local acidification of PG-containing vesicles
promotes inward tubulations [143].
GUVs exhibiting phase coexistence of Lo and Ld phases were also predicted to undergo
di↵erent shapes transformation which resemble biological membranes processes (i.e. budding)
and depend on the elasticity and boundary properties of the coexisting domains [144, 145].
Using high-resolution fluorescence imaging and two dyes which preferentially label the Lo or
Ld phase, Baumgart and colleagues [146] showed for the first time experimentally that domain
composition and local membrane curvature are indeed directly correlated. In particular they
observed circular, stripe and ring domains in GUVs formed from a ternary mixture of the
lipids sphingomyelin, phosphatidylcholine and cholesterol. These domains show long-range
ordering in the form of locally parallel stripes and hexagonal arrays of circular domains as well
as curvature-dependent sorting. Later the role of several sterols other than cholesterol was
investigated in GUVs by Bacia and colleagues [95]. The authors showed that the structure of
sterols used for the preparation of GUVs determines whether a positive or negative curvature
of the sterol-dependent phase is formed. In both cases vesicle were produced in low osmolarity
sucrose solutions (100 and 12 mM, respectively). If the same experiments are reproduced in
presence of salt or at higher osmolarity (300 mM sucrose) closer to the physiological value the
domains do not bulge out (Diego Ramirez and Dr. Henri Franquelim, Max Planck Institute of
Biochemistry, Martinsried, Germany, personal communication). Indeed both sugars and salts
and known to influence the bending rigidity of membranes [147]. When GUVs are exposed
to mono- and oligosaccharide solutions with concentration up to around 300 mM a strong
decrease in the bending rigidity of membranes was observed [148]. The reduction of the
bending rigidity could be explained by the thinning of the membrane which was reported to
take place in the used concentration range [149]. On the other hand, the e↵ect of salts on
the bending rigidity of membranes is not fully understood and a unified vision is still missing
[147]. that is, it is not clear whether upon adsorption salts decrease [150], increase [151] or
not change [152] the bending rigidity of the membrane. Independently from the underlying
mechanism, the absence of bulging in presence of salts and high concentrations of sugars
makes these phase separated GUVs not suitable for protein studies which require the usage
of physiological bu↵ers for the reconstituted proteins to correctly function.
In this chapter we described how transbilayer lipid asymmetry can induce changes in
the shape of giant liposomes. We first show that asymmetric intramembrane domains can
bulge out in conditions in which symmetric domains do not, such as at high osmolarity or
in absence of any Lo specific dyes. We then report four di↵erent GUV transformations that
can be induced by enriching the outer leaflet of the vesicles with PG: (1) prolate ellipsoid to
spherical vesicle, (2) discocyte to stomatocyte, (3) vesicle budding, and (4) vesicle endocytosis.
We finally developed a FRAP assay to determine whether the two daughter vesicles originated
by a budding event are still connected or if they are completely separated.
5.1 Bulging of intramembrane asymmetric domains in GUVs
In chapter 4 we showed that asymmetric domains can be formed in DOPC GUVs originally
containing 20 %mol cholesterol and at least 5 %mol bSM if the outer leaflet of the GUVs
was enriched in bSM via cyclodextrin-mediated lipid exchange [86]. For this purpose HPaCD
5.1 Bulging of intramembrane asymmetric domains in GUVs 63
needed to be used. Having a smaller ring size than MbCD (Figure 5.1, A-B), HPaCD shows no
or little a nity for cholesterol, whereas it is still able to mediate phospholipid exchange [97].
These features are extremely advantageous in our experimental setup, allowing the exchange
of DOPC for bSM without extracting cholesterol from the membrane. Thus, we are able to
move from a single fluid phase to a coexistence of fluid ordered and disordered phases, keeping
the temperature (25￿) and the cholesterol molar ratio fixed (Figure 5.1, C).
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Figure 5.1 – HPaCD-mediated asymmetric domain induction in GUVs. [A-B] chemical structures
of MbCD and HPaCD, respectively. Both adapted from http://www.sigmaaldrich.com/. [C] Phase
diagrams for bSM/DOPC/Chol at 15￿ (solid) and 25￿ (dotted) adapted from Petruzielo and col-
leagues [123]. Red dots and arrow visualize the position of the external leaflet of the GUVs in the
phase diagram before and after HPaCD-bSM mediated lipid exchange.
The asymmetric Lo domains bulged out in a fraction of the asymmetric GUVs exhibiting
coexistence of Lo and Ld phases. Importantly the bulging out of Lo domains was only observed
in samples containing 5 %mol bSM in the inner leaflet, but not in samples containing 10 or
20 %mol bSM, and it was lost together with the leaflet asymmetry after 24 h incubation.
Additionally, the bulging out of the Lo domain was rarely observed in GUVs containing a
single Lo domain, whereas it was common in GUVs containing multiple Lo domains. In
particular two di↵erent geometries were observed: GUVs with several Lo domains regularly
arranged throughout the vesicle surface (Figure 5.2, A) and GUVs with two or three Lo
domains irregularly arranged throughout the vesicle surface (Figure 5.2, B-C). In both cases
Lo domains in a GUVs can be of similar or various size. The curvature of each Lo domain can
be estimated by measuring its Radius of curvature (R) that is the radius of the circular arc
which best approximates the Lo domain curve. R is defined as the inverse of the curvature.
In the former geometry Lo/GUV R is significantly higher than in the latter one (0.61±0.19
vs 0.41±0.06; p<0.001). One possible explanation for this di↵erence is the way GUVs adhere
to the support; lower Rs were measures in GUVs whose adhesion area included the edges of
Lo domains. The direct contact between surface and Lo domains could stabilize the bulging
out of the domain.
Similar geometries were already described for symmetric GUVs exhibiting coexistence of
Lo and Ld phases [146]. However several observations suggest that the bulging in our system
is directly related to the asymmetric nature of the domains rather than exclusively due to
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Figure 5.2 – Bulging of intramembrane asymmetric Lo domains in GUVs. GUVs were labeled with
NBD-DOPE in the inner leaflet and fluorescence confocal images were taken after HPaCD-mediated
lipid exchange. Scale bars are 10 µm.
the presence of intramembrane domains. First of all bulging out is absent in symmetric,
scrambled (after 24h incubation time) or poorly asymmetric GUVs (containing 10 or 20%mol
bSM in the inner leaflet). Secondly bulging out takes place in conditions in which it is usually
not observed in symmetric GUVs such as high osmolarity, absence of cholera toxin, other Lo
specific dyes or a hyperosmotic external bu↵er.
5.2 Shape transformations in GUVs asymmetrically enriched
with PG
To further investigate the role of transbilayer lipid asymmetry on membrane shape, we selec-
tively enrich the outer leaflet of GUVs with PG, which is known to e↵ect vesicle shape when
asymmetrically distributed across the membrane leaflets [141, 143]. In particular DOPC
GUVs were incubated with di↵erent amount of MbCD-DOPG complexes and time-lapse im-
ages were acquired every 30 s up to 1 h in several areas of the sample chamber. When
a high concentration of MbCD-DOPG complexes was used (nominal concentration of 35.5
mM) the most common shape change observed was the transformation from a prolate ellip-
soid to a spherical vesicle (Figure 5.3). Sometimes the transformation reversed back to the
original shape. It should be note that most GUVs did not survive when treated with high
concentrations of MbCD-DOPG.
When the concentration of the MbCD-DOPG complexes was lowered to 7.1 mM, further
shape changes could be observed. In particular discocytes transform into stomatocytes (Figure
5.4). The invagination can eventually form an inside budded vesicle. Moreover spherical
vesicles undergo vesicle budding after transforming into a pear-like (Figure 5.5) vesicles. At
this concentration, most GUVs survived the treatment with MbCD-DOPG.
When an even lower concentration of MbCD-DOPG complexes was used (nominal con-
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Figure 5.3 – GUV transformation: prolate ellipsoid to spherical vesicle. GUVs were labeled with
NBD-DOPE and time lapse confocal fluorescence images were taken while treating with high con-
centrations of MbCD. The scale bar is 10 µm and time labels are in m:s from the observation start.
Figure 5.4 – GUV transformation: discocyte to stomatocyte. GUVs were labeled with NBD-
DOPE and time lapse confocal fluorescence images were taken while treating with intermediate
concentrations of MbCD. The scale bar is 10 µm and time labels are in m:s from the observation
start.
centration 1.42 mM) invagination and endocytosis of long tubular structure is commonly
taking place. First, spherical vesicles protrude in a pear-like shape, then membrane tubules
invaginate from the protrusion tip. The tubules are finally released inside the vesicle while
the vesicle itself becomes spherical again. Very few GUVs were lost when treated with this
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Figure 5.5 – GUV transformation: vesicle budding. GUVs were labeled with NBD-DOPE and
time lapse confocal fluorescence images were taken while treating with intermediate concentrations
of MbCD. The scale bar is 10 µm and time labels are in m:s from the observation start.
low concentration of MbCD-DOPG.
Figure 5.6 – GUV transformation: endocytosis. GUVs were labeled with NBD-DOPE and time
lapse confocal fluorescence images were taken while treating with low concentrations of MbCD. The
scale bar is 10 µm and time labels are in m:s from the observation start.
The fact that so di↵erent GUV transformations can take place upon treatment with
MbCD-DOPG is probably due to a specific combination of lipid extraction and exchange
exerted on the GUV membrane by di↵erent amount of MbCD. As shown for SLBs (Figure
4.2), the e↵ect of MbCD on membranes changes dramatically according to its concentration.
At high concentration MbCD can extensively extract lipids from the bilayer whereas at low
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concentrations lipid extraction is not detectable any more and lipid exchange takes place.
In a narrow range of intermediate concentrations lipid exchange is maximized while lipid
extraction is still present. We assume that similar processes are taking place when GUVs
are exposed to di↵erent amounts of MbCD-DOPG, namely predominantly lipid extraction
at high concentrations, predominantly lipid exchange at low concentrations and both lipid
extraction and exchange at intermediate concentrations. The described transformations were
already experimentally observed, for example in DMPC vesicles upon temperature changes
[153]. When the temperature is increased the membrane expands more than the enclosed
volume, thus varying the excess area Ae, that is the di↵erence between the actual area and
that which would be required to form a sphere of the same volume. In our system we
can change the Ae keeping the temperature fix, but depleting, exchanging or enriching the
lipids in the outer leaflet of the vesicle membrane. The transformation from a spherical
vesicle to a prolate ellipsoid requires an increased Ae while its transition back a reduction.
This transition was in fact observed at high concentrations of MbCD-DOPG when the lipid
extraction is predominant. Both the transition from discocyte to stomatocyte with formation
of an inside budded vesicle and from prolate ellipsoid to pear-like vesicle with formation of
an outside budded vesicle requires a higher increase in Ae. This is achieved at intermediate
concentrations of MbCD-DOPG, when the lipid exchange is maximized. Finally the inward
budding of protruded and tethered vesicles was reported at very low Ae, which could be the
case of GUVs treated with very low concentrations of MbCD-DOPG.
5.3 FRAP assay for vesicle fission
Among the observed transformations, vesicle budding attracted our attention because it re-
sembles the corresponding biological processes of cell division and exocytosis. It is particularly
interesting to verify whether a vesicle can divide in two daughter cells in absence of intramem-
brane domains [154] and/or without the help of membrane shaping peptides or proteins [155],
but only because of the transbilayer lipid asymmetry. Therefore we developed a FRAP assay
to determine whether the two daughter vesicles are still connected via a neck or if they are
completely distinct. When two adjacent vesicles are imaged at their equators it is not possible
to distinguish if they are completely separated from each other or not, unless the neck is big
enough, that is, bigger than the resolution limit of the optical setup used (Figure 5.7).
The idea underlying the FRAP assay is described in Figure 5.8. Briefly only one of the
two daughter vesicles is bleached and the fluorescence intensity is monitored in both vesicles.
If the two vesicles are separated no change in the average intensity will be detected; on the
other hand if the two vesicles are still connected, the intensity of the bleached vesicle will
eventually recover while the fluorescence intensity of the unbleached vesicle will decrease. In
order to perform this assay, the original GUVs need to be filled with a fluorescence probe.
To validate the method, we used a well known artificial budding system [95]. In this
system, domain budding can be induced in GUVs made of a canonical raft lipid mixture in
a low osmotic medium by increasing the osmolarity of the external bu↵er (Figure 5.9, B).
Both Ld and Lo domains can be specifically labeled (Figure 5.9, A). Most of the known lipid
dyes and fluorescently labelled lipids partition preferentially into the Ld phase, allowing to
select within a large spectrum of dyes. To label the Lo phases on the other hand only few
strategies are available [156]: fluorescent polycyclic aromatic hydrocarbons with a flat ring
system i.e. perylene, [146] or fluorescently labeled Cholera Toxins bound to GM1 [64]. In the
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Figure 5.7 – Imaging of adjacent GUVs. Schematic representation of two adjacent GUVs: fully
separated [A] and connected by a neck smaller than resolution limit of the optical setup used [B]. If
imaged at their equator both GUVs pairs appears as two touching circles. [C]
latter strategy GM1, which partitions preferentially into the Lo phase, must be previously
incorporated in the GUV lipid mixture at low molar ratio to avoid changes in the lipid spatial
distribution.
Phase-separated GUVs filled with AlexaFluor 488 were subjected to hyperosmotic shock
and underwent budding. For each GUV pair analyzed, only one of the two daughter vesicles
was bleached; the average fluorescence intensity inside the bleached GUV was then monitored
for several minutes, single (Bkg) or double (Bkg/ref) normalized and plotted against time. We
first select GUV pairs for which it was obvious to determine whether or not the vesicle fission
took place. In GUV pairs still connected by an optical resolvable neck (Figure 5.10, A; image),
the di↵usion of the dye between the two vesicles is fast and the mixing is complete within the
bleaching time. This results in an apparent simultaneous bleaching of both daughter vesicles
as shown by the double corrected curve (Figure 5.10, A; graph). Even if there is a net loss of
fluorescence intensity, both bleached and unbleached vesicles experience the same degree of
fluorescence loss. In GUV pairs clearly separated from each other (Figure 5.10, B; image), no
recovery of fluorescence signal is detected within the bleached vesicle. If very little acquisition
bleaching is present, the two single and double normalized curves lay on top of each other
(Figure 5.10, B; graph). Among the measured vesicles, we could identify GUV pairs which
were only apparently separated (Figure 5.10, C; image) or connected (Figure 5.10, D; image).
In the first case, the small size of the neck slows the di↵usion of the dye between the two
vesicles which does not reach equilibrium within the bleaching time. This allows us to record
the fluorescence recovery inside the bleached vesicle (Figure 5.10, C; graph). In the second
case both normalized curves will show no recovery of fluorescence signal (Figure 5.10, D;
graph) as expected for vesicles after fission.
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Figure 5.8 – FRAP assay for vesicle fission. Schematic representation of the FRAP assay developed
to distinguish complete budding events.
A B
Figure 5.9 – Budding of intramembrane domains after hyperosmotic shock. [A] GUV filled with
AlexaFluor 488 (green) exhibiting coexistence of Lo and Ld phases labeled with DiI (magenta) and
CtxB-647 (blue) bound to GM1, respectively. [A] GUV undergoing budding after hyperosmotic
shock. Only the Ld phase is labeled. Scale bars are 10 µm and time labels are in m:s from the
observation start.
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Figure 5.10 – FRAP measurements of budded intramembrane domains after hyperosmotic shock.
[A-D] Phase-separated GUVs filled with AlexaFluor 488 (green) underwent budding after hyper-
osmotic shock. One of the two daughter vesicles was bleached (yellow square) and the average
fluorescence intensity was monitored for several minutes, normalized for either only Bkg or Bkg/ref
and plotted next to the corresponding vesicle pair. Lo and Ld phases were originally labeled with
DiI (red/magenta) and eventually with CtxB-647 (blue) bound to GM1, respectively.

The experimental work presented in Chapter 6 was designed together with Dr. Salvatore
Chiantia (Humboldt Universita¨t zu Berlin, Germany).
Chapter 6
Lateral organization of the
influenza virus hemagglutinin
transmembrane helix into
asymmetric model membranes
Influenza virus HA is one of two types of glycoproteins embedded in the viral lipid envelope.
Although the name originates from its ability to agglutinate erythrocytes in vitro [157], HA
pathological functions are not related to agglutination. HA is instead responsible for the
recognition of the host cells, binding to terminal sialic acids of glycoproteins and glycolipids
of the host cell membranes, as well as for the fusion of the viral envelope with the host cell
lysosomal membranes [158]. The structure of HA in the pre-fusion state was solved in 1981
[159]. HA is a homotrimeric integral membrane protein; each monomer is synthesized as
precursors that is proteolytically cleaved in the Golgi into two disulfide-linked subunits, HA1
and HA2. The HA2 subunit consists of a helical chain anchored in the membrane by a TM
helix.
HA has been found to be enriched in Detergent Resistant Membrane (DRM) fractions
[160]. Schei↵ele and colleagues could demonstrate that the raft association is indeed an
intrinsic property of the TM domain of the protein. Mutant HA molecules with foreign TM
domains lose their ability to associate with lipid raft. The same e↵ect is exerted by selected
mutations of the HA TM domain, i.e. the GS520AA mutation, showing that hydrophobic
residues in contact with the exoplasmic leaflet of the membrane play a role in the protein
partitioning behavior. This is supported by the observation that the influenza virus envelope
is enriched in raft lipids [161] and by in vivo Fo¨rster Resonance Energy Transfer (FRET)
studies [162, 163]. Interestingly the HA TM domain is able to form heat-resistant oligomers
composed of two to five subunits in SDS micelles [164] and stable dimers when expressed
in cells [162]. However when the reconstitution of the HA full length protein or of its TM
domain was attempted both in GUVs and Giant Plasma Membrane Vesicles (GPMVs), they
did not partition into Lo domains [131].
Possible explanations for the di↵erent partitioning behavior of the HA in cell and model
membranes are: the reduced lipid packing of Lo domains in cell membranes and the absence
of cytoskeletal components or transbilayer asymmetry in model membranes. Combining con-
focal spectroscopy XY-scan and photon-counting histogram analyses, Hussain and colleagues
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could recently demonstrate that bilayer asymmetry influences integrins partitioning in raft-
mimicking lipid mixtures [117]. In particular they showed that integrins which partition
into the Ld domains of symmetric bilayers, sequester preferentially to the Lo phase in the
asymmetric counterparts. Similarly DRM partitioning and FRET studies showed that the
induction of transbilayer asymmetry leads to a preferential partitioning of the nicotinic acetyl-
choline receptor in Lo domains [165]. Therefore, we hypothesized that the lack of asymmetry
in the used model membranes could also be the reason why HA partitions into Ld domains
rather than into Lo domains.
Figure 6.1 – Partitioning of the HA TM peptide in SLBs containing symmetric and asymmetric
domains. Schematic diagram of the working hypothesis: the HA TM peptide partitions di↵erently
in symmetric and asymmetric SLBs, that is into Ld and Lo domains, respectively.
In this chapter we investigate the role of lipid bilayer asymmetry in the partitioning
behavior of HA in model membranes (Figure 6.1). A peptide corresponding to the HA TM
domain and its GS520AA mutant were reconstituted in asymmetric phase-separated SLBs
and in GUVs. In both model systems, the asymmetry was induced via cyclodextrin-mediated
lipid exchange whereas the %Lo was measured following two di↵erent approaches: line-scan
FCS for SLBs and confocal microscopy for GUVs. Line-scan FCS was successfully used to
accurately measure di↵usion coe cients and concentrations in model membranes [99]. It
o↵ers interesting advantages to conventional point-FCS: it is a calibration-free technique and
thus it is insensitive to optical artifacts, saturation, or incorrect positioning of the laser
focus, it is virtually una↵ected by photobleaching, and, most importantly for us, it allows to
simultaneously probe adjacent domains, thus to drastically reduce measuring time. Line-scan
FCS can be performed also on the top pole of GUVs; however the probability that a Ld and a
Lo domain are simultaneously at the top pole of a GUV and stay there for the time required
for the measurement is extremely low. For this reason, we opted for a more conventional
approach to determine the %Lo in GUVs, that is measuring the fluorescence intensities of
the Ld and Lo phases in confocal images taken at the GUV equatorial plane [100]. Our data
clearly show that the HA TM peptide partitioning in both SLBs and GUVs asymmetric model
systems do not change significantly in comparison to the respective symmetric systems, ruling
out the hypothesis that transbilayer asymmetry plays a major role in the HA raft association.
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6.1 Line-scan FCS can probe lipid dynamics independently in
each SLB leaflet
Line-scan FCS using a commercial CLSM was used to accurately measure di↵usion and Lo
partition coe cients of fluorescent lipids in phase-separated SLBs of commonly used raft-
mimicking mixtures [99]. Similarly we aimed to use line-scan FCS to quantify the %Lo of the
HA TM peptide in SLBs containing symmetric and asymmetric domains. For this purpose
we collect line scans with a Zeiss LSM 780 system and analyzed them with a self-written
MATLAB script (Dr. Salvatore Chiantia, Figure 6.2).
In order to optimize the scanning parameters (Table 3.1), we first characterized the lipid
dynamics of both Lo and Ld domains in SLBs with an asymmetric lipid composition (original
SLB composition: DOPC:bSM:Chol 7:1:2). To induce asymmetry and domain formation the
bilayer was treated with 40 mM HDaCD-SM, as previously shown for GUVs. We probed each
leaflet independently applying the leaflet-specific labeling described in Chapter 4; Atto655-
DOPE was used instead of Atto647N-SM as a fluorescent lipid for the upper layer. The
di↵usion coe cients obtained by line-scan FCS for both Ld and Lo domains as well as the
%Los (Figure 6.2, Table 6.1) are in line with previously published values for symmetric SLBs
[99]. In contrast to our results, previous measurements performed in asymmetric systems
failed to detect di↵erences in lipid packing between Lo and Ld phases [117, 114]. On the
other hand, Ld and Lo di↵usion coe cients do not di↵er dramatically between the two leaflets,
suggesting that there are no substantial di↵erences in the lipid packing of each phase across
the bilayer.
DLd [µm2/s] DLo [µm2/s] %Lo
Upper Leaflet 3.06± 0.49 0.25± 0.12 0.01
Lower Leaflet 3.42± 0.37 0.46± 0.26 0.28
Table 6.1 – Di↵usion and Lo partitioning coe cients of fluorescent lipids in each leaflet of asym-
metric SLBs. D and %Lo of Atto655-DOPE (upper leaflet dye) and NBD-DOPE (lower leaflet dye)
in asymmetric SLBs (mean ± standard deviation).
6.2 Partitioning of influenza HA into symmetric and asym-
metric domains in SLBs
To quantify the %Lo of the HA TM peptides in symmetric and asymmetric SLBs, the peptides
were either mixed with the phospholipids to form SUVs or incorporated into the bilayer after
the SLB was already formed, adding the peptide in the solution above the bilayer with or
without the help of non solubilizing concentrations of OG. In the latter case, the domain
formation was induced either before or after the peptide was incorporated. To induce domain
formation the bilayer was treated as described in Chapter 4 with 12 mM MbCD-SM and
subsequently with 5 mMMbCD-Chol. Alternatively SLBs which already contained cholesterol
were directly treated with HDaCD-SM.
Regardless the chosen reconstitution methods and the asymmetry/domain formation strat-
egy used, the %Los of both WT and GS520AA mutant peptides did not change significantly
in comparison to their symmetric counterpart. Results averaged from all symmetric and
asymmetric samples are summarized in Table 6.2.
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B2
Figure 6.2 – Line-scan FCS on SLBs containing asymmetric domains. Line scans of the upper [A]
and lower leaflet [B] can be arranged in a pseudo-image where the vertical axis is the time. The
line-scan was perform through an Ld (bright left region) and Lo phase (dim right region). Typical
spatiotemporal correlation curves of the upper [Ld A1, Lo A2] and lower leaflet [Ld, B1; Lo, B2] for
ti = t1-t5 with best fit to Equation 3.5.
HA TM WT GS520AA
Symmetric SLBs 0.04± 0.003 0.01± 0.004
Asymmetric SLBs 0.03± 0.018 0.01± 0.008
Table 6.2 – Lo partitioning coe cients of HA TM peptides in symmetric and asymmetric SLBs.
%Los of the HA TM WT and GS520AA mutant peptides in symmetric and asymmetric SLBs (mean
± standard deviation).
Independently whether it was incorporated before or after SLB formation, the peptide had
a patchy appearance (Figure 6.3, A) and its di↵usion coe cient (DLd WT 0.22 ± 0.18 µm2/s)
was lower than expected for a single TM helix especially in a Ld phase [166]. In line with the
observations of Hussain and colleagues [117], but still surprisingly the di↵usion coe cients of
the HA TM peptide in asymmetric Ld and Lo domains do not show any statistically significant
di↵erence (DLo WT 0.11 ± 0.02 µm2/s; Mann-Whitney Rank Sum Test, t(4)=18, p=1). This
behavior could be explained with the formation of peptide clusters whose di↵usion is not
majorly a↵ected by the surrounding phase state of the membrane. To rule out an hypothetical
influence of the support on the peptide clustering and thus on the partitioning behavior of the
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HA TM [63], we run specular experiments in the GUV free-standing membrane model, where
the HA peptide can be homogeneously incorporated [131] (Figure 6.3, B) and its di↵usion
coe cient is in the expected range (DLd WT 3.43 ± 0.50 µm2/s).
A
B
A1
B1
Figure 6.3 – Line-scan FCS on SLBs and GUVs containing the HA WT peptide. Line scans of a
typical SLB [A] and GUV [B] containing the HA WT peptide arranged in a pseudo-image where the
horizontal axis is the time. The line-scans were performed through a SLB Ld domain and on top of
a GUV in Ld phase, respectively. Typical spatiotemporal correlation curves of the SLB [A1] and the
GUV [B1] for ti = t1-t5 with best fit to Equation 3.5.
6.3 Partitioning of influenza HA into symmetric and asym-
metric domains in GUVs
6.3.1 Both WT and GS520AA mutant HA TM peptides partition into the
Ld domains of symmetric GUVs
To compare di↵erences between the partitioning of the HA TM peptide into symmetric and
asymmetric domains of GUVs, we first controlled the behavior of both WT and GS520AA
peptides in symmetric vesicles. To do so, we reproduced a set of experiments previously
published [131]. Similarly to Nikolaus and colleagues, we directly incorporated the labeled
peptides in the lipid mixture together with a fluorescently labeled lipid (NBD-DOPE) which
is known to partition in the Ld phase [156] and confirmed that both peptides has a strong
preference (%Lo WT 0.20 ± 0.06; GS520AA 0.11 ± 0.02) for the Ld phase as shown by the
fluorescence overlap with the Ld dye NBD-DOPE (Figure 6.4).
78
6. Lateral organization of the influenza virus hemagglutinin transmembrane
helix into asymmetric model membranes
WT
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Figure 6.4 – Partitioning of the HA TM WT and GS520AA peptides into the symmetric domains
of GUVs. GUVs with a lipid composition of DOPC:bSM:Chol (2:2:1, molar ratio) containing 0.5
%mol NBD-DOPE as Ld label and 1 %mol of either the WT or the GS520AA peptide were formed
and imaged. Both peptides has a strong preference for the Ld phase. Scale bars are 5 µm.
6.3.2 Both WT and GS520AA mutant HA TM peptides partition into the
Ld domains of asymmetric GUVs
To study the partitioning behavior of the HA TM peptides in asymmetric GUVs, we prepared
vesicles with di↵erent DOPC:bSM:Chol lipid ratios (3:3:1, 7:1:4 and 15:1:4) and treated them
with HDaCD-SM to enrich the bSM content of the outer leaflet, similarly as described in
Chapter 4 and 5. These GUVs had the same total amount of cholesterol and presumably the
same outer leaflet composition, but di↵er in the amount of bSM of the internal leaflet (20,
10, 5 and 0 %mol). Independently of the composition of the internal leaflet, both WT and
GS520AA peptides partition preferentially into the Ld domains as shown by the fluorescence
overlap with the Ld dye NBD-DOPE (Figure 6.5). The %Los of the HA TM WT and
GS520AA peptides do not significantly di↵er between symmetric and asymmetric GUVs with
di↵erent original DOPC:bSM:Chol lipid ratios (Table 6.3).
Symmetric Asymmetric
DOPC:bSM:Chol 2:2:1 3:3:1 7:1:4 15:1:4
WT 0.20± 0.06 0.16± 0.14 0.05± 0.03 NA
GS520AA 0.11± 0.02 0.09± 0.04 0.11± 0.04 0.13± 0.03
Table 6.3 – Comparison of Lo partitioning coe cients. %Los of the HA TM WT and GS520AA
peptides in symmetric and asymmetric GUVs with di↵erent original DOPC:bSM:Chol lipid ratios
(mean ± standard deviation).
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Figure 6.5 – Partitioning of the HA TM WT and GS520AA peptides into the asymmetric domains
of GUVs. GUVs with a lipid composition of DOPC:bSM:Chol (7:1:2, molar ratio) containing 0.5
%mol NBD-DOPE as Ld label and none (Before and After bigger images) or 1 %mol of either the
WT or the GS520AA peptide were formed, treated with HDaCD-SM and imaged.
6.3.3 The WT HA TM peptide induce phase separation in symmetric and
asymmetric GUVs
Although significant di↵erences in the partitioning behavior of the HA TM peptides could not
be detected, an unexpected observation was made during the same set of experiments. The
HA TM WT peptide was able to induce phase separation in symmetric GUVs, which contain
20 %mol of both bSM and cholesterol (Figure 6.6) as well as in asymmetric GUVs, which
do not contain bSM in the internal leaflet (Figure 6.7). Both GUV mixtures do not show
phase separation in absence of HA TM WT peptide nor in presence of the HA TM GS520AA
peptide.
6.4 Discussion
Lo domains have been extensively employed as model system for lipid rafts in cells and
have provided many clues about their possible nature [167]. However cell membranes are
more complex than model membranes [168]. Not only the higher lipid diversity, but also the
presence of high amount of proteins (up to 60% dry mass [169]) in biological membranes makes
model membranes not always an ideal experimental tool. The importance of a crowded protein
environment in biological membranes was recently pointed out by Parton and colleagues
[170]. Using Coarse-Grained Molecular Dynamics (CGMD) simulations, they investigated the
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Figure 6.6 – The WT HA TM peptide induces phase separation in symmetric GUVs. GUVs with
a lipid composition of DOPC:bSM:Chol (3:3:1, molar ratio) containing 0.5 %mol NBD-DOPE as
Ld label and none (Before and After bigger images) or 1 %mol of either the WT or the GS520AA
peptide were formed, treated with HDaCD-SM and imaged. Only in presence of the HA TM WT
peptide, GUVs showed phase separation even before lipid exchange.
interactions between HA and raft lipids in phase separated membranes and could show that
raft lipids are enriched within dynamic nanoclusters of HA proteins when the HA is included
at a high concentration, comparable to that of a typical cell membrane or of an influenza
virus [170]. This suggests that a high local concentration of HA may trigger its association to
rafts. Unfortunately, it is not possible to incorporate such amounts of protein/peptide into
model membranes, yet; thus this hypothesis is not easy to prove experimentally.
More generally, TM helices are expected to poorly partition into Lo domains irrespective
of the hydrophobic mismatch and amino acid sequence, and thus TM proteins to locate in
Ld rather than in Lo domains [171, 172, 173]. Although detergent insolubility studies have
proven that some TM proteins exhibit a tendency to locate in rafts, the same TM proteins
have shown low a nity for Lo domains in model membranes. This is the case of the HA.
Additional factors that could explain this a nity di↵erence include: TM helix oligomerization,
inclusion of the TM proteins in Ld puddles embedded within larger Lo domains and, covalent
attachment of palmitoyl fatty acyl groups to TM proteins [168]. Dimerization, for example,
has being proven to be responsible for the raft partitioning of the urokinase plasminogen
activator receptor both in cells and model membranes [174], whereas multimerizable HIV
Gag derivative failed to bind Lo phases in model membranes [175]. Palmitoylation together
with other saturated lipid modifications is considered to be important for protein association
with membrane rafts [176]; in the case of the HA, the non-palmitoylated full protein and
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Figure 6.7 – The WT HA TM peptide induces phase separation in asymmetric GUVs. GUVs with
a lipid composition of DOPC:bSM:Chol (4:0:1, molar ratio) containing 0.5%mol NBD-DOPE as Ld
label and 1%mol of the WT HA TM peptide were formed, treated with HDaCD-SM and imaged.
Only in presence of the WT peptide, GUVs showed phase separation after lipid exchange.
TM peptide show a lower a nities for rafts, both in DRM partitioning and FRET studies
[162, 163], but at the same time palmitoylation is not su cient to rescue the DRM partitioning
of HA mutated in the TM domain [160].
The observation that the HA TM WT helix can induce domain formation both in sym-
metric and asymmetric GUVs was unexpected. Similar observations are rare, but present and
discussed in the literature. Two major mechanisms have been hypothesized to explain this
behavior. On one hand, proteins could influence domain formation because of their strong
a nity for Lo domains which increases the mutual insolubility of high Tm and low Tm lipids
[168]. Cholera toxin represents the best example of this mechanism. It has been shown to
induce phase separation in model membrane vesicles whose lipid composition would be either
in a homogeneous Ld or Lo phase in absence of the protein [177]. Moreover, the HA TM
peptide and several fusion peptides, including the wt20 fusion peptide from the the influenza
HA, are known to increase membrane-ordering upon binding [164, 178]. On the other hand,
proteins could influence domain formation because they strongly associate with lipids that
form Ld domains and thus act as nucleators. This mechanism is easier to imagine for TM
helices. [168] Using CG MD, Doman´ski and colleagues showed that TM helices which prefer-
entially bind to one lipid component can amplify non-ideal lipid mixing and bring the system
closer to a miscibility critical point, thus inducing domain formation [179]. In all simulations
TM helices partitioned into the Ld phase. Additionally cytochrome c, which preferentially
adsorbs onto Lo domains, was shown to induce micron-sized domains and to expand the
region of coexistence of Lo and Ld phases [180].
The theory and experimental work presented in Chapter 7 was designed together with
Dr. Franziska Thomas (FT, Max Planck Institute of Biochemistry, Martinsried, Germany),
Dr. Zdeneˇk Petra´sˇek (Graz University of Technology, Graz, Austria), Dr. Fabian Heinemann
(Roche Diagnostics, GmbH, Penzberg, Germany) and Prof. Petra Schwille (Max Planck
Institute of Biochemistry, Martinsried, Germany).
Measurements and data analysis presented in Figures 7.3-7.6 and Table 7.1 (GUV-FCS
and GUV-imaging) - 7.2 were performed by FT.
Chapter 7
Quantification of protein partitiong
into giant unilamellar vesicles by
fluorescence correlation
spectroscopy and confocal imaging
Peripheral membrane proteins are involved in various key cellular processes, e.g. signaling and
cell division [181, 182]. They can interact with lipid membranes in di↵erent ways, for example
by lipid modifications or through membrane targeting domains. Besides a direct interaction
with a specific lipid molecule, the membrane binding site of a protein can selectively interact
with several outer head groups and/or with the internal hydrocarbon backbone of a lipid area
[183, 184, 185]. The quantification of membrane a nity of peripheral proteins is challenging
but crucial, in order to elucidate the role of lipid composition and the properties of anchoring
segments on binding specificity. The KP is an important parameter that describes the a nity
of a molecular species for lipid bilayers independently from the underlying binding mecha-
nism. For KP determination in model membrane systems, several methods are known, e.g.
equilibrium dialysis, centrifugation or calorimetry. Besides specific advantages, all of them
have particular experimental drawbacks, such as changes in lipid and/or protein concentra-
tion during the measurement and low sensitivity. These methods and their drawbacks were
discussed in detail in several review articles [186, 187, 188, 189].
Besides the above-mentioned established approaches, few additional microscopy based
methods have been proposed to determine the a nity of diverse molecular species for lipid
membranes. A quantitative FRAP approach was applied in live cells to obtain the associa-
tion and dissociation rate constants kon and koff of intracellular binding-reaction di↵usion
processes [190]. Total Internal Relection Fluorescence (TIRF) imaging was used to deter-
mine the membrane-binding equilibrium constants of a peptide binding to supported lipid
bilayers [191]. Finally, confocal imaging of single liposomes was employed to investigate cur-
vature sensing motifs [192]. However, none of these assay-specific microscopy based methods
is generally applicable to determine KP s.
FCS, on the other hand, has been used to determine the KP of fluorescently labeled
peptides to LUVs [74]. In this approach the vesicle-bound and free peptide fractions can
be distinguished by their di↵erent correlation times. Although this method o↵ers appealing
advantages (e.g. measurement time, extended accessible concentration range) and could be
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successfully applied [181, 78, 182, 76, 75], numerous potential pitfalls in the data analysis
were reported [183, 193, 184, 194, 185, 195]. In particular, the determination of the KP can
be negatively a↵ected by multiple peptides binding to a single vesicle, light scattering and not
point-like di↵using particles. In addition, protein aggregation at high vesicle concentrations,
as well as variations in protein concentration throughout the measurements are experimental
challenges which may sometimes preclude the use of this approach. A generalized method
that still profits from the advantages of using FCS to study membrane dynamics [186, 71,
187, 67, 188, 68, 189], e.g. sensitivity, and at the same time overcomes the above-mentioned
drawbacks is desirable.
In this chapter we describe a new and robust assay in which GUVs are employed. This
well-established model membrane system possesses the advantage to be free standing, and
thus, protein-lipid interactions are not a↵ected by any support. GUVs have a diameter of
1-100 µm, which easily allows imaging by confocal fluorescence microscopy and permits the
simultaneous measurement of both free and bound protein fractions. Also, protein binding
to GUVs is hardly a↵ected by curvature, being the GUV membrane virtually flat on the
nanoscale. Furthermore, GUVs can in principle be produced with any biologically relevant
lipid composition and by various methods [190, 49].
In our assay, the concentrations of both free and GUV-bound protein are determined at in-
creasing protein concentrations via FCS or confocal fluorescence microscopy. Both approaches
provide the advantages to account for potential loss of protein during the measurement (e.g.
by protein interaction with the surface of the measurement chamber) as well as for changes
in the lipid concentration (e.g. by GUV bursting), and to be sensitive down to nanomolar
range. In addition, the partitioning coe cient can be directly calculated from the measured
concentrations, bypassing the problems reported for the data analysis of LUVs assay. For
the validation of the method, we chose the well-characterized system of HexaHistidine (His6)
binding to Nickel Nickel (Ni) chelated with NitriloTriacetic Acid (NTA) [191, 196, 197]. We
used eGFP with a C-terminal His6-Tag (eGFP-His6) as membrane associating protein and
GUVs containing 2-5 mol% NTA(Ni) functionalized lipid as membrane model (Figure 7.1).
Finally, to prove the accuracy of our results, we performed the LUV assay [74], whose data
analysis was improved to take into account multiple binding of peptides to a single vesicle.
7.1 Theory
As illustrated in Figure 7.2 A, molecules with high membrane a nity partition proportionally
more into the bilayer than molecules with low membrane a nity. The a nity of molecular
species for membrane surfaces is described by the relation between the concentration [Pf ]
(mol/m3) of the unbound species freely di↵using in solution, and the concentration [Pm]
(mol/m3) of the membrane associated fraction. If the total accessible lipid concentration [L]
(mol/m3) is su ciently large [L]  [Pm], so that no saturation of the binding sites under the
used experimental condition takes place, and given that the volume of the sample chamber V
and [L] of the system are kept constant, the relation between the two concentrations is linear:
[Pm] = ↵[Pf ] (7.1)
The proportionality constant ↵ is dimensionless and depends on the amount of surface
(expressed, for example, by the lipid concentration) and on the characteristics of the interac-
tion between the molecule and the surface. KP can be derived from [Pm] and [Pf ] as follows:
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Figure 7.1 – GUV- and LUV-based methods to measure protein-lipid a nity. Schematic represen-
tation of [A] a lipid bilayer containing DGS-NTA(Ni) lipids and their coordination by two adjacent
histidine residues of a His-tagged eGFP, and [B] the three applied methods to determine the KP of
this interaction.
[KP ] =
[Pm]/[L]
[Pf ]/[W ]
(7.2)
according to the equilibrium of chemical potentials. A detailed derivation as well as a discus-
sion of the required assumptions can be found in White and colleagues [192, 186]. The water
concentration [W ] is constant with [W ] =W = 55.5M . [L] is also constant in a given sample
and can be expressed by:
[L] =
A
ALNAV
(7.3)
In Equation 7.3, A is the total accessible lipid area, AL the area per lipid, and NA the
Avogadro’s constant. The advantage of Equation 7.2 is that it does not make any assumptions
about the binding stoichiometry. Nevertheless, if the stoichiometry is known and appropriate
to describe the protein-lipid binding, an alternative approach not depending on the area per
lipid can be formulated using the Dissociation constant (Kd). In equilibrium, an identical
number of molecules P will dissociate from and associate to the lipid phase L per area and
time P + nL! nPL. For 1:1 binding stoichiometry n = 1, Kd is defined as:
Kd =
[Pf ][Lf ]
[PL]
(7.4)
where [PL] = [Pm] and [Lf ] = [L]  [Lm] with [L]  [Lm]. Thus,
Kd =
[Pf ][L]
[Pm]
=
koff
kon
(7.5)
Comparing Equation 7.5 with Equation 7.2 leads to the following conversion:
KP
W
=
1
Kd
(7.6)
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Figure 7.2 – Membrane volume and surface concentrations of proteins with di↵erent membrane
a nities. Schematic representation of how molecules equilibrate between the liquid phase and the
lipid vesicles according to their membrane a nity. [A] At fixed volume and lipid surface, the ratio ↵
(dimensionless, Equation 7.1) between membrane associated and freely di↵using molecules is constant
independently from the concentration of molecules. [B] Schematic representation of how the number
of molecules per lipid surface varies according to their membrane a nityKP and to the concentration
of free molecules in solution. The slope a (unit of length (m), Equation 7.17) is constant for a lipid
system and depends on both the partitioning coe cientKP and the lipid surface concentration [L2D].
In this example, the number of eGFP-His6 molecules associated to a lipid patch of 30x30 lipids (10.8
nm2) were calculated with Equation 7.18 for membranes with di↵erent amount of DGS-NTA(Ni).
KP s values measured by FCS in GUVs (Table 7.1) and AL calculated as described in Section 7.2
were used. [Pf ] concentrations were chosen in the range of the GUV assay.
7.1.1 Measurement of KP by fluorescence correlation spectroscopy in GUVs
A convenient way to determine the concentrations in question is to conduct FCS. [Pf ] can
be quantified performing FCS on free molecules in solution. In particular, the number of free
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particles N 0f in the FCS observation volume can be obtained from the fit of the fluorescence
auto-correlation curves with the suitable FCS model function for 3D di↵usion:
G(⌧) =
1
N 0f (1+
⌧
⌧D )(1+
⌧
S2⌧D
)1/2
(1 +
⌧
1 T exp( 
⌧
⌧T
)) (7.7)
Here, the variable ⌧ is the correlation time, ⌧D the di↵usion time, ⌧T the triplet lifetime, and
T the fraction of molecules in the triplet state. Especially at low protein concentrations, and
therefore at low fluorescence intensities, the fluorescence background will a↵ect the particle
number N 0f obtained from the fit. Thus N
0
f should be background corrected [198] to get Nf .
[Pf ] can be calculated from Nf as follows:
[Pf ] =
Nf
VFCSNA
(7.8)
The focal volume VFCS can be determined by:
VFCS = ⇡
3/2Sw30 (7.9)
where the values for the structural parameter S and the focal waist w0 were obtained from a
calibration measurement using a dye with known di↵usion coe cient D:
w0 =
p
4D⌧D (7.10)
[Pm] can be obtained by measuring FCS on the membrane of the GUVs. Conveniently, in our
assay it is su cient to measure the surface concentration [P2D] (mol/m2) on the top pole of
the GUVs[70] instead of determining [Pm]. In particular, the number of GUV-bound particles
N2D in the FCS observation area AFCS = ⇡w20 can be obtained from the fit of the fluorescence
auto-correlation curves with a combined FCS model function for 2D-3D di↵usion. Both freely
di↵using and membrane bound molecules are, in fact, present in the detection volume:
G(⌧) =
1
N 02D3D
((1  F ) 1
(1+ ⌧⌧2D
)
+ F (
1
(1+ ⌧⌧3D
)(1+ ⌧
S2⌧3D
)1/2
))(1 +
⌧
1 T exp( 
⌧
⌧T
)) (7.11)
The di↵usion time in solution ⌧3D should be fixed to the value obtained using the free molec-
ular species. From the fit, the fraction F of free protein in solution and the total particle
number N 02D3D in the focal volume will be obtained. After correcting N
0
2D3D for the back-
ground, N2D and [P2D] can be calculated:
N2D = (1  F )N2D3D (7.12)
[P2D] =
N2D
AFCSNA
(7.13)
[P2D] can be converted to [Pm] by multiplying it with the total accessible lipid area A:
[Pm] = [P2D]
A
V
(7.14)
A rearrangement of Equation 7.2 yields in analogy to Equation 7.1:
[Pm] =
KP [L]
W
[Pf ] (7.15)
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Combining Equation 7.15 with Equations 7.3 and 7.14 gives the following main equation (A
and V cancel out):
[P2D] =
KP
ALNAW
[Pf ] (7.16)
Thus, measuring a set of [P2D], [Pf ] pairs for several concentrations of the binding species
lead to a linear behavior with slope:
a =
KP
ALNAW
(7.17)
When the AL for the used lipid mixture is known, KP can be obtained from a, which is not
dimensionless (unit of length (m)) but is analog to ↵. Moreover, 1ALNA is the lipid surface
concentration [L2D] (mol/m2), which is constant for a given lipid mixture. Therefore by
knowing KP and [Pf ] of the system, one can always calculate the number of molecules per
lipid surface, which depends on the combined constant c = [L2D]
W
(Figure 7.2, B):
[P2D] = c KP [Pf ] (7.18)
Similarly Kd can be calculated combing Equations 7.6 and 7.17:
KD =
1
a AL NA
(7.19)
7.1.2 Measurement of KP by fluorescence confocal imaging in GUVs
Alternatively, both [Pf ] and [P2D] can be determined imaging GUVs at their equator. A
similar approach was reported for analysis of living cells [199]. When a GUV is imaged
at its equatorial plane the fluorescence intensity of its surface I2D is proportional to the
concentration of the membrane bound molecules [P2D], whereas the fluorescence intensity If
of the surrounding solution is proportional to the concentration of the free molecules [Pf ]:
[P2D] = b2DI2D (7.20)
[Pf ] = bfIf (7.21)
The two proportionality constants b2D and bf can be determined by calibration with FCS.
The semi-automated software described in Chapter 3 has been used to extracts the intensity
values I2D and If from confocal images of GUVs.
7.1.3 Measurement of KP by fluorescence correlation spectroscopy in LUVs
When LUVs are mixed with lipid binding protein an equilibrium between free and LUV-
bound protein is established. This equilibrium can be described by Kd using Equation 7.5,
where [L] is total LUV concentration [LUV ] = [L]NLUV , NLUV the number of lipids contained
in a LUV, [Pm] = m[LUV ] and m the mean number of protein bound to one LUV. Thus:
KD =
[Pf ]
m
(7.22)
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If LUVs are much larger than the protein, FCS can be used to determine the free F and
bound fractions 1 F of protein on basis of their di↵erent di↵usion times. The autocorrelation
function, consisting of two di↵usion components, can be expressed as:
G(⌧) =
1
N
(
F
(1+ ⌧⌧f )(1+
⌧
S2⌧f
)1/2
+
1 F
(1+ ⌧⌧m )(1+
⌧
S2⌧m
)1/2
)(1 +
⌧
1 T exp( 
⌧
⌧T
)) (7.23)
where N is the total number of protein and the di↵usion time of the molecules bound to
LUVs ⌧m is much larger that the di↵usion time of the free molecules ⌧f : ⌧m > ⌧f . The free
and LUV-bound fractions can be written as the autocorrelation amplitudes gf0 = FN and
gm0 =
1 F
N
, respectively.
Assuming that the number of the protein bound to one LUV is Poisson-distributed with
the mean value m, the two autocorrelation amplitudes are related to the total LUV [LUV ]
and protein concentrations [P ] = [Pf ] +m[LUV ] in the following way:
gf0 =
1
[P ]V
1
1+
[P ]
Kd
(7.24)
gm0 =
1
[P ]V
1
Kd+[LUV ]
(1 +
[P ]
Kd+[LUV ]
) (7.25)
It is useful to consider the autocorrelation amplitude G0(0) normalized by its value in the
absence of LUV ([LUV ] = 0), 1[P ]V :
G00 = [P ]V (gf0 + gm0) = 1 +
[P ][LUV ]
(Kd+[LUV ])2
(7.26)
By varying (increasing) the LUV concentration while keeping [P ] constant and measuring
G0(0), Kd can be found by fitting G0(0) to Equation 7.26. [P ] can be determined by FCS
before the addition of LUV. Knowing NLUV , Kds can converted to KP s using Equation 7.5:
KP =
WNLUV
[Kd]
(7.27)
7.2 GUV-FCS assay
For the calculation of the partitioning coe cient KP , it is essential to precisely determine
the amount of both freely di↵using and DGS-NTA(Ni)-coordinated eGFP-His6. In order to
quantify both concentrations, we conducted point-FCS in solution and on the top pole of
several GUVs per probe.
Before measurement of each sample, the system was carefully calibrated with Alexa488 to
calculate the focal waist w0, VFCS and AFCS . The later two need to be determined precisely,
since an error of their values propagates in the calculation of all protein concentrations. The
average values obtained of all measurements are w0 = 218.0± 6.0 nm (mean±s.e.m, n = 19),
VFCS = 3.98 ± 0.36 · 10 19 m3 (mean±s.e.m, n = 19) and AFCS = 1.49 ± 0.08 · 10 13 m2
(mean±s.e.m, n = 19). As an additional control, the red channel was calibrated as well using
Atto655, which has a focal waist w0 = 246.2 ± 4.6 nm (mean±s.e.m, n = 19) due to greater
di↵raction.
Thereafter, an overall image of the well in which the experiment was carried out was taken
by a tile scan. Sequentially, more GFP-His6 was added into the chamber and incubated until
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equilibrium was reached. For each protein concentration, the auto-correlation functions of
both the free and bound protein signal were recorded. The system was very stable over time
and therefore for each of the increasing amounts of protein exactly the same GUVs could
be surveyed. Additionally the Atto647N-DOPE signal was taken simultaneously as control.
In case the fluorescence time traces showed a strange behavior, the curves of both channels
were rejected. At higher concentrations of DGS-NTA(Ni), the laser power of the 488 laser
line needed to be reduced to avoid detector saturation, which does not significantly a↵ect the
concentration measurement by FCS, but has to be considered for the image analysis by using
an appropriate calibration curve.
The successive auto-correlation curves taken in solution were fitted using a 3D function
in PyCorrFit [104] and Equation 7.8 was used to calculate [Pf ]. The average di↵usion time
of eGFP-His6 in solution is ⌧D = 1.23± 0.02 · 10 4 s (mean±combined s.e.m., n = 890), from
which the average di↵usion coe cient can be calculated. The obtained value of D = 103± 6
µm2/s (mean±combined s.e.m.; 26.0±0.5￿) is in agreement with previous measurement [102].
Analogously, the corresponding auto-correlation functions taken on membrane were fitted
using 2D3D fit function to get the average number of particles, which was used to calculate
the bound protein concentration [P2D] according to Equations 7.12 and 7.13.
In Figure 7.3 a typical graph of a measurement is shown with the obtained [Pf ] and [P2D]
plotted against each other. The relatively high error bars for [P2D] are possibly a result of
uneven distribution of the DGS-NTA(Ni) among the GUVs in the sample [200]. As assumed
in the theory, the linear relation between [Pf ] and [P2D] confirm that no saturation of the
binding sites takes place.
Figure 7.3 – Protein concentrations determined by GUV-FCS assay. [P2D] plotted vs. [Pf ] for an
individual sample of 2% DGS-NTA(Ni). Error bars represent the standard deviation. The ratio of
[P2D]/[Pf ] stays constant with increasing protein concentrations. No saturation occurs.
To calculate the partitioning coe cient KP for a particular percentage of DGS-NTA(Ni),
the slope a and AL for the given system are required. For our calculations, we used 72.4 A˚2
for DOPC [201] and for DGS-NTA(Ni) an AL of 60.0 A˚2 [202]. We estimated AL by linear
interpolation of the two values, yielding 72.2 A˚2, 72.0 A˚2, 71.9 A˚2 and 71.8 A˚2 for the molar
ratios 2%, 3%, 4% and 5% of DGS-NTA(Ni) in the lipid mixture with DOPC.
7.2 GUV-FCS assay 91
Fitting all data points of at least three independent measurements results in a slope a for
the percentage of DGS-NTA(Ni), out of which the KP was calculated using Equation 7.17.
In Table 7.1 and Figure 7.4, A the results of our investigations are summarized.
DGS-NTA(Ni) AL KP GUV-FCS KP GUV-imaging KP LUV-FCS*
2% 72.2A˚2 2.54± 0.27 · 106 2.79± 0.10 · 106 1.33± 0.23 · 106
3% 72.0A˚2 4.34± 0.88 · 106 4.56± 0.34 · 106 1.74± 0.10 · 106
4% 71.9A˚2 1.54± 0.11 · 107 1.35± 0.05 · 107 1.90± 0.18 · 106
5% 71.8A˚2 4.82± 1.13 · 107 3.55± 0.14 · 107 2.21± 0.22 · 106
Table 7.1 – Comparison of KP s. Calculated partitioning coe cients by fitting all data points for
increasing amounts of DGS-NTA(Ni) via the GUV and LUV methods (mean±combined s.e.m.).
*Di↵erences at higher DGS-NTA(Ni) molar fraction (3-5 mol%) between GUV and LUV assays are
most likely due to the increased LUVs aggregation at high DGS-NTA(Ni) molar fraction.
Identical values are gained by averaging the individual measurements and using a com-
bined standard deviation, small variations are due to di↵erences in sample size.
Assuming that the binding stoichiometry of eGFP-His6 coordinated to DGS-NTA(Ni) is
1:1 [203, 196], we could easily calculate the dissociation constant Kd for our system from the
partitioning coe cient KP (Equation 7.6) or directly from the slope a (Equation 7.19).
In Table 7.2 and Figure 7.4 B the values of the dissociation constant Kd are given for
di↵erent contents of DGS-NTA(Ni). They correspond to the upper range of values reported
in the literature, which vary from 10 nM to 10 µM [204, 203, 205]. The Kd of the NTA(Ni)-
His6 system depends in fact primarily on the NTA-backbone itself as well as on the attachment
side of the His-tag. Our results clearly show that eGFP-His6 binds stronger to the membrane
of the GUVs with increasing amounts of DGS-NTA(Ni) in the lipid mixtures.
DGS-NTA(Ni) Kd in M
2% 2.18± 0.23 · 10 5
3% 1.28± 0.26 · 10 5
4% 3.60± 0.27 · 10 6
3% 1.15± 0.27 · 10 6
Table 7.2 – Kd determined by GUV-FCS assay. Calculated dissociation constants by fitting all
data points for increasing amounts of DGS-NTA(Ni) via the GUV method (mean±combined s.e.m.)
Additionally, we determined the average di↵usion constants of eGFP-His6 attached to
DGS-NTA(Ni) in the lipid bilayer and of Atto647N-DOPE as a control (Figure 7.5). A statis-
tical analysis indicated a significance of deviation for the average di↵usion constant of eGFP-
His6 in presence of di↵erent DGS-NTA(Ni) concentrations (one-way ANOVA, F (3, 78) =
19.48, p<0.001). With increasing amount of DGS-NTA(Ni), the eGFP-His6 average di↵u-
sion constant decreases from D = 4.36 ± 1.12 µm2/s (mean±combined s.e.m., n = 548) to
D = 1.90± 1.01 µm2/s (mean±combined s.e.m., n = 593). In contrast, the average di↵usion
constant of Atto647N-DOPE was D = 9.81± 0.70 µm2/s (mean±combined s.e.m., n = 3123)
and did not show any statistical significant di↵erence (one-way ANOVA, F (3, 86) = 3.24,
p=0.026). The reduction of the eGFP-His6/DGS-NTA(Ni) D with increasing amounts of
DGS-NTA(Ni) might be explained by a higher surface crowding of the bulky eGFP-His6
compared to the smaller labeled lipid probe Atto647N-DOPE [196].
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Figure 7.4 – KP and Kd determined by GUV assay. Graphic presentation of [A] partitioning
coe cients KP s obtained by fitting of all data points from FCS analysis (filled squares) and image
analysis (circles) for a certain concentration of DGS-NTA(Ni); [B] dissociation constant Kd obtained
by FCS analysis. Error bars represent the combined standard error of mean. KP shows a stronger-
than-linear behavior. Results of LUV-FCS are excluded, since they are presumably distorted by
LUV aggregation (See Section 7.4).
7.3 GUV-imaging assay
Besides measuring FCS on the top pole of the GUVs as described in the previous paragraph,
we additionally imaged the equator of the same GUVs. In Figure 3.3 A-E, the typical output
of the analysis of a GUV image is shown. It is necessary to correlate only once the mean
intensity obtained by image analysis to the concentration determined by another method, in
our case FCS.
In Figure 7.6 example plots of all pairs of data points for 2% DGS-NTA(Ni) for [P2D] and
[Pf ] and their corresponding mean intensities I2D and If are shown. The slope b obtained
by a linear fit does not depend on the amount of DGS-NTA(Ni), neither for the free nor
for the bound eGFP-His6. Hence, the combined mean slope b2D and the mean intensity of
the membrane bound eGFP-His6 for a particular laser power can be used to calculate the
concentration of membrane bound protein [P2D]. Similarly, [Pf ] can be determined using
bf and the mean intensity of the free eGFP-His6. KP s were calculated as described for the
GUV-FCS assay. The results (Table 7.1) are equivalent to those obtained with the GUV-FCS
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Figure 7.5 – Di↵usion coe cients determined by GUV-FCS assay. Dss of the His-tagged eGFP co-
ordinated to NTA(Ni) (filled squares) and of the fluorescently-labeled lipid Atto647N-DOPE (circles)
plotted vs increasing amounts of DGS-NTA(Ni). Error bars represent the combined standard error
of mean. The Atto647N-DOPE D shows no significant di↵erences, whereas eGFP-His6 D decreases
with increasing amounts of DGS-NTA(Ni).
approach.
7.4 LUV-FCS assay
To validate our assay, we measured the a nity of eGFP-His6 for DGS-NTA(Ni)-containing
vesicles with an alternative LUV-based FCS assay [74]. Here, the calculation of KP relies on
the precise measurement of the total amount Nf+m of eGFP-His6 particles in solution; eGFP-
His6 particles can be both freely di↵using or coordinated to the DGS-NTA(Ni) embedded in
the vesicles. In order to quantify the total amount of eGFP-His6 particles, we performed
one-color point-FCS in solution at di↵erent time points per probe.
Before measuring each sample, the system was calibrated using Alexa488 as described for
the GUV-FCS assay. The average values obtained for all measurements are w0 = 205.7± 1.6
nm (mean±s.e.m, n = 15) and VFCS = 2.98± 0.10 · 10 19 m3 (mean±s.e.m, n = 15).
In contrast to the GUV-FCS assay, the amount of eGFP-His6 was kept constant and
equilibrated with di↵erent LUV concentrations. In particular, eGFP-His6 was gently mixed
with the vesicles and subsequently transferred to the observation chamber to assure that the
protein would be evenly distributed all over the chamber and the binding equilibrium would
be reached faster. Moreover, to minimize changes in the total volume of the sample, each
LUV concentration was sequentially probed in a separate chamber; FCS measurements were
performed always at the same distance from the bottom of the chamber to avoid any surface
related dependencies [206, 207]. In these conditions background correction was not necessary,
since the eGFP signal is stable and significantly higher than the background level.
The auto-correlation functions of eGFP-His6 in solution were recorded in the absence
of LUVs and fitted using a 3D+T function to obtain [P ] and the average di↵usion time
⌧f = 0.96±0.05·10 4 s (D = 110±7 µm2/s; mean±combined s.e.m.; 26.0±0.5￿), respectively.
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Figure 7.6 – Calibration curve for GUV-image analysis. Mean intensities obtained by image analysis
plotted against concentrations determined by FCS [A] on the membrane and [B] in solution for all
2% DGS-NTA(Ni) samples. Both curves show a linear behavior and the slopes b2D and bf are used
to calculate the protein concentrations directly from the mean intensities.
The auto-correlation functions of eGFP-His6 in presence of increasing amounts of LUVs were
fitted with a two component 3D+T function, keeping ⌧f constant, to get the total number
of eGFP-His6 particles Nf+m. As expected, the eGFP-His6 di↵usion time increases upon
binding to LUVs (Figure 7.7, A), as far as the vesicles are significantly larger than the protein.
At the same time, Nf+m decreases, meaning that more than a single eGFP-His6 molecule
bind each LUV. At higher LUVs concentration Nf+m starts increasing again to reach the
original value of freely di↵using eGFP-His6, suggesting that upon further addition of LUVs
the eGFP-His6 molecules redistribute so that the probability of more than one eGFP-His6
binding to one LUV is negligible (Figure 7.7, B).
From the total number of eGFP-His6 particles values measured in at least three indepen-
dent samples (e.g. Figure 7.7, B), a G(0) was calculated for each LUV concentration and
normalized to the G(0) in absence of LUVs. The data points were then fitted with Equa-
tion 7.26 to obtain Kd for a particular percentage of DGS-NTA(Ni) in the lipid mixture.
The protein and accessible lipid concentration values used for the fit were determined exper-
imentally. The total protein concentrations were calculated from the number of eGFP-His6
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Figure 7.7 – LUV-FCS assay. [A] Auto-correlation curves obtained in solution for eGFP-His6 in
absence (0 M) and presence of increasing amounts of LUVs (1 µM, 10 µM, 100 µM, 1 mM, and 10
mM). Solid lines are the best fit of the data to a single (0 M) or two-components (all other curves) 3D
di↵usion model. [B] Normalized G(0) data points for a single 2% DGS-NTA(Ni) sample are plotted
against the ratio [LUV ]/Kd. The solid line is the best fit of the data to Equation 7.26. [C] Graphic
presentation of partitioning coe cients KP s calculated from Kd (Equation 7.27) by a combined fit
of all data points for each DGS-NTA(Ni) concentration.
particles measured by FCS in absence of LUVs, whereas the accessible lipid concentrations
were obtained measuring both the total lipid concentrations and vesicle sizes (see Chapter 2
for details). The dissociation constant Kd values were finally transformed into KP values for
comparison applying Equation 7.27 (Figure 7.7, C).
7.5 Comparison of methods
In both GUV based approaches, GFP-His6 shows a strong a nity for the membrane, which
derives from the nature of the His-tag NTA(Ni) chelation, which is not purely electrostatic,
but involves the formation of a more stable coordination bond. GFP-His6 a nity for the
membrane clearly increases with higher contents of Nickel-lipid in the bilayer in a stronger-
than-linear fashion. B. Ernst and colleagues analyzed the binding/dissociation of di↵erent
oligo-His-tags to NTA(Ni) [196] and showed that for high surface densities of NTA(Ni) a
rebinding e↵ect plays an important role. Under these conditions eGFP-His6 might interact
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with several DGS-NTA(Ni) [208, 209]. Hence, for higher DGS-NTA(Ni) contents, the equi-
librium is strongly shifted to the bound fraction, resulting in stronger-than-linear increase of
KP . The LUVs assay failed to capture this trend.
The results obtained for GUVs and LUVs containing equal amounts of DGS-NTA(Ni)
are shown in Table 7.1. At low DGS-NTA(Ni) molar fraction (2 mol%), the KP s measured
with both GUV- and LUV-methods di↵er by a factor of two (GUV-method: 2.51± 0.19 · 106;
LUV-method: 1.33± 0.23 · 106), whereas at higher DGS-NTA(Ni) molar fraction (3-5 mol%)
they di↵er up to one order of magnitude. We assume that the observed di↵erences are
an artifact of the LUV-FCS method, due to LUV aggregation, which increases with DGS-
NTA(Ni) molar fraction. It was shown that vesicles containing DGS-NTA(Ni) can aggregate
after addition of synthetic peptides with poly-histidine residues and that the aggregation
is dependent on the DGS-NTA(Ni) amount present in the vesicles [210]. Vesicle aggregation
causes partial loss of the vesicles available for the eGFP-His6 to bind, thus apparently reducing
its a nity. On the other hand, in both GUVs based approaches, the protein and accessible
lipid concentrations need to be carefully chosen in order to measure precisely in solution and
at the membrane. For high binding a nities, the concentration at the membrane could be
already high while there are no detectable amounts of proteins in solution. Interestingly
the GUV-FCS approach appears to be less precise than the GUV-imaging one, as shown by
the relatively high error bars for [P2D]. This can be explained taking into account how the
free protein concentration is measured in the FCS and imaging approaches, only once for
the whole chamber and close by each GUV, respectively. Technically it should be enough
to measure the free protein concentration once, but more precise values can be determined
with the GUV-imaging approach. The precision of the GUV-FCS assay could be improved
measuring FCS in solution next to each GUV, but this would almost double the measuring
time.
GUV-FCS GUV-imaging LUV- FCS
Measurement time per sample 5 h 2 h 2h
Accuracy/Precision High/Low* High/High Low**/High
Accessible lipid concentration 10-9-10-6 M 10-9-10-6 M 10-6-10-3 M [74]
Protein concentration 10-9-10-6 M 10-8-10-4 M 10-9-10-6 M [74]
Table 7.3 – Comparison of methods.*if the free protein concentration is calculated only once; **for
protein exhibiting rebinding e↵ect.
Importantly, both GUV based approaches possess the advantage over the LUV method of
directly visualizing the binding event and thus of being able to correct anomalies in the sample.
Having an overview of the whole chamber, it is possible to select and continuously measure
the same GUVs after repeated protein additions as well as to discard samples with unevenly
distributed eGFP-His6 within the chamber or samples in which the lipid concentration varies
over the measuring time (i.e. due to GUVs burst). Moreover, the lipid dynamics of each
GUV can be probed simultaneously, thus adding a further control point.
Finally, one should consider the actual measurement time of each of these assays. In order
to be able to precisely measure the average number of particles as well as the di↵usion time in
the GUV-FCS approach, it is necessary to collect data over a time period of several minutes.
Thus, the time for an experiment easily sums up when averaging several GUVs per protein
concentration. On the other hand, in both GUV-imaging and LUV-FCS assays the actual
measurement time reduces to less than two hours, while having approximately the same work
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load for calibration and data treatment.
The experimental work presented in Chapter 8 was inspired by the collaboration with the
research group of Prof. Tony Hyman, in particular with Dr. Carsten Hoege (Max Planck
Institute of Molecular Cell Biology and Genetics, Dresden, Germany); and designed together
with Prof. Petra Schwille (Max Planck Institute of Biochemistry, Martinsried, Germany).
Part of the measurements presented in Table 8.1 and Figure 8.4 were performed by Lisa
Tu¨bel during her traineeship and submitted as a project report to the Berufskolleg fu¨r
Biotechnologie (Staatsschule fu¨r gartenbau und landwirtschaft, Landwirtschaftliche Schule
Hohenheim, Stuttgart, Germany).
Measurements and data analysis presented in Figure 8.5 and 8.6 were performed under the
guidance of Elisabeth Weyher-Stingl (Biochemistry Core Facility of the Max Planck Institute
of Biochemistry, Martinsried, Germany).
Chapter 8
Reconstitution of a functional
LGL/aPKC membrane binding
switch
In the PAR polarization process two subsequent steps can be distinguished: a symmetry
breaking or establishment phase and a maintenance phase [211]. aPARs are originally dis-
tributed throughout the cortex whereas pPARs are predominantly in the cytoplasm. The
symmetry breaking is initiated by an asymmetric contraction of the actomyosin cortex which
generates a cortical flow that carries the aPARs toward the anterior pole of the cell. The dis-
placement of aPARs by cortical flows allows pPARs to load on the posterior cortex. pPARs
can also access the posterior cortex in absence of cortical flows via a mechanism that involves
a temporary interaction between the microtubules nucleated by the paternal centrosome and
PAR-2 [91]. The maintenance phase is instead governed by a complex set of interactions
among the PAR proteins: aPARs and pPARs reciprocally antagonize their binding to the
cortex, mutually excluding each other, as well as promote their own binding to the cortex
and activation, generating positive feedback loops. The details of these interactions are de-
scribed in several recent reviews, which summarized the experimental and modeling work of
the last three decades [11, 212, 213].
Several mathematical models have been developed to help describing the emergence of
polarity in the C. elegans embryos [214, 215, 216, 217]. Besides individual di↵erences, all
models are based on a reaction-di↵usion system with bistable kinetics [28], in which the
anterior and posterior PARs, taken as a two single entities, shu✏e between an active slow
di↵using membrane-bound and an inactive fast di↵using cytosolic form. Tostevin and Howard
assumed both mutual exclusion and cooperative binding of both aPARs and pPARs in their
model, and introduced a contracting actomyosin cortex on top of it. aPARs are assumed
to have higher a nity for the cortex and at the same time promote its contraction [214].
Goehring and colleagues [216] combined mutual exclusion with cytoplasmic depletion of the
unbound PARs and, similarly to Tolstevin and Howard, introduced a cortical flow to account
for the symmetry breaking. In this model, the aPARs do not exhibit an higher a nity for
the contracting cortex, but are advectively transported by the flowing cortex. Even if both
models are based on experimental evidences and measurements, they do not account for the
observation that actomyosin asymmetry is not essential for symmetry breaking [91]. The
model of Dawes and Munro on the other hand generates stable PAR domains without an
100 8. Reconstitution of a functional LGL/aPKC membrane binding switch
actomyosin, allowing aPARs to dimerize and thus introducing nonlinearity in the mutual
exclusion mechanism [215]. In agreement with this model, PAR-3 has an oligomerization
domain that is important for the localization and activity of the aPARs complex [218].
Taken together, experimental and modeling findings suggest that the PAR system does
not rely only on the mutual exclusion of the aPARs and pPARs to robustly polarize the C.
elegans embryos; redundancy of the symmetry breaking inputs and positive feedback loops
are required to make the system more robust [5] and to bu↵er the network from imprecisions
in the aPARs/pPARs balance [11]. The tumor-suppressor protein LGL is the main player of
one of these redundant circuits [26].
In C. elegans embryos LGL-1 acts redundantly with PAR-2 to maintain polarity and can
compensate for PAR-2 depletion [14, 15]. In contrast to PAR-2, which is only found in the
genus Caenorhabditis [219], LGL is highly conserved in eukaryotes [26] where it takes over
the role of PAR-2 in counteracting the action of the aPARs. The domain structure of LGL
proteins is also well conserved; the N-terminal part of the protein contains multiple WD40 do-
mains which fold into b-propeller structures providing a docking platform for interaction with
multiple proteins [26]. In Drosophila for example the N-terminal WD40 domain-containing
part of LGL was predicted to fold into two b-propeller structures [220], and has been shown
to interact with both the C-terminus of LGL itself as well with PAR-6 [221, 222]. The C-
terminal part of LGL consists of an LGL-specific domain which contains several conserved
sites for serine and/or threonine phosphorylation by aPKC [26]. It was proposed that the not
phosphorylated LGL is the active form of the protein and it assumes an open conformation,
whereas the phosphorylated LGL is inactive because its C-terminus interacts intramolecularly
with the N-terminus closing the protein in an auto-inhibitory state [220].
Interestingly LGL-1 and PAR-2 share several common features in the C. elegans early
embryos: they both localize to the posterior cortex, their activity is regulated by PKC-3
phosphorylation, and they can displace anterior aPARs from the posterior cortex [11]. PAR-2
acts indirectly, recruiting PAR-1 to the membrane [13, 91], which phosphorylates PAR-3 on
a conserved site in the C-terminal domain [223]; whereas LGL-1 is thought to act directly on
PAR-6. LGL-1 in fact has been shown to bind PKC-3 and PAR-6 in immunoprecipitation
assay [14] and to lower both cortical and cytoplasmatic PAR-6 levels [224]. Based on these
data two non exclusive models emerged. On one hand, Hoege and colleagues proposed the
so called “mutual elimination model”, in which the PAR-6/PKC-3/LGL-1 complex is formed
at the boundary between the aPARs and pPARs domains, where PKC-3 can phosphorylate
LGL-1 causing the whole complex to leave the cortex [14]. On the other hand LGL-1 could
act as a bu↵er against the expansion of the aPARs domain [224], similarly to the mechanism
described for the peripheral nervous system of Drosophila [225]. Even if evidences supporting
or contradicting one or the other model are accumulating, the molecular mechanism of LGL
remains elusive.
In this chapter we focus on the cortex localization of LGL-1. We identified a region of
the protein that can directly bind negatively charged membranes. The binding specificity
depends on a stretch of positively charged amino acids surrounding the PKC-3 phosphory-
lation sites. Di↵erently from what described for the Myristoylated Alanine-Rich C Kinase
Substrate (MARCKS) e↵ector domain peptide, which is unstructured and elongated both
in solution and when bound to membranes [226, 128], the LGL-1 MTS folds in an helical
conformation upon membrane binding. In the membrane bound helix, three regions can be
identified: a positive charged area responsible for the lipid specificity, a switch area containing
the three PKC-3 phosphorylation sites and a hydrophobic area which is probably buried in
8.1 LGL-1 directly binds membranes containing negatively charged lipids via a
stretch of basic amino acids 101
the membrane. Phosphorylation reduces dramatically the binding a nity of the LGL-1 MTS
to negatively charged model membranes inducing its detachment. We were able to directly
visualize the phosphorylation-induced detachment of the LGL-1 MTS in GUVs as well as to
determine its partitioning coe cient KP with two independent approaches.
8.1 LGL-1 directly binds membranes containing negatively
charged lipids via a stretch of basic amino acids
It was recently shown that PAR-2 can interact with phospholipids and in particular with
phosphoinositides [91]. In vivo localization of PAR-2 to the posterior cortex depends on a
central domain rich in basic amino acids, suggesting that PAR-2 uses electrostatic interactions
to interact with phospholipids at the plasma membrane [227, 11].
Residue  #
470                 520                    570                    620                    670           700  
B
H
-­s
c
o
re
1.2
1.0
0.8
0.6
0.4
0.2
0.0
-­0.2
0.8
0.6
0.4
0.2
0.0
-­0.2
0.6
0.4
0.2
0.0
-­0.2
WT  /  AAA
EEE
pWT
BH
Ser
=  -­0.13
BH
Thr
=  -­0.14
BH
Ala
=  -­0.17
BH
Glu
=  -­2.02
BH
pSer/Thr
=  -­4.04
Pick  18  aa
Area  5.88/5.79
Pick  10  aa
Area  2.20
No  Pick
Figure 8.1 – BH-search identified a putative membrane binding region in LGL-1. BH-search score
plots for LGL-1 WT, nonphosphorylatable AAA mutant, phosphomimetic EEE mutant and fully
phosphorylated LGL-1 are reported. Pick length in number of amino acid (aa) and area are given
next to the identified region. The BH parameters used for selected amino acids are shown next to
the corresponding chemical structures.
We hypothesized that LGL-1 uses a similar mechanism to localize to the cell cortex.
To identify putative membrane binding regions in LGL-1, we analyzed its sequence with
an experimentally-based search program (BH-search) which is able to identify unstructured
membrane-binding sites [228]. LGL-1 in fact possesses neither hydrophobic membrane-
penetrating segments nor lipid-binding domains with highly defined tertiary structures. BH-
search identified a single region in the LGL-1 protein which can putatively bind membranes
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(Figure 8.1; WT, Peak 1: 659-FKSLKKSLRKTFRRKKKG-676 (18 aa), area 5.88). Interest-
ingly, this region contains the three phosphorylation sites for PKC-3 (S661/S665/T669) and,
similarly to PAR-2, is rich in positively charged amino acids (7K, 3R).
In order to experimentally confirm that this region is able to directly bind phospholipids,
a fragment of LGL-1 corresponding to the part of the C-terminal LGL-specific domain which
contains the PKC-3 phosphorylation sites (469-702) was expressed in E. coli as a fusion
protein with eGFP-His6. The endings of the fragment were chosen based on a previous
solubilization screening (Dr. Carsten Hoege, personal communication). The purified LGL-
1(469-702):eGFP-His6 fragment was incubated with GUVs containing di↵erent lipid mixtures
and imaged with a CLSM. LGL-1(469-702) did not bind to GUVs containing pure DOPC
(Figure 8.2, A), but it bound to GUVs doped with di↵erent negatively charged phospholipids
(Figure 8.2, C-F). The relative amount of each negatively charged lipid was chosen in order
to maximize the overall GUV charge and to keep it constant [229]. As a positive control we
used GUVs doped with DGS-NTA(Ni) (Figure 8.2, B), which is able to bind His6 tagged
proteins [230]. Among several acidic phospholipids screened, LGL-1(469-702) was found to
bind to GUVs containing phosphatidylserine or PIP2, the most abundant phospholipid and
phosphoinositide of the cytosolic side of the cell membrane, as well as phosphatidylglycerol or
cardiolipin, which do not normally belong to the plasma membranes. These findings support
the hypothesis that LGL-1, analogously to PAR-2, localizes to the membrane interacting
electrostatically with negatively charged phospholipids through a MTS containing a stretch
of positively charged amino acids.
8.1.1 The position of the basic amino acids modulate LGL-1 membrane
binding specificity
We further investigate the role of the positively charged amino acids of the LGL-1 MTS
observing the e↵ect of selected mutations on membrane binding. In a membrane yeast two-
hybrid screening [231] the positive charged amino acids of the LGL-1 MTS were systematically
mutated and only two mutations R658A/K660A and RR671AA were found to compromise the
yeast growth at a higher temperature (Dr. Carsten Hoege, personal communication). LGL-
1(469-702):eGFP-His6 carrying a combined quadruple mutation R658A/K660A/RR671AA
(LGL-1-AAAA) was incubated with SLBs containing pure DOPC or DOPC doped with ei-
ther DOPS or bPI(4,5)P2. Upon binding, the fluorescence signal at the level of the SLB
membrane is maximized while the fluorescence signal in the bu↵er above the membrane de-
creases (Figure 8.3, A). Z-scans of several region of each SLB were acquired with CLSM
and fluorescence intensity values at the membrane were extracted from the picks in the z-
stack intensity profiles. Interestingly the LGL-1-AAAA mutant maintains the ability to bind
DOPS-containing membranes, whereas its binding to bPI(4,5)P2-containing membranes de-
creases (Figure 8.3, B: WT = 5.83±0.81, AAAA = 3.00±0.98). These data suggest that the
positively charged amino acids in the LGL-1 MTS are not only contributing to the membrane
binding with their charges, but also with their individual positions, which may enable the
binding to specific phospholipids, i.e. phosphoinositides.
8.1.2 LGL-1 binds preferentially PIP2-containing membranes
Besides numerous well characterized globular domains which bind, more or less specifically,
acidic phospholipids at the membrane surface [232], short basic amino acids sequences are also
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Figure 8.2 – LGL-1 binds GUVs containing negative-charged lipids. LGL-1(469-702):eGFP-His6
was expressed in E. coli, purified and incubated with GUVs containing di↵erent lipid mixtures: [A]
DOPC 100; [B] DOPC:DGS-NTA(Ni) 95:5; [C] DOPC:DOPS 80:20; [D] DOPC:Cardiolipin 85:15;
[E] DOPC:DOPG 80:20; [F] DOPC:bPI(4,5)P2 92.5:7.5. GUVs were imaged at the equator with a
confocal laser scanning microscope. Scale bars are 10 µm.
known to interact electrostatically with phosphoinosites. As an example, the unstructured
basic e↵ector domain of MARCKS binds with high a nity but little headgroup specificity
PI(4,5)P2 to form an electroneutral complex [233, 234]. In order to determine if the LGL-
1 MTS binds phosphoinositides and in particular PI(4,5)P2 with higher a nity than other
acidic phospholipids we incubate a peptide corresponding to the LGL-1 MTS with DOPC
LUVs containing DOPS or phosphoinositides and measured their electrokinetic potential (z)
at di↵erent peptide concentrations. z-potential is not a direct measure of a particle charge,
but it is used to quantify its magnitude [235]. The z-potential is defined as the electric
potential that exists at the slipping plane, that is, the boundary within the di↵use liquid
layer surrounding a particle, beyond which the movements of the particle and its counterions
are decoupled [236]. It was recently demonstrated that z-potential can be used to determine
binding a nities of positively charged peptides to negatively charged liposomes [107]. The
rationale behind this approach is simple: the more peptide binds to the vesicles, the higher
the z-potential of the vesicle-peptide complex becomes until it eventually reaches zero or
positive values. Care was taken to ensure that no vesicle aggregation took place in the
peptide concentration range used and during the measurements. For this reason, the particle
size was checked with DLS before and after addition of the peptide (Figure 8.4, A) as well as
at the end of the measurement runs. The particle size and Polydispersity Index (PdI) increase
with higher LGL-1 MTS concentrations (Table 8.1), due to the increasing amount of peptide
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A B
Figure 8.3 – LGL-1-AAAA binds bPI(4,5)P2-containing membranes less than LGL-1-WT. LGL-
1(469-702):eGFP-His6 R658A/K660A/RR671AA (LGL-1-AAAA) was incubated with SLBs contain-
ing di↵erent lipid mixtures: DOPC 100, DOPC:DOPS 80:20, and DOPC:bPI(4,5)P2 92.5:7.5. [A]
Typical z-scans intensity profiles acquired with CLSM for LGL-1 bound (black) or not bound (red)
to the SLB. [B] LGL-1 fluorescence intensity values at the membrane were extracted from the picks
in z-stack intensity profiles, background corrected, averaged and normalized by the value obtained
in SLBs containing DOPC only. *t-test, t(4)=3.84, p=0.02
bound to the vesicles and due to the presence of vesicles with di↵erent amounts of peptide
bound, respectively.
LGL-1 MTS Concentration [µM] Particle Size [nm] PdI
0.00 120.33±6.72 0.09±0.04
0.50 132.19±4.17 0.11±0.02
1.00 137.97±8.19 0.13±0.04
2.00 159.67±23.61 0.15±0.03
4.00 175.61±29.50 0.13±0.03
8.00 162.04±32.15 0.16±0.05
Table 8.1 – Particle Size and polydispersity index values. Particle Size and PdI for LUVs in absence
and presence increasing concentration of LGL-1 MTS.
For the LGL-1 MTS peptide the z-potential does not increase linearly with increasing
peptide concentrations (Fig. 1.4, B), thus the mathematical model proposed by Freire and
colleagues [107] could not be used to fit our data and obtain a partition coe cient. An
alternative mathematical model was used to fit the z-potential curves and an apparent bind-
ing constant KB was obtained [237] (Figure 8.4, B). The peptide shows the highest KBs
for PI(3,4)P2 and PI(4,5)P2 containing LUVs, followed by PI(3,5)P2, the three monophos-
phoinositides, PI(3,4,5)P3 and DOPS (Figure 8.4, C). Interestingly, in both PI(3,4)P2 and
PI(4,5)P2 the phosphate groups seats in two adjacent positions of the inositol ring. The
ionization behavior of the phosphoinositides is known to be linked to the specific position of
the phosphate groups and most importantly to the ability of a protein to target a specific
membrane environment [238]. Similarly to the basic e↵ector domain of MARCKS, LGL-1
MTS KBs for PIP2 are in the µM range [74], however the KB for DOPS is higher, resulting
in an even less pronounced headgroup specificity; the a nity for PI(3,4)P2 and PI(4,5)P2 is
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in fact approximately one order of magnitude higher than for DOPS. Nevertheless PI(4,5)P2
is most probably the in vivo partner of LGL-1: the PI(4,5)P2 generating enzyme PPK-1 is
in fact posteriorly enriched in the C. elegans embryos, suggesting that PI(4,5)P2 localized
synthesis contributes to the polarized distribution of LGL-1 [239]. More generally PI(4,5)P2
is the most abundant phosphoinositide of the inner leaflet of the plasma membrane and is
normally targeted by phosphoinositide recognition domains with low headgroup specificity
[232].
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Figure 8.4 – LGL-1 MTS binds preferentially PIP2-containing membranes. LGL-1 MTS was in-
cubated with DOPC LUVs containing di↵erent acidic lipids: DOPS 5%, PI(3)P, PI(4)P or PI(5)P
2.5%, PI(3,4)P2, PI(3,5)P2 or PI(4,5)P2 1.67%, and PI(3,4,5)P3 1.25%. The relative amount of each
negatively charged lipid was chosen in order to keep the over all LUVs charge constant at 5%. [A]
Typical Intensity Particle Size Distribution (PSD) plot acquired for vesicles in absence (continuous
line) or presence (dashed lines) of increasing concentration of LGL-1 MTS. [B] z-potential mean
values obtained for PI(3)P, PI(3,4)P2 and PI(3,5)P2 at increasing LGL-1 MTS concentration; the
values were normalized by the value obtained in absence of peptide and fit to Equation 3.7 to get
the apparent binding constant KB . [C] Mean KBs values obtained for each lipid mixture (one-way
ANOVA, F(7, 359)=6.62, p<0.001). Holm-Sˇ´ıda´k post-hoc comparisons confirmed that the pres-
ence of either PI(3,4)P2 and PI(4,5)P2 in the LUVs maximize LGL-1 MTS KB (*p<0.05 for all
comparisons except with PI(3,5)P2).
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8.1.3 LGL-1 MTS fold into an a-helix upon binding to negatively charged
membranes
We next investigate the conformation of the LGL-1 MTS at the membrane. To do so we
measured the circular dichroism of the corresponding peptide in absence and present of SUVs
containing di↵erent acidic lipids. Although it was reported that accurate circular dichroism
spectra can be collected in the presence of LUVs [240], in our hands the light scattering was
too high to allow reliable measurements. In circular dichroism bu↵er or in presence of pure
DOPC vesicles, to which the peptide does not bind, LGL-1 MTS shows a clear random coil
circular dichroism spectra with a residual a-helicity of about 7% (Figure 8.5, A; red line). In
order to check if the peptide has a propensity to fold into an a-helix, we acquired the circular
dichroism spectra of the peptide in TFE, which is known to stabilize secondary structure
strengthening the peptide H-bonds [241]. In TFE, LGL-1 MTS shows a clear a-helix circular
dichroism spectrum with the two characteristic minima at 208 and 220 nm (Figure 8.5, A;
blue line). The a-helix content was estimated to be ca. 66%. Similar circular dichroism
spectra were obtained when the LGL-1 MTS peptide was mixed with SUVs containing acidic
lipids (Figure 8.5, A; green/gray/yellow lines). The estimated a-helix content increases with
increasing vesicle:protein ratios (Figure 8.5, B), strongly suggesting that the peptide fold into
an a-helix upon binding to negatively charged vesicles. The isodichroic point in this type of
circular dichroism spectra indicates that there are only two peptide populations: disordered
in solution and largely helical at the membrane [186].
This behavior was previously described, among others, for melittin [186]. On the other
side, LGL-1 MTS conformation is di↵erent from what described for the basic e↵ector domain
of MARCKS, which binds the membrane in an extended conformation with the five Phe
residues penetrating to the level of the acyl side chains [74].
8.2 Phosphorylation by aPCK abolishes the binding of LGL-1
to negatively charged membranes
LGL-1 activity in C. elegans is regulated by PKC-3 phosphorylation. More specifically, the
nonphosphorylatable LGL-1 mutant in which the three PKC-3 sites were mutated to alanines
(AAA) is not restricted to the posterior pole anymore, but localizes uniformly to the whole
cortex; whereas the phosphomimetic LGL-1 mutant, in which the three PKC-3 sites were
mutated to glutamates (EEE), is unable to associate with the cortex, even in the absence
of a functional PAR complex [14]. Having demonstrated that LGL-1 can directly bind lipid
membranes, we hypothesized that the phosphorylation by PKC-3 interferes with its membrane
binding ability. This hypothesis was initially supported by the results obtained with the BH-
search program. When the sequences of the AAA and EEE mutants are fed into the search
program, two di↵erent outcomes are generated. The AAA mutant score does not substantially
di↵er from the LGL-1 WT (Figure 8.1, AAA, : 659-FKSLKKSLRKTFRRKKKG-676 (18 aa),
area 5.79), whereas the EEE mutant shows a shorter sequence and a lower pick area (Figure
8.1, EEE, : 663-KKSLRKTFRR-672 (10 aa), area 2.20). BH parameters are not available for
phosphoserine and phosphothreonine, but are expected to be similar to the glutamate value if
not more negative, that is, unfavorable for membrane localization. We therefore introduced a
customized parameter for phosphoserine and phosphothreonine. A value of -4.04 was enough
to completely loose the potential membrane binding site (Figure 8.1, pWT). These data
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Figure 8.5 – LGL-1 MTS fold into an a-helix upon binding to negatively charged membranes. [A]
Circular dichroism spectra (data, continuous lines; fits, dashed lines) of LGL-1 MTS in circular
dichroism bu↵er, TFE and in presence of di↵erent protein:lipid ratios of DOPC:DOPS 80:20 SUVs;
[B] a-helix content estimated with the CONTIN method was normalized by the value obtained in
TFE and plotted for each spectrum in A.
suggest that phosphorylation should change the membrane a nity of LGL-1 substantially.
8.2.1 Phosphomimetic LGL-1 does not bind GUVs containing negative-
charged lipids
To prove this point we performed parallel experiments in di↵erent membrane model systems.
We first repeated the GUV binding assay with purified LGL-1 proteins which carried either
the AAA or the EEE mutation. Similarly to what described for the LGL-1 WT, we incubated
the LGL-1 mutants with GUVs containing DOPC:bPI(4,5)P2 92.5:7.5 and imaged them with
CLSM. As expected LGL-1 AAA retains its ability to bind GUVs containing PI(4,5)P2,
whereas EEE does not. (Figure 8.7).
8.2.2 LGL-1 can be phosphorylated in vitro by the human PKC-z
We next worked with in vitro phosphorylated LGL-1. In order to confirm that LGL-
1 can be phosphorylated in vitro by PKC-z [221] and to optimize the phosphorylation
conditions, we visualized the incorporation of radiolabeled phosphate groups in the LGL-
1 MTS peptide via autoradiography (Figure 8.8). When the Protein Kinase C (PKC)
phosphorylation serines/threonines were mutated, the radiolabeled phosphates groups could
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Figure 8.6 – LGL-1 MTS a-helix content. The a-helix content was estimated with the CONTIN
method for each lipid mixtures at 1:100 protein:lipid ratio, normalized by the value obtained in TFE
and plotted.
not be incorporated, thus the phosphorylation did not take place. The corresponding
LGL peptide in D. Melanogaster covering the amino acid positions 651 to 676 (651-
LSRRKSFKKSLRESFRKLRKGRSTRT-676) was reported to inhibit the kinase activity of
the associated aPKC enzyme [242]. Our data clearly show that the LGL peptide is not an
inhibitor of aPKC, but a substrate. The LGL peptide in the experiments of Kalmes and col-
leagues acted most probably antagonistically to the full length protein, being a more accessible
phosphorylation target for the aPKC.
8.2.3 Phosphorylation of LGL-1 inside GUVs induce its detachment from
the vesicle membrane
Both phosphorylated and not phosphorylated LGL-1 MTS peptides were encapsulated in
GUVs using the droplet transfer method originally described by Pautot and colleagues [51].
For these experiments we used DOPS instead of PI(4,5)P2 because the amount of lipids re-
quired is too high to keep the price per experiment at a reasonable level. Although the a nity
of the LGL-1 MTS peptide for DOPS is one order of magnitude lower than for PI(4,5)P2
(Figure 8.4), we do not expect a di↵erent behavior upon phosphorylation. The same kinase
reaction used to phosphorylate LGL-1 MTS in the radioassay was encapsulated in DOPS-
containing GUVs either in presence or in absence of ATP. As expected, the peptide binds
the membrane in the mixture without ATP, that is in the mixture where no phosphorylation
can take place (Figure 8.9, A). On the other hand, LGL-1 MTS appears homogeneously dis-
tributed inside the GUV and does not bind the inner membrane when ATP was present in
the kinase mixture, that is when human PKC-z could phosphorylate the LGL-1 MTS peptide
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Figure 8.7 – The phosphomimetic LGL-1 EEE mutant does not bind GUVs containing negative-
charged lipids. Purified LGL-1 WT, AAA and EEE were incubated with GUVs containing
DOPC:bPI(4,5)P2 92.5:7.5 and Texas Red DHPE as lipid dye [B-C]. GUVs were imaged at the
equator with CLSM. Intensity radial profile plots were determined for each GUV [D] and pick values
were plotted [E]. *t-test, t(121)=14.549, p=2.405 10-28. Scale bars are 10 µm.
(Figure 8.9, B).
We finally wanted to trigger the phosphorylation in situ inside the GUVs and thus visu-
alize the detachment of the LGL-1 MTS peptide from the membrane. In order to perform
this experiment, we used a strategy developed by Pontani and colleagues to induce actin
polymerization at the inner membrane of giant liposomes [53]. The GUVs are permeabilized
by adding a-hemolysin in the bu↵er outside the vesicles. a-hemolysin is a toxin secreted by
Staphylococcus aureus; it is monomeric in solution, but it can bind lipid membrane where it
assembles in a hexameric ring structure and forms a transmembrane pore, which is permeable
to ions and small solutes [243, 244]. Once the pore are formed, ATP and MgCl2, both required
for the human PKC-z to work, are sequentially added to the external solution, enter the vesi-
cles where they eventually trigger the phosphorylation of the LGL-1 MTS peptide. LGL-1
originally localizes at the membrane where it remains after the addition of both a-hemolysin
and ATP (Figure 8.10, A-C); however it detaches after MgCl2 is added (Figure 8.10, D).
Several but not all GUVs in each sample show unbinding of the LGL-1 peptide; moreover
the unbinding takes place at di↵erent times after the addition of MgCl2. This asynchronous
behavior is most probably due to di↵usion of the single added components. In order to min-
imize the movement of the GUVs which where tracked over the all process, each component
was added in few µl without pipetting and even if the chamber was allowed to equilibrate after
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Figure 8.8 – LGL-1 can be phosphorylated in vitro by the human PKC-z. LGL-1 MTS WT and
EEE peptides were incubated with recombinant human PKC-z in presence of [g-32P]ATP. Kinase
reactions were terminated at di↵erent time points, separated electrophoretically, and visualized with
autoradiography.
each addition, solutes might be still inhomogeneous distributed in the chamber. Interestingly
when the same experiment is attempt with GUVs containing 20 %mol DOPS the unbinding
of LGL-1 does not take place, suggesting that when the peptide is completely bound to the
membrane, is not accessible for the human PKC-z and thus it cannot be phosphorylated.
A similar observation was made for PAR-2, whose binding to microtubules is su cient to
protect it from the action of aPKC [91]. This mechanism of protection could also explain why
in some GUVs LGL-1 MTS only partially stays at the membrane forming a domain which
shrinks with time until it eventually disappears (Figure 8.11).
Taken together these findings support the hypothesis that phosphorylation by aPKC,
or phosphomimetic mutations of the PKC-3 sites, interferes with the binding of LGL-1 to
negatively charged lipids, as similarly described for Par-2 [91].
8.3 Determination of the LGL-1 partitioning coe cient to
negatively charged membranes
8.3.1 KP can be determined from images of GUVs encapsulating LGL-1
We showed that the LGL-1 MTS peptide can be encapsulated in GUVs. The fraction of the
peptide bound to the inner leaflet of the vesicles can be modulated varying the DOPS molar
ratio in the lipid mixture (Figure 8.12).
Additionally, the amount of peptide encapsulated within a GUV is variable, meaning that
the vesicles in one preparation are filled with di↵erent amounts of peptide, which can be up
to one hundred times more concentrated that in the original internal solution (Figure 8.13).
A similar observation was previously made for the spontaneous formation of liposomes in
aqueous phase [245, 246] and recently theoretically investigated [247, 248].
Both abilities to modulate the peptide bound fraction, and to encapsulate the peptide at
di↵erent concentrations proved to be extremely convenient for measuring the peptide mem-
brane partitioning coe cient KP directly from GUVs confocal images. In particular, the
DOPS molar ratio can be set at 5 %mol, a value for which the peptide is easily detectable
both in solution and at the membrane and the inherent encapsulation variability of the pep-
tide provides a wide range of peptide concentrations in a single experiment. Similarly to
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Figure 8.9 – Phosphorylated LGL-1 MTS does not bind GUVs containing negative-charged lipids.
The same kinase reaction used to phosphorylate LGL-1 MTS in the radioassay was encapsulated
in GUVs containing 20 %mol DOPS either in absence [A] or in presence of ATP [B]. Images of
representative GUVs are reported with their corresponding normalized intensity profiles [A1-B1].
Scale bars are 10 µm.
the image approached described in details in Chapter 7, the fluorescence intensities at the
membrane and inside the GUVs can be extracted with a customized MATLAB script and
converted into concentrations ([P2D], bound; [Pf ], free), provided that a calibration curve was
previously acquired using an independent measuring method (i.e. FCS). The membrane bind-
ing molecules are in this case encapsulated in a close environment, whose internal area serves
as an interacting surface. Here not only the water concentration W (5.53x10-14 mol/µm3),
but also the lipid surface concentration [L2D] (2.30x10-18 mol/µm2 for DOPC:DOPS 95:5
[249]) is constant.
The binding of a peptide to a lipid membrane was described by White and colleagues as
a partitioning between two immiscible fluid phases (water and lipid membrane) [186]:
KP =
[Pm]/[L]
[Pf ]/W
(8.1)
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Figure 8.10 – In situ LGL-1 phosphorylation inside a GUV. LGL-1 MTS was encapsulated in GUVs
containing 5 %mol DOPS. a-hemolysin [B], ATP [C], and MgCl2 [D] were sequentially added to the
external solution. Images of a representative GUV are reported before [A] and after each addition
[B-D]. Scale bars are 10 µm.
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Figure 8.11 – LGL-1 bound to the membrane is protected from the action of PKC-z. LGL-1
MTS was encapsulated in GUVs containing 5 %mol DOPS and a-hemolysin, ATP, and MgCl2 were
sequentially added to the external solution. Images taken at di↵erent time points after the addition
of MgCl2 are reported for two representative GUVs. Scale bars are 10 µm and labels in minutes.
Here [L] is the lipid volume concentration, whereas [Pm] and [Pf ] are the peptide concen-
trations at the GUV membrane and inside the GUV, respectively. In Chapter 7, we show that
the lipid [L2D] and peptide [P2D] surface concentrations can be used instead of the respective
volume concentrations and that both [P2D] and [Pf ] can be extracted directly from confocal
images:
KP =
[P2D]/[L2D]
[Pf ]/W
(8.2)
The ratio between surface AGUV and volume VGUV of a vesicle is not constant, but it
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Figure 8.12 – LGL-1 MTS encapsulated in GUVs via droplet transfer method. LGL-1 MTS was
encapsulated in GUVs containing di↵erent molar ratios of DOPS. Images of representative GUVs
are reported with their corresponding normalized intensity radial profiles. Scale bars are 10 µm.
Figure 8.13 – LGL-1 MTS encapsulation variability. Internal solutions with di↵erent LGL-1 MTS
concentrations were used to generate GUVs containing 5 %mol DOPS. The actual peptide concen-
trations in the GUVs are plotted against the corresponding peptide concentrations in the original
internal solutions.
scales with the radius AGUV /VGUV = 3/rGUV . The total number of particles attached to the
internal surface of a GUV P2D = [P2D]AGUV and free inside the GUV Pf = [Pf ]VGUV can be
calculated knowing rGUV . When several P2D, Pf/rGUV pairs are plotted against each other,
KP can be determined fitting the date points to equation:
P2D =
3KP [L2D]
[W ]
Pf
rGUV
(8.3)
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The partitioning coe cient of the LGL-1 MTS peptide to GUVs containing 5 %mol DOPS
can be therefore estimated to be 9.05±0.2x104 (Figure 8.14).
Figure 8.14 – Determination of the LGL-1 MTS partitioning coe cient in GUVs. LGL-1 MTS
at 25 nM initial concentration was encapsulated in GUVs containing 5 %mol DOPS. Fluorescence
intensities at the membrane and inside the GUV were extracted from 117 GUVs belonging to four
independent samples, converted into number of molecules and plotted against each other. A global
linear fitting to Equation 8.3 was applied in order to determine the LGL-1 MTS partitioning coe -
cient KP .
Model Membrane Membrane Composition Method LGL-1 MTS KP
GUVs PS 5 %mol Imaging 9.05±0.2x104
LUVs PS 20 %mol FCS 6.48±0.5x105
Model Membrane Membrane Composition Method LGL-1 MTS KB [M-1]
LUVs PS 5 %mol z-potential 0,17±0,05x10-6
LUVs PI(3)P 2.5 %mol z-potential 0,65±0,17x10-6
LUVs PI(4)P 2.5 %mol z-potential 0,61±0,11x10-6
LUVs PI(5)P 2.5 %mol z-potential 0,62±0,14x10-6
LUVs PI(3,5)P2 1.67 %mol z-potential 0,96±0,30x10-6
LUVs PI(3,4)P2 1.67 %mol z-potential 1,67±0,35x10-6
LUVs PI(4,5)P2 1.67 %mol z-potential 1,55±0,26x10-6
LUVs PI(3,4,5)P3 1.25 %mol z-potential 0,36±0,07x10-6
Table 8.2 – LGL-1 MTSKP andKB values. LGL-1 MTSKP s andKBs values to vesicles containing
di↵erent acidic lipids measured by a FCS, imaging or z-potential approach.
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8.3.2 LGL-1 KP determined with a LUV-FCS based method
The partitioning coe cient KP of the LGL-1 MTS peptide to negatively charged membranes
was alternatively measured with the LUV-FCS method [74] described in details in Chapter
7. The kinase reaction mix described above for the in vitro phosphorylation of the LGL-1
MTS peptide was used and the LUV-FCS binding assay was performed either in presence or
absence of ATP, that it with phosphorylated and not phosphorylated peptides. When LUVs
were increasingly added to the chamber containing the not phosphorylated peptide, fluores-
cent spikes appeared (Figure 8.15, A; LGL-1 MTS). These spikes originate from vesicles,
to which the fluorescent peptide is bound, passing through the focal volume. The di↵erent
heights of the spikes suggest that more than one single peptide molecule can bind each vesicle.
The phosphorylated peptide cannot bind the vesicles, thus no fluorescence spikes could be
detected in its presence (Figure 8.15, A; LGL-1 MTS P). FCS of both phosphorylated and
not phosphorylated peptides was measured in solution before and after each vesicle addition.
The autocorrelation curves of the not phosphorylated peptide move left with increasing LUVs
concentrations (Figure 8.15, B; LGL-1 MTS), meaning that the di↵usion of the peptide de-
creases with increasing LUVs concentrations. This is due to the fact that more and more
peptide binds the vesicles and consequently di↵uses slower than in the unbound state. Con-
versely the autocorrelation curves of the phosphorylated peptide do not change (Figure 8.15,
B; LGL-1 MTS P), as well as the peptide di↵usion. LGL-1 MTS P in fact does not bind
the vesicle and thus its di↵usion do not decrease with increasing LUVs concentrations. The
autocorrelation functions were fitted to a two components 3D+T di↵usion model (Equation
7.23), an averaged normalized G(0) value for each LUVs concentration was then calculated
and plotted against the vesicle concentration itself (Figure 8.15, C). All data points were
finally fitted to Equation 7.26 and converted with Equation 7.27. The partitioning coe cient
of the LGL-1 MTS peptide to LUVs containing 20 %mol POPS could be therefore estimated
to be 6.48±0.5x105. This value is in line with those obtained for other conditional peripheral
proteins [250] and higher than the one measured with the imaging approach in GUVs (Table
8.2). The amount of acidic lipids in the LUVs was in fact four times higher than in the GUVs.
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Figure 8.15 – Determination of the LGL-1 MTS partitioning coe cient with the LUV-FCS method.
Not phosphorylated and phosphorylated (P) LGL-1 MTS peptides at 50 nM initial concentration were
incubated with increasing concentrations of LUVs containing 20 %mol POPS. FCS was measured
in solution in absence and after each vesicle addition [A]. The autocorrelation functions were fitted
to a two components 3D+T di↵usion model (Equation 7.23) [B], then G values for each LUVs
concentration were calculated and the data points were fitted to Equation 7.26 and converted with
Equation 7.27 to determine the LGL-1 MTS partitioning coe cient KP [C].
Part IV
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Chapter 9
Conclusion and Outlook
In this thesis, we explored di↵erent “bottom-up” approaches to reconstitute membrane un-
mixing and cell polarization events in model membranes. On one hand, we worked with pure
lipid systems, in which we exchanged selected lipids to generate lipid transbilayer asymme-
try, induce lipid lateral segregation, and trigger vesicle shape transformations. On the other
hand, we reconstituted a functional LGL/aPKC membrane binding switch in GUVs as a first
module of a minimal polarization system inspired by the C. elegans embryo at one-cell stage.
In both cases, we collected observations that helped us understanding the biological inspiring
processes. Moreover, because of their reduced complexity, the reconstituted systems could be
readily characterized by biophysical methods. In particular, we made use of both fluorescent
imaging and correlation spectroscopy to quantify lipid dynamics and phase behavior as well as
protein-lipid interactions in the very same system used to reconstitute the desired membrane
proteins. The ability to retrieve quantitative information is, in fact, a generally desirable and
increasingly required feature of any minimal synthetic system.
9.1 Pure lipid systems
9.1.1 Reconstitution of lipid transbilayer asymmetry in model membranes
In Chapter 4, we described how the cyclodextrin-mediated lipid exchange method can be
extended to SLBs formed by VF to produce temporarily stable asymmetric SLBs. This
approach is quick and easy to implement, does not require organic solvents, nor specialized
equipment or skills, and can be used with a variety of di↵erent lipids to produce bilayers
with the desired composition in each leaflet, as already showed for LUVs and GUVs [85, 86,
251, 97]. It also provides a more naturally generated asymmetric system in the way that
specific lipids are incorporated when the bilayer already exists. The local lipid composition of
biological membranes is, in fact, known to change continuously because of membrane recycling
and enzymatic activity [125]. This is the case, for example, of SM, being synthesized at
the endoplasmic reticulum and Golgi apparatus and eventually transported to the plasma
membrane, or directly at the outer leaflet of the plasma membrane by the SphingoMyelin
Synthase 2 (SMS2). Our approach has additionally the potential to be combined with other
conventional SLB preparation techniques to fine-tune the lipid composition of the bilayer,
as suggested by the successful vesicle-mediated phospholipids exchange recently reported for
tethered bilayers [252].
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9.1.2 Reconstitution of lipid lateral segregation in model membranes
In Chapters 4, we also showed that aSLBs generated via cyclodextrin-mediated lipid exchange
are a suitable membrane model system to study phase separation of raft-mimicking lipid
mixtures. Using such a system, we showed how small changes in the composition of the inner
leaflet (e.g. of the plasma membrane), although not su cient to support phase separation in a
corresponding symmetric bilayer, a↵ect the overall lipid miscibility of the whole bilayer. Our
system provides an alternative strategy to follow domain dynamics without heating/cooling
the sample above/below its phase transition temperature. In fact, de novo formation of Lo
domains is induced though cholesterol incorporation in the bilayer rather than by temperature
control. Moreover, in contrast to what was described for other aSLB systems [129], the
support does not exert any negative influence on domain registration in our system; when
domains can be formed, they are always in registration. If the total cholesterol amount
of a single bilayer could be precisely measured, for example, with mass spectrometry, our
system could be also used to investigate how cholesterol distributes between the lower and
upper leaflet of SM-containing aSLBs. In fact, even if cholesterol is expected to preferentially
interact with SM, experiments performed in various cells types revealed that cholesterol is
enriched in the cytosolic leaflet of biological membranes [253]. For example recent quantitative
quenching analysis in CHO cells indicated that 60-70% of the plasma membrane sterols resides
in the cytoplasmic leaflet [254].
9.1.3 Using lipid transbilayer asymmetry to induce shape transformations
of GUVs
In Chapter 5, we showed that cyclodextrin-mediated lipid exchange can be used to induce
changes in the shape of GUVs. Varying the amount of cyclodextrin results in di↵erent vesicle
transformations: prolate ellipsoid to spherical vesicle transformations are observed at high
cyclodextrin concentrations, discocyte to stomatocyte transformations and vesicle budding
at intermediate cyclodextrin concentrations, whereas vesicle endocytosis is common at low
cyclodextrin concentrations. Additionally it would be beneficial to stop the vesicles from
further changing once they reach the desired shape. Although we did not try it yet, we are
confident that removing the cyclodextrin-lipid complexes in excess by extensive wash would
be enough to freeze the vesicle shape.
Besides PG, we expect that other lipids could be employed to induce shape transformation
in giant liposomes. Those lipids should be cone- (i.e. phosphatidylethanolamine) or inverted
cone-shaped (i.e. lysolipids) [255] to significantly modify the area of the outer leaflets relative
to the inner one. L-PC, for example, is known to induce vesicle fission in GUVs, but only
if GUVs are in Lo phase [256, 257]. We therefore plan to use the described FRAP assay to
determine whether or not cyclodextrin mediated lipid exchange is able to induce vesicle fission
in absence of intramembrane domains [154], phase transition [258] or protein machineries [155]
and as a consequence of the transbilayer lipid asymmetry only.
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9.2.1 Lipid transbilayer asymmetry is not su cient to restore the correct
lateral organization of the influenza virus HA TM helix in model
membranes
In Chapter 4, we also demonstrated that the cyclodextrin-mediated lipid exchange can pro-
duce asymmetric bilayers in the presence of reconstituted proteins. Interestingly, this method
o↵ers the advantage of providing in the same sample the state before and after the estab-
lishment of the asymmetry or of the shape transformation, thus opening the possibility of
directly probing the e↵ect of leaflet-specific lipid composition and system geometry on pro-
tein structure and function.
In Chapter 6, we hypothesized that the lack of asymmetry of the Lo domains in model
membranes could be the reason why raft-associating proteins, such as the influenza HA,
partition into Ld domains, rather than into Lo domains. Unexpectedly, our results do not
support this hypothesis. In both SLBs and GUVs asymmetric model system, we could not
observe any significant di↵erence in the partitioning behavior of the HA TM peptide. There
must be additional features of the lipid rafts in cells that model membranes still fail to
mimic. Further development of model membranes, beyond their asymmetry, are therefore
needed to truly mimic the partitioning behavior of raft-associated proteins and TM helices.
In particular, protein crowding should be implemented. GPMVs are often presented as a
better alternative to GUVs as far as they resemble the lipid and protein diversity of native
biological membranes closer than any other model membrane [259]. However, at least in
the case of the influenza HA, they did not help to correctly reproduce the raft-partitioning
observed in cell membranes [131].
9.2.2 Direct quantification of protein-lipid interactions in GUVs
In Chapter 7, we provided a new and versatile method to determine KP s, which overcomes
several disadvantages of established assays. Moreover, we showed how to understand the
relation between KP and the number of molecules per lipid surface (Equation 7.18), which
can always be determined for a protein-lipid system, whose soluble protein and lipid surface
concentrations are known. To our knowledge, this is the first assay based on GUVs, which
combines confocal imaging with FCS to precisely determine protein concentrations at equi-
librium. Small amounts of sample are needed, since the measurement can be conducted in
low volume chambers and FCS as well as photon-counting imaging are known to be sensitive
down to the nanomolar range. In addition, our assay accounts for loss of protein due, for
example, to unspecific interactions with the chamber or pipetting errors, since free and mem-
brane associated protein are always directly determined. The use of free standing membranes
excludes any e↵ects of the support on protein-lipid interaction. Apart from studying the
interaction of peripheral proteins with lipid membranes, any fluorescent species, e.g. labeled
peptides or small molecules, could be investigated with this assay.
The comparison of our results with a FCS-based LUV assay revealed that the latter
method is not accurate for the NTA(Ni)-His6 system, even when the multiple binding of
peptides to a single vesicle is taken into account. Due to vesicle aggregation, no significant
increase of the partitioning coe cient was detected (one-way ANOVA, F (3, 14) = 3.3, p =
0.061) even in presence of 2.5 times the amount of binding sides in the membrane. The KP s
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obtained with our dual approach correspond to the upper range of the values reported in the
literature and clearly show a dependence on the content of NTA(Ni) lipids in the membrane.
Our imaging-based GUV assay could be readily combined with an automated GUVs anal-
ysis software [260] or performed in a microarray setup [261] to directly extract the mean
intensities of several GUVs in one image or simultaneously probe di↵erent lipid-binding pro-
teins in a single experiment, while significantly reducing both measuring and analysis time.
9.2.3 Reconstitution of a functional LGL/aPKC membrane binding switch
In Chapter 8, we were able to reconstitute a functional LGL/aPKC membrane binding switch
in GUVs. In this system a PKC-z co-encapsulated with the LGL-1 MTS peptide can be
activated, thus it phosphorylates LGL-1 MTS inducing the detachment of the peptide from the
vesicle inner membrane. This direct visualization of the phosphorylation-dependent LGL-1
MTS detachment, together with complementing experiments, indicates that phosphorylation
by PKC-3 regulates LGL-1 cortex localization lowering dramatically its a nity for negatively-
charged membranes.
In order to reconstitute LGL-1 in model membranes, we had to clarify the mechanism
of the LGL-1 localization at the cortex. We identified a region (659-676) in the C-terminal
LGL-specific domain, which is rich in positively charged amino acids and can directly bind
negatively charged membranes. Although the membrane binding takes place independently of
what type of acidic lipid is used, LGL-1 shows the highest a nity for the diphosphoinositides
PI(3,4)P2 and PI(4,5)P2, whose phosphate groups seat in two adjacent positions of the inositol
ring. This finding has a biological relevance: the PI(4,5)P2 generating enzyme PPK-1 of C.
elegans is, in fact, enriched in the posterior domain, where LGL-1 localizes [239]. Upon
membrane binding, LGL-1 MTS folds into an a-helix, which forms three regions with distinct
properties: (1) all basic amino acids align and form a positive charged patch; (2) the three
amino acids that serve as phosphorylation sites for PKC-3 are located close to each other,
creating a “switch” area; and (3) all remaining hydrophobic adjacent residues are probably
buried in the membrane (Figure 9.1, A).
Interestingly, only mutations of specific basic amino acids of the positive patch interfere
with the cortical localization of LGL-1 in yeast. A combined quadruple mutation of those
residues lowers the a nity of LGL-1 MTS for PI(4,5)P2-containing membranes in our in vitro
GUV binding assay, suggesting that the position of the single basic amino acids in the LGL-1
MTS is important for its membrane binding specificity (Figure 9.1, B).
The observation that LGL-1 binds the membrane through the same region that controls its
cortex/membrane localization is consistent with the intramolecular auto-inhibition model pro-
posed by Betschinger and colleagues [220] and complements it, although they assumed that
the membrane association takes place through the N-terminal b-propeller domains. When
LGL does not bind the membrane, its MTS has a random coil conformation and acts as a
flexible hinge, allowing the N- and C- termini of the protein to come together. This condition
can be triggered or stabilized by PKC-dependent phosphorylation, having the phosphory-
lated LGL low membrane a nity. On the other hand, when LGL binds the membrane, the
MTS folds into an a-helix structure with reduced flexibility [262], eventually preventing the
intramolecular association of the N- and C- termini of the protein. In this condition LGL is
protected from the PKC-3 action [91], signaling that an additional player must be involved
in the LGL activation/deactivation cycle. PAR-6 for example through its direct association
with LGL [222] could enable PKC-3 to phosphorylate LGL even in its membrane-bound state.
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Figure 9.1 – Secondary structure of the LGL-1 MTS WT and AAAA peptide at the membrane.
Upon membrane binding, LGL-1 MTS folds into an a-helix structure with three distinct regions: a
positive charged area responsible for the lipid specificity, a switch area containing the three PKC-
3 phosphorylation sites and a hydrophobic area which is probably buried in the membrane [A].
Mutation of four basic residues R658A/K660A/RR671AA changes the a nity of LGL-1 MTS for
PI(4,5)P2-containing membranes.
PAR-6 is, in fact, known to activate aPKC, given that its CRIB/PDZ domain, the same in-
volved in the binding with LGL, is engaged in a binding with Cdc42 [263]. Nevertheless,
additional experimental work is needed to prove the truth of this model.
We finally adapted the GUV-imaging method described in Chapter 7 to directly measure
the partitioning coe cient of the LGL-1 MTS encapsulated in GUVs. Besides the KP value
obtained, which is in line with the values of other conditional peripheral proteins [250], this
modified version of the GUV-imaging method provides an experimental advantage. It can be
used even with peptides/proteins that strongly adhere to glass surfaces and plastic tubing,
like LGL-1, without compromising its accuracy.
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